Crystal engineering of organic compounds including pharmaceuticals by Bis, Joanna A
University of South Florida
Scholar Commons
Graduate Theses and Dissertations Graduate School
2006
Crystal engineering of organic compounds
including pharmaceuticals
Joanna A. Bis
University of South Florida
Follow this and additional works at: http://scholarcommons.usf.edu/etd
Part of the American Studies Commons
This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in
Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
scholarcommons@usf.edu.
Scholar Commons Citation
Bis, Joanna A., "Crystal engineering of organic compounds including pharmaceuticals" (2006). Graduate Theses and Dissertations.
http://scholarcommons.usf.edu/etd/2459
Crystal Engineering of Organic Compounds Including Pharmaceuticals 
 
 
 
 
by 
 
 
 
 
Joanna A. Bis 
 
 
 
 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
Department of Chemistry 
College of Arts and Sciences 
University of South Florida 
 
 
 
 
 
 
Major Professor:  Michael J. Zaworotko, Ph.D. 
Julie P. Harmon, Ph.D. 
Edward Turos, Ph.D. 
Matthew L. Peterson, Ph.D. 
 
 
 
Date of Approval: 
April 12, 2006 
 
 
 
Keywords:  Supramolecular chemistry, Supramolecular Synthon, Hydrogen Bond, Co-
crystal, Polymorphism 
 
 
© Copyright 2006, Joanna A. Bis
 
 
 
 
 
 
 
 
 
Dedication 
To my parents and grandparents 
 
 
 
 
 
 
 
 
 
  
 
 
 
Acknowledgements 
 
I would like to thank my advisor, Professor Michael J. Zaworotko, for the 
opportunity to conduct research under his supervision, and for his advice and guidance 
throughout the Graduate Program.  
  I would also like to thank Dr. Julie P. Harmon, Dr. Edward Turos, and Dr. 
Matthew L. Peterson, my committee members, for their helpful comments and 
encouragements.  
  I wish to express my appreciation to Dr. Elisabeth Rather, Dr. Brian Moulton, and 
Dr. Victor Kravtsov for their invaluable contribution to my crystallography experience, 
and Dr. Peddy Vishweshwar for his helpful discussions related to the preparation of 
scientific manuscripts. In addition, I would like to acknowledge all members of my 
research group, as well as Faculty and Staff of the Chemistry Department of University 
of South Florida, for their friendly accommodation.   
  At last, I would like to express my deepest thanks to my closest family and friends 
who constantly supported me throughout the years of studies.  
  
  
 i
 
 
 
Table of Contents 
 
 
 
 
List of Tables vii 
List of Figures xix 
List of Schemes  xvi 
Abstract xvii 
Chapter 1 ─ Introduction 1 
1.1. Supramolecular Chemistry 1 
1.1.1. Fundamentals 1 
1.1.2.  Supramolecular Interactions and the Role of Hydrogen 
Bonds 2 
1.2.  Crystal Engineering 3 
1.2.1.  Fundamentals 4 
1.2.2.  Hydrogen Bonded Supramolecular Synthons 6 
1.2.3. The Cambridge Structural Database 8 
1.3.  Hydrogen Bonded Organic Co-crystals 9 
1.3.1.  Co-Crystals in the Context of Investigation of 
Supramolecular Heterosynthons 12 
1.3.2.  Co-Crystals in the Context of Green Chemistry 14 
 ii
1.3.3. Co-Crystals in the Context of Polymorphism 16 
1.3.4. Co-Crystals in the Context of Pharmaceuticals 18 
1.4.  Summary 22 
Chapter 2 ─ Recurrence of hydroxyl···aromatic nitrogen supramolecular 
heterosynthon in the presence of a competing cyano acceptor 24 
2.1. Focus 24 
2.2.  Results and Discussion 25 
2.2.1. CSD Analysis 26 
2.2.2.  Structural Features of Neutral and Ionic 
Hydroxyl···Aromatic Nitrogen Interaction 29 
2.2.3. Crystal Structure Descriptions 30 
2.3. Conclusions 46 
2.4.  Experimental 47 
2.4.1. Syntheses 47 
2.4.2. Single Crystal X-ray Crystallography 51 
Chapter 3 ─ Methods of Preparation of Co-crystals and Polymorphism in Co-
crystals 56 
3.1. Focus 56 
3.2. Results and Discussion 57 
3.2.1.  Methods of Preparations of Co-crystals 57 
3.2.2. Polymorphism in 4-cyanophenol•trans-1,2-bis-(4-
pyridyl)ethylene co-crystal 60 
 iii
3.2.3. Polymorphism in (4-cyanopyridine)2•4,4’-biphenol co-
crystal 63 
3.3.      Conclusions 74 
3.4.  Experimental 76 
3.4.1.  Syntheses 76 
3.4.2. Single Crystal X-ray Crystallography 77 
Chapter 4 ─ Robustness of Supramolecular Heterosynthons: 2-Aminopyridinium 
Carboxylate 80 
4.1. Focus 80 
4.2.  Results and Discussion 81 
4.2.1. CSD Analysis 82 
4.2.2.  Structural Features of Neutral and Ionic 2-
Aminopyridine···Carboxylic Acid Interaction 86 
4.2.3. Crystal Structure Descriptions 88 
4.3.      Conclusions 103 
4.4. Experimental 104 
4.4.1.  Syntheses 104 
4.4.2.  Single Crystal X-ray Crystallography 107 
Chapter 5 ─ Crystal Engineering of Pharmaceuticals 110 
5.1.  Focus 110 
5.2. Results and Discussion 111 
5.2.1.  CSD Analysis and Literature Overview 111 
 iv
5.2.2.  Bicalutamide 116 
5.2.3.  Indomethacin 125 
5.3. Conclusions 129 
5.4. Experimental 132 
5.4.1.  Syntheses 132 
5.4.2. Single Crystal X-ray Crystallography 133 
Chapter 6 ─ Summary and Future Directions 136 
6.1. Summary 136 
6.2.  Future Directions 139 
Appendices 159 
Appendix 1. Experimental data for compound 1 160 
Appendix 2. Experimental data for compound 2 161 
Appendix 3. Experimental data for compound 3 162 
Appendix 4. Experimental data for compound 4 163 
Appendix 5. Experimental data for compound 5 164 
Appendix 6. Experimental data for compound 6 165 
Appendix 7. Experimental data for compound 7 166 
Appendix 8. Experimental data for compound 8 167 
Appendix 9. Experimental data for compound 9 168 
Appendix 10. Experimental data for compound 10 169 
Appendix 11. Experimental data for compounds 11a and 11b 170 
Appendix 12. Experimental data for compound 12 171 
 v
Appendix 13. Experimental data for compound 13a and 13b 172 
Appendix 14. Polymorphism screen data for compound 1 173 
Appendix 15. Polymorphism screen data for compound 2 174 
Appendix 16. Polymorphism screen data for compound 3 175 
Appendix 17. Polymorphism screen data for compound 4 176 
Appendix 18. Polymorphism screen data for compound 5 177 
Appendix 19. Polymorphism screen data for compound 6 178 
Appendix 20. Polymorphism screen data for compound 7 179 
Appendix 21. Polymorphism screen data for compound 8 180 
Appendix 22. Polymorphism screen data for compound 9 181 
Appendix 23. Polymorphism screen data for compound 10 182 
Appendix 24. Polymorphism screen data for compound 11a and 11b 183 
Appendix 25. Polymorphism screen data for compound 12 185 
Appendix 26. Polymorphism screen data for compound 13a and 13b 186 
Appendix 27. Experimental data for compound 14 187 
Appendix 28. Experimental data for compound 15 188 
Appendix 29. Experimental data for compound 16 189 
Appendix 30. Experimental data for compound 17 190 
Appendix 31. Experimental data for compound 18 191 
Appendix 32. Experimental data for compound 19 192 
Appendix 33. Experimental data for compound 20 193 
Appendix 34. Experimental data for compound 21 194 
 vi
Appendix 35. Experimental data for compound 22 195 
Appendix 36. Experimental data for compound 23 196 
Appendix 37. Experimental data for compound 24 197 
Appendix 38. Experimental data for compound 25 198 
Appendix 39. Experimental data for compound 26 199 
About the Author End Page 
 
 vii
 
 
 
 
 
List of Tables 
 
 
Table 1.1. Comparison of selected chemical bond types and their features 3 
Table 1.2. The occurrence of polymorphism in organic compounds 18 
Table 1.3. Occurrence of hydrogen bonding moieties in APIs 19 
Table 2.1.  CSD statistics related to supramolecular synthons that occur in 
structures containing only OH, Narom, and CN 28 
Table 2.2. Comparison of the melting points of co-crystals 1-12 and the 
corresponding components 51 
Table 2.3. Crystallographic data and structure refinement parameters for co-
crystals 1-12 53 
Table 2.4. Geometrical parameters of supramolecular heterosynthon I present in 
co-crystals 1-12 55 
Table 3.1. Crystallographic data and structure refinement parameters for co-
crystals 11b, 13a, and 13b 78 
Table 3.2. Geometrical parameters of supramolecular heterosynthon I present in 
co-crystals 11b, 13a, and 13b 79 
Table 4.1. Percentage occurrence, distance ranges, and average distance for 
supramolecular synthons IV-VII 84 
 viii
Table 4.2. Crystallographic data and structure refinement parameters for 
compounds 14-22 108 
Table 4.3. Geometrical parameters of selected intermolecular interactions present 
in compounds 14-22 109 
Table 5.1. Comparison of the melting points of co-crystals 23-25  and the 
corresponding components 125 
Table 5.2. Crystallographic data and structure refinement parameters for 
compounds 23-26 134 
Table 5.3. Geometrical parameters of supramolecular heterosynthons present in 
compounds 23-26 135 
 
 
 
 
 
 
 ix
 
 
 
 
 
List of Figures 
 
 
 
 
Figure 1.1. Examples of supramolecular synthons: carboxylic acid homosynthon 
(left) and carboxylic acid···pyridine heterosynthon (right) 7 
Figure 1.2. Crystal structure of the triclinic form of quinhydrone 10 
Figure 1.3. The Hoogsteen base-pairing in the structure of 9-methyladenine 1-
methylthymine co-crystal 10 
Figure 1.4. Distribution of hydrogen bonded co-crystal structures archived in the 
CSD between 1978-2004 11 
Figure 1.5. Itraconazole•succinic acid co-crystal 21 
Figure 1.6. Carbamazepine•saccharin co-crystal 22 
Figure 2.1. Histograms of contacts for supramolecular synthons: a) O–H···Narom 
in I; b) O–H···N≡C in II; and c) O–H···O in III 29 
Figure 2.2. Histograms representing the distribution of carbon-oxygen bond 
lengths in a) neutral phenolic moieties and b) deprotonated phenolic 
moieties 30 
Figure 2.3. Crystal structure of 3-cyanophenol•4-phenylpyridine, 1 31 
Figure 2.4. Crystal structure of (3-cyanophenol)2•1,2-bis-(4-pyridyl)ethane, 2 32 
Figure 2.5. Crystal structure of (3-cyanophenol)2•t-1,2-bis-(4-pyridyl)ethylene, 3 33 
 x
Figure 2.6. Crystal structure of 3-cyanophenol•t-1,2-bis-(4-pyridyl)ethylene, 4 35 
Figure 2.7. Crystal structure of phenazine•hydroquinone, FOQHEY 35 
Figure 2.8. Crystal structure of 4-cyanophenol•4-phenylpyridine, 5 36 
Figure 2.9. Crystal structure of (4-cyanophenol)2•4,4’-bipyridine, 6 37 
Figure 2.10. Crystal structures of (4-cyanophenol)2•1,2-bis-(4-pyridyl)ethane, 7 37 
Figure 2.11. Crystal structure of (4-cyanophenol)2•t-1,2-bis-(4-pyridyl)ethylene, 
8 38 
Figure 2.12. Representation of the relative orientation of the adjacent 2:1 
adducts: a) down the a axis in 6, and b) down the b axis in 8 38 
Figure 2.13. Crystal structure of (3-cyanopyridine)2•4,4’-biphenol, 9 39 
Figure 2.14. Crystal structure of (4-cyanopyridine)2•resorcinol, 10 40 
Figure 2.15. Crystal structure of (4-cyanopyridine)2•4,4’-biphenol, 11a 41 
Figure 2.16. Crystal structure of (4-cyanopyridine)3•phloroglucinol, 12 42 
Figure 2.17. Crystal structure of (4,4’-bipyridine)3•phloroglucinol, TEKKOJ 43 
Figure 2.18. Supramolecular hetrosynthon I present in the crystal structure of 3-
hydroxypyridine 44 
Figure 3.1. Solid-to-liquid conversion occurring in a mixture of 3-cyanopyridine 
and 1-napthol 60 
Figure 3.2. Crystal structure of 4-cyanophenol•t-1,2-bis(4-pyridyl)bipyethylene 
form I, 13a 61 
Figure 3.3. Crystal structure of 4-cyanophenol•t-1,2-bis(4-pyridyl)bipyethylene 
form II, 13b 62 
 xi
Figure 3.4. X-ray powder diffraction patterns of 4-cyanophenol•t-1,2-bis(4-
pyridyl)bipyethylene polymorphs: bulk sample (green) and simulated 
patterns of form I (black) and form II (red) 63 
Figure 3.5. Concomitant polymorphs of (4-cyanopyridine)2•4,4’-biphenol co-
crystal: a) form I – irregular hexagons, b) form II – parallelepiped 
plates 64 
Figure 3.6. ORTEP plot of supramolecular adducts in (4-cyanopyridine)2•4,4’-
biphenol drawn at 50% probability level for non-hydrogen atoms: (a) 
form I, (b) form II 66 
Figure 3.7. Crystal packing in (4-cyanopyridine)2•4,4’-biphenol form II, 11b 66 
Figure 3.8. Histogram representing the torsion angle distribution in 22 crystal 
structures of 4,4’-biphenols 68 
Figure 3.9. a) Distribution of torsion angles in the 623 crystal structures that 
contain biphenyl moieties; b) Distribution of torsion angle deviations 
within pairs of conformers present in 67 crystal structures 68 
Figure 3.10. Polymorphic conversions between form I and form II of the (4-
cyanopyridine)2•4,4’-biphenol co-crystal 69 
Figure 3.11. PXRD patterns of  (4-cyanopyridine)2•4,4’-biphenol co-crystals: (a) 
simulated form I and (b) experimental form I obtained via slow 
evaporation from acetone; (c) simulated form II and (d) experimental 
form II obtained via acetone-drop grinding 70 
 
 xii
Figure 3.12. Crystal structures of the polymorphic forms of quinhydrone: a) form 
α and b) form β 72 
Figure 3.13. Crystal structures of the polymorphic forms of caffeine•glutaric acid 
co-crystal: a) form I and b) form II 73 
Figure 4.1. Examples of supramolecular homosynthons: a carboxylic acid 
homosynthon IV  and a 2-aminopyridine homosynthon V 81 
Figure 4.2. Histograms of contacts for crystal structures containing both 2-
aminopyridine and carboxylic acid moieties: a) N(py)···O contacts in 
supramolecular heterosynthon VI or VII, b) N(am)···O contacts in 
supramolecular heterosynthon VI or VII, c) N(am)···N(py) contacts 
in supramolecular homosynthon V 85 
Figure 4.3. Scatter plot of carbon-oxygen bond lengths in: a) neutral carboxylic 
acids, b) carboxylate anions 86 
Figure 4.4. Histograms that present distribution of the C–N–C angle in a) neutral 
2-aminopyridines, and b) protonated 2-aminopyridines 87 
Figure 4.5.  Supramolecular interactions in 2-aminopyridinium 4-aminobenzoate, 
14 89 
Figure 4.6. Crystal structure of  2-aminopyridinium 4-aminobenzoate,14. 1D 
hydrogen bonded chains are interconnected via a benzoate amine N–
H···O- interactions to form 2D corrugated supramolecular sheet 89 
Figure 4.7.  The angle between core planes parallel to the interactions OA···NA–
CA–NA···OA and OB···NB–CB–NB···OB 90 
 xiii
Figure 4.8. Hydrogen bonding interactions in 2-aminopyridinium isophthalate, 15 91 
Figure 4.9. Supramolecular interactions in bis(2-aminopyridinium) terephthalate, 
16 92 
Figure 4.10. Crystal structure of bis(2-aminopyridinium) terephthalate, 16 92 
Figure 4.11. Supramolecular adducts in 2-amino-5-methylpyridinium benzoate, 
17, are sustained via charge-assisted heterosynthons VII that form 1D 
chains 94 
Figure 4.12. Crystal structure of 2-amino-5-methylpyridinium benzoate, 17, 
viewed along the c axis (down the intercalating 1D chains which are 
colored green, red, blue and gray) 94 
Figure 4.13. Hydrogen bonding in bis(2-amino-5-methylpyridinium) 5-
tertbutylisophthalate, 18 96 
Figure 4.14. Crystal structure of bis(2-amino-5- methylpyridinium) terephthalate, 
19. 1D hydrogen bonded chains are cross-linked via N–H···O- 
interaction to form 2D sheets 97 
Figure 4.15. Crystal packing of bis(2-amino-5-methylpyridinium) 2,6-
napthalenedicarboxylate, 20 98 
Figure 4.16. Crystal structures of a) 2-amino-5-methylpyridinium adipate adipic 
acid, 21 100 
Figure 4.17. Crystal structure of 2-aminopyridinium adipate adipic acid dihydrate 100 
 
 
 xiv
Figure 4.18. Crystal structure of bis(2-amino-5-picolinium) 2,5-
thiophenedicarboxylate 2,5-thiophenedicarboxylic acid, 22: a) the 
supramolecular adduct reveals that the expected supramolecular 
heterosynthon VII is absent; b) a view of the chain that is generated 
by three 1-point supramolecular heterosynthons 102 
Figure 5.1. Co-crystal of barbital and N,N’-bis(4-bromophenyl)melamine, 
JICTUK10, sustained by 3-point recognition supramolecular 
heterosynthon 111 
Figure 5.2. Amide supramolecular homosynthon present the crystal structure of 
pure CBZ 112 
Figure 5.3. Carboxylic acid···amide supramolecular heterosynthon present in co-
crystals of a) CBZ•aspirin and b) piracetam•gentisic acid 113 
Figure 5.4. Carboxylic acid···pyridine supramolecular heterosynthon present in 
(ibuprofen)2•4,4’-bipyridine co-crystal 113 
Figure 5.5. Charge-assisted supramolecular heterosynthons are present in 
Prozac•succinic acid co-crystal 114 
Figure 5.6. (a) JATMEW, 3-[2-(N’,N’-dimethylhydrazino)-4-
thiazolylmethylthio]-N2-sulfamoylpropionamidine maleic acid. 
Structural parameters suggest formation of a salt, (b) SAGQEW – a 
propionic acid solvate of mebendazole 115 
Figure 5.7. Representation of the crystal packing of bicalutamide in a) form I and 
b) form II 118 
 xv
Figure 5.8. 2:2 supramolecular adducts formed between bicalutamide and 
4,4’bipyridyl in 23 120 
Figure 5.9. Histogram representing the N–H···Narom contact distribution in the 
crystal structures containing both N–H and Narom moieties 121 
Figure 5.10. Crystal  structure of bicalutamide•4,4’bipyridyl, 23 121 
Figure 5.11. 2:2 supramolecular adducts formed between bicalutamide and t-1,2-
bis(4-pyridyl)ethylene in 24 122 
Figure 5.12. Crystal structure of  bicalutamide•t-1,2-bis(4-pyridyl)ethylene, 24 123 
Figure 5.13. 5-member supramolecular aggregate formed between bicalutamide, 
t-1,2-bis(4-pyridyl)ethylene and acetone in 25 124 
Figure 5.14. Crystal structure of (bicalutamide)2• t-1,2-bis(4-
pyridyl)ethylene•(acetone)2, 25 124 
Figure 5.15. Representation of the crystal packing of bicalutamide in a) two 
triclinic forms and b) monoclinic form 126 
Figure 5.16. Methanol solvate of indomethacin, BANMUZ 127 
Figure 5.17. Supramolecular heterosynthon VII exhibited in 2-aminopyridinium 
indomethacin, 26 128 
Figure 5.18. Crystal structure of trimethoprim benzoate is sustained by the 2-
aminopyridine-carboxylate suparmolecular heterosynthon VII 129 
 
 
 
 
 xvi
 
 
 
 
 
List of Schemes 
 
 
 
 
Scheme 2.1. Co-crystal formers used in the investigation of the hierarchy of O–
H···Narom and O–H···N≡C supramolecular heterosynthons 26 
Scheme 2.2. Supramolecular synthons that can form when OH, N and CN are 
present in the same structure 27 
Scheme 4.1. Molecular structures of components present in complexes 14-22 82 
Scheme 4.2. Supramolecular heterosynthons that can be formed between 
carboxylic acids and 2-aminopyridines: 2-aminopyridine-carboxylic 
acid supramolecular heterosynthon VI and 2-aminopyridinium-
carboxylate supramolecular heterosynthon VII 83 
Scheme 5.1. Molecular structure of bicalutamide 117 
Scheme 5.2. Molecular structure of indomethacin 126 
 
 
 
 
 
 
 xvii
    
  
 
Crystal Engineering of Organic Compounds Including Pharmaceuticals 
Joanna Bis 
ABSTRACT 
 
 
 
Neutral or charge-assisted hydrogen bonds occurring between organic molecules 
represent strong and directional forces that mediate the molecular self-assembly into well 
defined supramolecular architectures. A proper understanding of hydrogen bonding 
interactions, their types, geometries, and occurrence in supramolecular motifs, is a 
prerequisite to crystal engineering, i.e. to the rational design of functional solid materials. 
Multiple-component organic crystals represent ideal systems to study the 
intermolecular interactions between the constituent molecules that can be pre-selected for 
their hydrogen bonding sites and geometrical capabilities. In particular, the systematic 
structural analysis of supramolecular systems that are comprised of simple molecules 
facilitates the development of strategies for the rational design of new multiple-
component compounds involving more complex components such as drug molecules.     
The work presented herein shows a combination of systematic database and 
experimental studies in the context of reliability and hierarchy of several hydrogen 
bonded supramolecular synthons that exist in a series of model co-crystals and organic 
salts. The acquired paradigms are ultimately utilized in crystal engineering of 
 xviii
pharmaceuticals. In addition, the viability of a mechanichemical approach toward 
supramolecular synthesis in the context of its efficacy and the effect on polymorphism in 
multiple-component compounds is also addressed.  
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Chapter 1 ─ Introduction 
 
1.1. Supramolecular Chemistry 
“Beyond molecular chemistry based on the covalent bond there lies the field of 
supramolecular chemistry, whose goal it is to gain control over the intermolecular bond” 
Jean-Marie Lehn 
 
 
1.1.1. Fundamentals 
Supramolecular chemistry,1-3 known also as chemistry beyond the molecule,4 is 
based on the underlying phenomena of mutual affinity and selective recognition of 
molecules interacting via a variety of non-covalent forces to form well organized 
assemblies. The origin of supramolecular chemistry can perhaps be traced back to the 
19th century, when the concepts of lock-and-key,5 “Corpora non agunt nisi fixata” 
(agents cannot act unless they are bound),6 and Übermolecüle (supermolecule)7 emerged. 
Much of this discipline has been delineated by 1960’s and 1970’s research involving 
host-guest systems8 for selective binding of small alkali metal cations by macrocyclic 
receptors, which encompassed mostly crown ethers9 and cryptands.10 The continued 
fascination of molecular recognition phenomena illustrated by Nature (the self-assembly 
of DNA, antigen-antibody recognition, protein folding, etc.), inspired chemists to further 
explore supramolecular systems in the context of weaker intermolecular interactions such 
as hydrogen bonds and π-π stacking.11-17 In particular, the manipulation of intermolecular 
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interactions, that leads to spontaneous, but controllable self-assembly of complementary 
moieties, has become one of the major interests in supramolecular design.   
The growing interest in the novel supramolecular approach can be considered as 
the manifestation of a conceptual change toward chemical synthesis.18 The emphasis on 
interaction, rather than reaction between molecules,19 has opened a great opportunity to 
generate a novel class of supramolecular structures, or supermolecules,20 with a wide 
range of complexity. Although supramolecular synthesis has not yet reached the level of 
sophistication represented by advanced organic syntheses (e.g. those of vitamin B1221 and 
taxol22), the influx of progress in this field has indicated its potential to generate 
recognition-directed assemblies in simple procedures and without the need of making or 
breaking covalent bonds.  
 
1.1.2.  Supramolecular Interactions and the Role of Hydrogen Bonds 
Generally, chemical bonds are considered to fall into two categories: short-range 
and long-range.23 While the short-range forces (e.g. covalent) are responsible for the 
formation of molecular systems, the long-range interactions, including dipole-dipole 
interactions, π-π stacking, and hydrogen bonds, are those that contribute to the 
association of molecules into supramolecular structures with defined stoichiometries. 
Thus, a thorough knowledge of the non-covalent bonds, their various types and their 
relative strengths is of crucial importance in the context of controlling supramolecular 
assemblies. A general comparison of selected chemical bond types is presented in Table 
1.1.  
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Table 1.1. Comparison of selected chemical bond types and their features  
 
Chemical Bonds Bond Energies (kJ/mol) 
Building 
blocks Products Features 
Covalent 200 - 400 Atoms Molecules 
ΔH > TΔS 
MW: 1 - 1000 Da 
Solvent effect: Secondary 
Hydrogen Bond 
 
Dipole-Dipole 
 
π-π stacking 
 
Van der Waals 
4 - 120 
 
5 - 50 
 
< 50 
 
< 5 
Molecules Supermolecules 
ΔH ≈ TΔS 
MW: 1 - 100 kDa 
Solvent effect: Primary 
 
“…I believe that as the methods of structural chemistry are further applied to 
physiological problems it will be found that the significance of the hydrogen bond for 
physiology is greater than that of any other single structural feature.” 
Linus Pauling  
 
In particular, hydrogen bonds24-26 are very important in the context of molecular 
recognition and, as anticipated at early stages by L. Pauling,27 they are responsible for 
numerous phenomena occurring in biological systems. Due to their strength and 
directionality, the role of hydrogen bonds in the formation of supramolecular assemblies 
has been studied with respect to molecular association in both solution and solid 
state.14,25,28-39 Specifically, the pre-determined formation of supramolecular species 
mediated via hydrogen bonds in the solid state, has become a foundation for generating 
novel materials with well defined structures and useful properties.   
 
1.2.  Crystal Engineering 
“Crystal engineering is the understanding of intermolecular interactions in the 
context of crystal packing and in the utilization of such understanding in the design of 
new solids with desired physical and chemical properties”   
Gautam Desiraju 
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1.2.1.  Fundamentals 
In an ultimate case of molecular recognition, molecules associate into a perfectly 
organized, single chemical entity held by periodic, three dimensional arrays of non-
covalent forces, thereby generating a crystal. As the formation of crystalline architectures 
involves a series of complex molecular recognition events that occur at a high level of 
precision, crystals have been described as the “supermolecules par excellence”.40 The 
idea of applying the principles delineated by supramolecular chemistry to solid state for 
the rational design of novel crystalline materials, has led to the development of the new 
field of crystal engineering.41-43 The term “crystal engineering” was originally introduced 
in 1955 by Pepinsky,44 who demonstrated that crystallization of organic ions with metal-
containing complexes results in structures with controllable cell dimensions and 
symmetries. Subsequently, from an important work of Schmidt45 related to the solid-state 
photodimerization, it became clear that a crystal can be thought as a self-assembly 
resulting from a series of molecular recognition events and that the physicochemical 
properties of a crystal depend upon the internal arrangement of the molecules in the 
crystal lattice. Now, as illustrated by Desiraju’s definition,41 crystal engineering has 
become synonymous with a broader discipline of “making crystals by design”42 toward 
the utilization of their specific properties. In particular, the area of organic compounds 
has witnessed a remarkable expansion in result of crystal engineered materials for 
specific applications, e.g.: non-linear optics (NLO),46 porous materials,47 photographic 
materials,48 and pharmaceuticals.49  
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Although the field of crystal engineering is indirectly related to the prediction of 
the ultimate crystal structure of the designed compound, it should be noted that there are 
fundamental differences between the two research areas.43 Crystal structure prediction 
(CSP) requires specification of molecular geometry and orientation, unit cell dimensions 
and the space group. In contrast, crystal engineering is much less restrictive in the 
perspective that it involves the design of crystals with well defined non-covalent 
connectivities and networks based upon pre-selected molecular components that possess 
specific moieties. 
 
“One of the continuing scandals in the physical sciences is that it remains in 
general impossible to predict the structure of even the simplest crystalline solids from a 
knowledge of their chemical composition”   
John Maddox  
 
 
A comprehensive prediction of the lowest energy crystal structure through 
computational methods50 still remains elusive,51-58 although the field is advancing 
rapidly.59-61 As highlighted by Maddox,62 the prediction of an unknown crystal structure 
in a complete fashion remains a formidable challenge, and supramolecular synthesis of 
crystals has alternatively been directed toward empirical approaches, based upon analysis 
of crystal packing modes present in selected sets of existing crystal structures. With the 
aid of extended databases, the broader anticipation of structural patterns resulting from 
molecular recognition has become an inherent practice in crystal engineering. In this 
respect, the suitability of hydrogen bonds to generate pre-determined motifs has already 
been mentioned. In particular, a solid knowledge of the hydrogen bonding capabilities 
and geometrical complementarities exhibited by specific moieties as well as a rational 
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selection of molecular building blocks can afford novel compounds with pre-defined 
composition and supramolecular architectures.   
 
1.2.2.  Hydrogen Bonded Supramolecular Synthons  
“Supramolecular synthons are structural units within supermolecules which can 
be formed and/or assembled by known or conceivable synthetic operations involving 
intermolecular interactions”  
Gautam Desiraju 
 
 
Given that the ultimate organization of molecules in a crystal, or crystal packing, 
results de facto from a series of molecular recognition phenomena, crystal engineering 
has naturally emerged around the idea of establishing, and later utilizing, intermolecular 
connectivities that are strong and directional enough to govern crystal packing with a 
reasonable degree of predictability. In this respect and based upon the analogy to covalent 
synthesis,63 the term supramolecular synthon64 has been introduced. Supramolecular 
synthons, also called motifs65 or patterns,66 can be regarded as regions within a crystal 
structure where the recognition between the constituent functional groups occurs, and this 
retrosynthetic approach67 helps to simplify the intrinsically difficult task of analyzing 
supramolecular architectures in the solid state.51,54 Considering that neutral and charge-
assisted68-74 hydrogen bonds have been recognized as the most important non-covalent 
interactions in solid state supramolecular chemistry,25,39 it is not surprising that the 
utilization of hydrogen bonded supramolecular synthons in crystal engineering of organic 
solids has become ubiquitous.41,75-79 Supramolecular synthons can be separated into two 
distinct categories: supramolecular homosynthons,80 that result from the interaction 
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between alike, self-complementary functional groups and supramolecular 
heterosynthons,80 composed of different but complementary functional groups. Examples 
of supramolecular homosynthons include the carboxylic acid81,82 and amide dimers,83 
whereas supramolecular heterosynthons include carboxylic acid···amide,84-87 
hydroxyl···pyridine,88-90 and carboxylic acid···pyridine.80,91-95 Examples of a 
supramolecular homosynthon and heterosynthon is presented in Figure 1.1. 
 
Figure 1.1. Examples of supramolecular synthons: carboxylic acid homosynthon (left) and 
carboxylic acid···pyridine heterosynthon (right)  
 
 
Supramolecular homosynthons tend to exist in structures of single-component 
compounds, although their existence has also been observed in several crystals comprised 
by, for example, two different carboxylic acids.96-98 On the other hand, if multiple 
functional groups are present, it is more likely that they would engage in supramolecular 
heterosynthons. Furthermore, if a preferential supramolecular heterosynthon can be 
formed between functional groups that are located on different molecules, a multi-
component compound would be generated. In this respect, a better understanding of the 
interplay between supramolecular synthons facilitated by the interpretation of existing 
crystal structures would help in the design of new multiple-component crystals. 
Specifically, the general trends observed in a series of relevant crystal structures, in terms 
of the prevalence of specific supramolecular synthons over others, would provide a 
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valuable insight for crystal engineering strategies toward the generation of new multiple-
component materials comprised of polyfunctional (therefore more complex) molecules.   
     
1.2.3. The Cambridge Structural Database 
“…studies of individual structures are of limited value: if an unexpected structural 
feature is observed, it may not be statistically significant and may well be ascribed to 
experimental errors or packing effects. (…) Thus, the systematic analysis of large 
numbers of related structures is a powerful research technique, capable of yielding results 
that could not be obtained by any other method.” 
Frank Allen, et al. 
 
 
The identification and analysis of specific supramolecular synthons existing in a 
large set of correlated crystal structures in order to assess their general organizational 
tendencies is now a prerequisite for crystal engineering. In this regard, investigating 
hundreds of thousands of crystal structures reported to date is currently facilitated by the 
Cambridge Structural Database, CSD.99 As a collection of X-ray and neutron diffraction 
data for over 350,000 organic and organometallic compounds (ConQuest V1.7, August 
2005), the CSD provides a great amount of statistically valuable information regarding 
the molecular and supramolecular structure of these compounds.100-103 In the context of 
the later, the quantitative (frequency of occurrence) and qualitative (geometrical 
attributes: distances, angles, etc.) analyses of intermolecular interactions allow for a 
comprehensive evaluation of the robustness of supramolecular synthons. In particular, 
earlier reports from Etter66,75,76 and Desiraju64,104 have concentrated on the investigation 
of hydrogen bonding patterns with the aid of the CSD and they have contributed to the 
proliferation of hydrogen bonded supramolecular synthons as design tools in crystal 
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engineering.    
  
1.3.  Hydrogen Bonded Organic Co-crystals  
“There is still plenty of room at the bottom” 
Richard Feyman 
 
 
The physicochemical properties of a crystalline material are inherently dependant 
upon the chemical nature of its constituents and the crystal packing. The properties of a 
compound can therefore be changed if the internal arrangement of molecules is altered.105 
An alternative to influence the crystal packing of a compound can be based on the 
manipulation of the non-covalent forces that hold the constituents together, by 
introduction of another, rationally pre-selected for its hydrogen bonding sites, 
component. In effect, a multi-component compound, or a co-crystal, results. The meaning 
of the term co-crystal is currently a subject of debate.106,107 A broad definition of a co-
crystal given by Dunitz: “a crystal containing two or more components together”107 
would include molecular adducts, salts, solvates/hydrates, inclusion compounds, etc. In a 
more specific perspective taken by others49,108 a co-crystal is perceived as a multiple 
component crystal formed between compounds that are solid under ambient conditions: 
at least one component is molecular and forms a supramolecular synthon with the 
remaining components. That all components of a co-crystal (co-crystal formers) are 
solids under ambient conditions has important implications with respect to the stability of 
a co-crystal and its susceptibility for preparation in the solid-state. 
In light of the above description, co-crystals have been encountered in the 
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literature for a long time under various terms, e.g. molecular compounds,109 organic 
molecular compounds,110 addition compounds,111 molecular complexes,112 solid-state 
complexes,113 or heteromolecular crystals.114 The first co-crystals appeared during the 
19th century. A prototypal example of co-crystallization is perhaps the synthesis of p-
benzoquinone and hydroquinone (quinhydrone), reported in 1844 by Wöhler, which was 
then followed by studies of halogen derivatives of quinhydrone.109,115 Structural 
information about quinhydrone (Figure 1.2), however, was not available until the 
1960’s.116,117 Inspired by the elucidation of DNA structure 118,119 through X-ray analysis, 
numerous nucleobase complexes were reported in the 1950’s and 60’s.120-123 The 
molecular recognition between methyl derivatives of adenine and thymine is presented in 
Figure 1.3.122  
 
Figure 1.2. Crystal structure of the triclinic form of quinhydrone   
 
 
Figure 1.3. The Hoogsteen base-pairing in the structure of 9-methyladenine 1-
methylthymine co-crystal 
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Figure 1.4. Distribution of hydrogen bonded co-crystal structures archived in the CSD 
between 1978-2004  
 
 
 
Although long known, co-crystals are not as widely studied as single-component 
crystals or solvates. There are ca. 1,487 hydrogen bonded molecular co-crystals which 
constitute only ca. 0.42 % of all structures archived in the CSD, as compared to 35,882 
hydrates (ca. 10%). However, based upon the increasing number of relevant literature, it 
is clear that the interest in co-crystals is growing, Figure 1.4. The salient feature of co-
crystals is that they can be designed from first principles. An appropriate knowledge of 
the supramolecular chemistry of the functional groups present in a given molecule can 
facilitate selection of an appropriate co-crystal fromer which will form supramolecular 
heterosynthon(s) with the target molecule.  
 In summary, co-crystals constitute a particularly attractive class of compounds 
that can be studied toward fundamental aspects such as: modification of 
physichochemical properties, understanding non-covalent interactions, viability toward 
green chemistry preparation, polymorphism, etc.  
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1.3.1.  Co-Crystals in the Context of Investigation of Supramolecular Heterosynthons 
The challenge of qualitative classification of hydrogen bonded motifs was 
addressed by Etter et al., based upon a graph-set system.75 In this approach, hydrogen 
bonded patterns can be described as chains (C), dimers (D), rings (R), or intramolecular 
hydrogen bonds (S). Each specific descriptor is then followed by the number of proton 
acceptors (superscript), number of proton donors (subscripts) and the number of atoms 
involved in a particular motif. For instance, R22(8) notation is used to describe an eight-
membered ring with two hydrogen bond acceptors and two hydrogen bond donors, and 
can be exemplified by carboxylic acid and amide homosynthons, or carboxylic 
acid···amide and carboxylic acid···pyridine heterosynthons. Graph-sets are useful to 
evaluate the frequency of a given hydrogen bonding pattern, however, they do not 
provide information related to the types of proton donors and proton acceptors engaged in 
the pattern. Therefore the frequency of supramolecular heterosynthons composed of 
specific hydrogen bond donors/acceptors could not be addressed via the graph-set 
systematization.  
As already mentioned, a thorough understanding of supramolecular 
heterosynthons is a prerequisite for developing crystal engineering of co-crystals. On the 
other hand, co-crystals represent ideal systems for systematic studies of non-covalent 
heterointeractions, as the majority of co-crystals is sustained by supramolecular 
heterosynthons rather than supramolecular homosynthons.124-127 Based on earlier studies 
of Robertson and Donohue,128 and from the work in the context of utilizing co-crystals to 
delineate hydrogen bonding preferences, Etter proposed several hydrogen bonding rules, 
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one of which states: “the best hydrogen-bond donor and the best hydrogen-bond acceptor 
will preferentially form hydrogen bonds to one another”.66,76  For instance, the studies 
based upon co-crystallizations of 2-aminopyrimidine (hydrogen bond acceptor) with two 
carboxylic acids of different strengths (hydrogen bond donors) revealed selective binding 
of the 2-aminopyrimidines to the stronger acid. These and related results were 
rationalized based upon the differences in pKa values of the interacting molecules.129-131 It 
should be noted, however, that there have been inconsistencies with the above rule, as 
exemplified by co-crystals, in which carboxylic acid moieties interact with the weaker, 
rather than the stronger sites of a basic co-crystal former.132 Such observations suggest 
that the differences in pKa may not reliably predict the interactions between the 
components in co-crystals. Considering that the pKa is a property of solution that is not 
defined in crystals, such relationships may not be simply transferred to the solid state.39 
In the context of systematization of different hydrogen bonded synthons, Aakeröy 
et al. presented systematic studies of the competition between three distinct hydrogen 
bonding moieties: primary amide, pyridine, and carboxylic acid. The study involved co-
crystals of iso-nicotinamide (4-pyridinecarboxamide) and a range of aromatic and 
aliphatic acids.91,133  The generated co-crystals revealed consistent hydrogen bonding 
patterns comprised of two robust supramolecular synthons: acid···pyridine heterosynthon 
and self-complementary amide homosynthon. The reproducibility of the hydrogen 
bonded motifs suggests a dominant tendency of the acid···pyridine heterosynthon over the 
acid···amide heterosynthon, that is formed in acid/amide-containing compounds in the 
absence of pyridines.81,84,134-137 Further examples based on these results include rational 
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design of ternary co-crystals of iso-nicotinamide with two different carboxylic acids.138  
Notwithstanding the valuable contribution of the presented work, delineation of 
the hierarchies of supramolecular heterosynthons that can occur within a variety of 
functional groups in a competitive environment represents a crystal engineering 
challenge. Furthermore, the utilization of the CSD to assess the prevalence of one 
supramolecular heterosynthon over another can be addressed only in a few instances, i.e. 
the most ubiquitous functional groups.139 Thus, the relative ranking involving numerous 
supramolecular hetrosynthons, such as hydroxyl···pyridine vs. hydroxyl···amine, 
hydroxyl···pyridine vs. hydroxyl···cyano, hydroxyl···amine vs. hydroxyl-cyano, etc. still 
remains an issue that needs to be addressed experimentally.140 
   
1.3.2.  Co-Crystals in the Context of Green Chemistry  
 The advantage of obtaining well defined single crystals of a synthesized product 
is inherently related to the possibility of direct determination of its crystal structure. 
Additional benefits linked to the speed and accuracy of single crystal X-ray diffraction 
instrumentation have directed supramolecular synthesis of crystalline materials toward 
solution-based methods, e.g. slow evaporation, heating/cooling, addition of anti-solvent 
(solvent in which the components are not or sparingly soluble), etc. However, other 
aspects associated with solution co-crystallization, namely, mismatched solubility of the 
reactants, the possibility of unexpected solvate formation, or uncontrollable effects of 
solvents on polymorphic behaviors, could represent significant challenges for a crystal 
engineer. With this viewpoint, using less conventional methods of co-crystallization141 
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such as growth from the melt or grinding the co-crystal formers not only overcomes 
aforementioned problems, but also can be of interest from the perspectives of green 
chemistry,142 which seeks to reduce and prevent pollution via implementation of 
environment-friendly chemical processes. In particular, the mechanochemical143 
approach to supramolecular reactions, represented by grinding of two or more solids 
entirely eliminates some of the aspects accompanied with solution crystallizations, e.g. 
the recovery, storage and disposal of organic solvents. 
 Whereas grinding has been a commonplace in the context of classic covalent 
synthesis,144,145 its utilization with respect to co-crystallization has not been as common. 
Even though grinding by mortar and pestle to induce co-crystal formation has been 
known since late 19th century,109 it was implemented nearly one century later by Etter, in 
the research originally directed toward the understanding of preference of hydrogen 
bonds, and their role in the structures of a variety of organic co-crystals that involved 
nucleobases and acentric organic molecules.95,146-150 Recent advances in the area have 
introduced a novel grinding technique, termed “solvent-drop grinding”.151 The addition 
of small amounts of solvent to a grinding procedure in order to accelerate the reaction has 
been found to be a method especially effective for the preparation of multiple-component 
compounds, such us inclusion compounds, salts and co-crystals.152-154     
 Although, the recent reports illustrate that the grinding approach is a viable means 
of preparing hydrogen bonded co-crystals, mehcanochemical techniques have not been 
routinely used on the academic level of research, and their further exploration in the 
context of co-crystal reproducibility, stability, and polymorphism still remains to be 
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addressed.  
 
1.3.3. Co-Crystals in the Context of Polymorphism 
 “A polymorph is a solid crystalline phase of a given compound resulting from the 
possibility of at least two different arrangements of the molecules of that compound in 
the solid state”  
Walter C. McCrone 
 
 
Polymorphism,155-158 a phenomenon recognized in 1822,159 can be described as 
the existence of a substance in more than one crystalline form. The inability to reliably 
predict the existence of polymorphs or, for that matter, crystal structures in general, has 
important intellectual property and scientific implications.156,160 For example, the 
appearance of an undesired polymorph can invoke problems during the formulation 
process of a commercial compound and lead to patent litigations.156 On the other hand, a 
novel polymorph can offer an opportunity in terms of better physicochemical 
performance and new product development. Furthermore, since physicochemical 
properties of a compound can differ critically from one form to another, inducing and 
controlling a specific polymorph is of utmost importance in the chemistry of 
pharmaceuticals,156,161 explosives,162,163 pigments,164,165 etc.  
Although the awareness among chemists of polymorphism increases, the 
frequency of occurrence of polymorphic compounds is not entirely obvious. The 
generality of McCrone’s statement that the “number of forms known for a given 
compound is proportional to the time and money spent in research on that compound” 
remains unclear, despite the indications that the frequency of polymorphism represented 
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by the CSD may be underestimated.56,166 As suggested by Desiraju,167 polymorphism 
may not be equally apparent in different categories of compounds, and it tends to be 
prominent in molecules that contain multiple hydrogen bonding moieties (thereby 
forming multiple supramolecular synthons), and/or possess conformational 
flexibility.18,168 Considering that these two features are inherently exhibited by drug 
molecules, polymorphism, as well as solvate formation (pseudopolymorphism),169,170 in 
pharmaceuticals is well documented.61,161,171-173 Specific examples of the existence of 
polymorphism in popular compounds include, for instance, ROY,174,175 aspirin,61 
piracetam,176,177 and virazole.178 
Conformational flexibility of molecules can also lead to conformational 
isomorphism,156,168,179,180 where more than one molecular conformer exists in the same 
crystal structure. In addition, simultaneous crystallization of polymorphs, known as 
concomitant polymorphism, can occur under certain conditions.181 
Despite the fact that most of the polymorphs have been observed in single-
component compounds, co-crystals also exhibit polymorphism.182,183 A CSD survey 
reveals ca. 94,900 single-component organic compounds, of which ca. 1,600 are 
polymorphic.184 On the other hand, there are only ca. 1,487 hydrogen bonded molecular 
co-crystals (comprised of components that are solid at room temperature), of which 21 
are polymorphic; yet only 11 have 3D coordinates determined for two or more forms.185  
The percentage occurrences of polymorphism in single-component compounds and co-
crystals suggest that its extent is comparable (1.7 % vs. 1.5%).  
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Table 1.2. The occurrence of polymorphism in organic compounds. Data adapted from 
Zaworotko M. et al, J. Pharm. Sci., 2006 
 
Category Total Polymorphic compounds 
Single-component compounds 94,900 1600 (1.7 %) 
Co-crystals 1,487 21 (1.4 %) 
 
Interestingly, a comparative structural study of co-crystal polymorphs (albeit 
based upon limited data), revealed that the supramolecular synthons exhibited in all cases 
are persistent and polymorphism is related to rather subtle conformational or crystal 
packing variations.182,183  
In general, the existence of polymorphism is not yet entirely understood, however, 
there have been advances in controlling this phenomenon. Specifically, recent literature 
revealed that the utilization of solvent-drop grinding approach can be an efficient way to 
achieve selective transformations between specific polymorphs in both single-component 
compounds and co-crystals.186-188    
 
1.3.4. Co-Crystals in the Context of Pharmaceuticals  
The idea of utilizing co-crystals to modify physicochemical properties of 
compounds has attracted considerable attention with respect to pharmaceuticals. The 
majority of active pharmaceutical ingredients (APIs) occur as solids and their crystalline 
forms are highly preferred over the amorphous forms, due to the physicochemical 
stability considerations.171 Although amorphous APIs often exhibit enhanced solubility in 
aqueous systems, they are thermodynamically unstable and tend to revert into more stable 
crystalline products. The rejection of impurities and the ease of the isolation of single 
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crystals are additional benefits associated with dealing with crystalline materials. The 
problems with the utilization of crystalline APIs are related to their poor solubility which 
in turn negatively affects the bioavailability of an API. Therefore the development of 
crystalline forms of API that exhibit optimized physicochemical performance is of utmost 
importance in the field of pharmaceuticals.    
 
Table 1.3. Occurrence of hydrogen bonding moieties in APIs 
 
Functional  
Group 
 
 
Top 100 
Prescription 
Drugs 
% 
Alcohol 39 
3º amine 37 
Carbonyl 35 
Ether 33 
2° amine 31 
Carboxylic acid 30 
Ester 22 
Aromatic N 12 
2° amide 11 
Sulfonamide 3 
 
The inherent nature exhibited by APIs, namely their hydrogen bonding sites amenable 
to engage in supramolecular heterosynthons, constitutes a particularly suitable system for 
crystal engineering studies. Indeed, the 100-top selling prescription drugs contain 
hydrogen bond donors and acceptors, e.g. hydroxyl (39%) and carboxylic acid (30%) 
moieties, Table 1.3.189 In this respect, the interest in developing new forms of APIs 
resulted in the emergence of a new class of APIs, pharmaceutical co-crystals. A 
pharmaceutical co-crystal can described as “a multiple component crystal in which at 
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least one component is molecular and a solid at room temperature (the co-crystal 
former) and forms a supramolecular synthon with a molecular or ionic API”.49,190  
Crystalline APIs have traditionally been limited to solvates/hydrates, polymorphs, 
and salts.171 Solvates/hydrates are usually discovered as a result of adventitious uptake of 
solvent/water upon crystallization and, like polymorphs, they are difficult to be rationally 
designed. Additional complications of the usage of API solvates/hydrates may be related 
to the possibility of desolvation/dehydration, followed by formation of amorphous 
material, which may occur as a function of time and storage conditions. In this respect, 
co-crystals are less likely to exhibit such behavior as their components are solids. Salt 
forms of APIs are commonplace and their role in the optimization of API properties, 
including  solubility, has been established.191-194 Nevertheless, it is important to note, that 
salt formation is targeted in the case of drugs possessing ionizable (basic or acidic) 
moieties. In contrast, co-crystallization of APIs can be expanded over molecules that 
possess a broader range of hydrogen bonding moieties. Thus, API co-crystals exhibit 
advantages over API solvates/hydrates, polymorphs, and salts in the way that based upon 
rational design it is possible to generate diverse range of API forms with optimized 
physicochemical properties, e.g. solubility, thermal stability, and hygroscopicity, without 
the need of covalent modification and without altering their original biological activity.     
Co-crystals of several important APIs have been reported in the scientific and 
patent literature, and they include: carbamazepine (CBZ), aspirin, profens, piracetam, 
caffeine, loracarbef, cephalexin, cefaclor, conazoles, topiramate, modafinil, phenytoin, 
olanzapine, nabumetone, fluoxetine, theophylline, sulfadimidine, trimethroprim, and 
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paracetamol.61,80,86,132,154,186,195-208 Detailed investigations of physicochemical 
performance of some of the reported APIs showed that their co-crystallization is 
inherently related to the modification of the physical properties, such us solubility, 
dissolution rate, thermal stability, etc. For instance, the dissolution studies in aqueous 
medium of co-crystals of itraconazole (Sporanox) and dicarboxylic acids, e.g. 
itraconazole•succinic acid (Figure 1.5), indicate that the co-crystals achieve and sustain 
from 4 to 20-fold higher concentrations as compared to the highly insoluble pure 
itraconazole.132 
 
Figure 1.5. Itraconazole•succinic acid co-crystal 
 
Another example, carbamazepine (Tegretol®) co-crystal with saccharin, Figure 
1.6, in addition to its enhanced solubility, was found to be resistant to undesired hydrate 
formation and has not exhibited polymorphism based upon 1200 high-throughput 
(HT)209,210 screening experiments.211  
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Figure 1.6. Carbamazepine•saccharin co-crystal 
 
 
 
In summary, the application of the concepts of supramolecular chemistry and 
crystal engineering to the development of pharmaceuticals offers an opportunity towards 
the generation of novel API forms. Specifically, the alteration of the physical properties 
of the solid dosage form with simultaneous retention of the therapeutic attributes of an 
API represents an attractive approach to balance the bioavailability, stability and other 
performance characteristics.  
       
1.4.  Summary  
The presented work will focus on applying the concepts of crystal engineering to 
the design and generation of novel multi-component compounds with pre-determined 
composition and intermolecular interactions. Particular emphasis will be placed upon co-
crystals and their further exploration toward the following aspects:  
• Delineation of the reliability of hydrogen bonded supramolecular 
heterosynthons and their hierarchies in a competitive enviroment. Advances in 
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understanding the mechanisms that govern molecular recognition in the 
crystalline state will lead to insights toward rational design of co-crystals of more 
complex molecules. In addition, the investigation of neutral and charge-assisted 
supramolecular heterosynthons (co-crystal vs. salt) will be addressed.    
•  Viability of mechanochemical methods toward preparation of multiple-
component compounds (organic salts and co-crystals). Reduction or entire 
elimination of organic solvents from the experimental co-crystallization 
procedures can be advantageous from the perspectives of green chemistry 
principles, as well as from the viewpoint of reproducibility of the products 
obtained from solution crystallizations. 
• Polymorphism in co-crystals. The susceptibility of co-crystals toward 
polymorphism or solvate formation will be addressed based upon traditional 
solution techniques and innovative solvent-drop grinding screening methods.  
• Pharmaceutical co-crystals. Rational co-crystallization of API molecules, 
which represent more complex systems due to their multiple hydrogen bondong 
sites, with judiciously selected co-crystals formers will be demonstrated as a 
result of the acquired knowledge from the preceding model compound 
investigations. 
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Chapter 2 ─ Recurrence of hydroxyl···aromatic nitrogen supramolecular 
heterosynthon in the presence of a competing cyano acceptor 
 
2.1. Focus 
As already mentioned, the CSD contains enough information to evaluate 
competitiveness of some supramolecular homosynthons vs. supramolecular 
heterosynthons.65,137,212 However, the prevalence of one supramolecular heterosynthon 
over another can be addressed only in a few instances, i.e. the most ubiquitous functional 
groups.139,140 Therefore, assessing the hierarchies that exist within a given set of 
supramolecular heterosynthons still represents a challenge and complicates crystal 
engineering of compounds that possess multiple functionalities. 
In an effort to explore pharmaceutical co-crystals, studies on model co-crystals 
that contain hydroxyl (OH), aromatic nitrogen (Narom), and cyano (CN) moieties have 
been conducted. A combination of such functionalities is present in a range of vitamins 
and API’s, e.g. vitamin B1, cimetidine, bicalutamide, etc. An analysis of the crystal 
structures of the model co-crystals is expected to facilitate the delineation of hierarchies 
between hydroxyl···aromatic nitrogen (O–H···Narom) and hydroxyl···cyano (O–H···N≡C) 
supramolecular heterosynthons.  
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2.2.  Results and Discussion 
The co-crystallization experiments involved co-crystal formers that possess the 
OH, Narom, and/or CN moieties, and these functional groups: (a) are sterically accessible, 
(b) are not involved in intramolecular interactions, and c) are not accompanied by other 
competing hydrogen bond donors and acceptors. In an individual experiment two co-
crystal formers were combined. Within a pair, one co-crystal former possessed two of the 
three moieties (e.g. Narom/CN) and the second co-crystal former possessed the remaining 
moiety (e.g. OH). According to this strategy, the individual pairs of co-crystal formers 
are combined as follows: Narom/CN with OH, OH/CN with Narom, and OH/Narom with CN. 
Such an approach to delineate the hierarchies of two supramolecular heterosynthons 
relies on the idea that a co-crystal can result only if the favored supramolecular 
heterosynthon is formed between the co-crystal formers. Conversely, a co-crystal is not 
expected to be formed if a dominant supramolecular heterosynthon already exists in one 
of the pure components. The formation of a co-crystal is determined by multiple 
techniques: melting point measurements, DSC, IR spectroscopy, powder X-ray 
diffraction (PXRD), and single crystal X-ray diffraction. The crystal structures of all 
obtained co-crystals were analyzed in the context of the existence of specific 
supramolecular heterosynthons.  
Small organic molecules that contain OH, Narom, and CN moieties used in this 
study are shown on Scheme 2.1. Co-crystallizations of these chemicals afforded the 
following co-crystals: 3-cyanophenol•4-phenylpyridine, 1; (3-cyanophenol)2•1,2-bis(4-
pyridyl)ethane, 2; (3-cyanophenol)2•trans-1,2-bis(4-pyridyl)ethylene, 3; 3-
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cyanophenol•trans-1,2-bis(4-pyridyl)ethylene, 4; 4-cyanophenol•4-phenylpyridine, 5; (4-
cyanophenol)2•4,4’-bipyridine, 6; (4-cyanophenol)2•1,2-bis(4-pyridyl)ethane, 7; (4-
cyanophenol)2•trans-1,2-bis(4-pyridyl)ethylene, 8; (3-cyanopyridine)2•4,4’-biphenol, 9; 
(4-cyanopyridine)2•resorcinol, 10; (4-cyanopyridine)2•4,4’-biphenol, 11; and (4-
cyanopyridine)3•phloroglucinol, 12. 
OH OH
OH
CN
OH CN
N
N
N
NN N
N
CN
NNC
N
OHOH
OHOH
OH
N
OH OH
N
OH
OH
CN
CN
NC CN
CN
     4-Phenylpyridine                         4,4'-Bipyridine               1,2-Bis(4-dipyridyl)ethane            Trans-1,2-bis(4-dipyridyl)ethylene
          (phenpy)                                      (bipy)                               (bipyeta)                                          (bipyete)
           1-Hexadecanol                     1-Naphthol                4,4'-Biphenol            1,3-Dihydroxybenzene     1,3,5-Trihydroxybenzene
                (hexdec)                           (naphth)                       (bphe)                                (res)                          (phlgl)
   3-Cyanophenol     4-Cyanophenol      3-Cyanopyridine       4-Cyanopyridine       3-Hydroxypyridine        5-Hydroxyisoquinoline
       (3cyph)                 (4cyph)                  (3cypy)                     (4cypy)                    (3hypy)                      (5hyquin)
1-Cyanonaphthalene (cynaphth)            1,3-Dicyanobenzene (o-cyben)              1,4-Dicyanobenzene (p-cyben)
 
 
Scheme 2.1. Co-crystal formers used in the investigation of the hierarchy of O–H···Narom and O–
H···N≡C supramolecular heterosynthons 
 
2.2.1. CSD Analysis  
There are three possible supramolecular synthons that can be formed when OH, 
Narom, and CN moieties are present in the same crystal structure: a hydroxyl···pyridine 
supramolecular heterosynthon I, a hydroxyl···cyano supramolecular heterosynthon II, and 
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a hydroxyl supramolecular homosynthon III (Scheme 2.2).  
N
R
O H N RO H
R
O H
R
O H
R
I     II                                III  
Scheme 2.2. Supramolecular synthons that can form when OH, N and CN are present in the same 
structure 
 
A CSD survey of compounds that contain OH, Narom, and CN moieties was 
conducted to evaluate the frequency of occurrence of supramolecular synthons I, II and 
III.213 In order to determine appropriate distance ranges, within which I, II and III exist, 
distance distribution plots were generated, Figure 2.1.214 Based on visual inspection of 
the resulting histograms, the lower and higher cut offs for hydrogen bonds were 
determined. The histograms reveal that the supramolecular heterosynthon I and II occur 
within the ranges of 2.50 - 3.00 Å and 2.70 - 3.20 Å, respectively, whereas 
supramolecular homosynthon III exhibits range of 2.50 – 3.00 Å.215 Based upon these 
limits the number of entries that exhibit the targeted supramolecular synthons was 
determined, Table 2.1. It should be noted that the frequencies of occurrence of 
supramolecular synthons can be influenced by the presence of other hydrogen bond 
donors and acceptors, therefore the competing moieties, such us carboxylic acids, amines, 
amides, sulfonamides, carbonyls, water, chloride and bromide ions, etc. were removed 
from the analyzed sets of structures. 
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Table 2.1.  CSD statistics related to supramolecular synthons that occur in structures 
containing only OH, Narom, and CN 
 
Moieties present in a 
structure 
No. of 
structures 
Supramolecular 
synthon 
Structures 
with synthon 
D···A 
[Å] 
Mean (σ) 
[Å] 
OH and Narom 136 
O–H···Narom 
O–H···O 
135 (99%) 
37 (27%) 
2.50-3.00 
2.50-3.00 
2.77(8) 
2.78(8) 
OH and CN 61 O–H···N≡C O–H···O 
56 (92%) 
18 (29%) 
2.70-3.20 
2.50-3.00 
2.9(1) 
2.78(8) 
OH, Narom and CN 3 
O–H···Narom 
O–H···N≡C 
O–H···O  
3 
0 
0 
- 
- 
- 
- 
- 
- 
         
 
Supramolecular heterosynthon I is well established in crystal engineering.88,89,216 
The CSD analysis reveals that in the structures containing only OH and Narom I exists in 
135 of 136 crystal structures. Therefore I is favored over III as its occurrence reaches ca. 
99 % vs. 27% of the occurrence of III.217 On the other hand, of 61 crystal structures that 
contain only OH and CN, 56 (92%) entries exhibited supramolecular heterosynthon II, 
whereas 18 (29%) structures exhibited III, which indicates the dominance of 
heterosynthon II over homosynthon III, as shown in Table 2.1. It should be noted, that 
13 structures contained both II and III, due to the presence of multiple OH moieties. 
However, the number of crystal structures archived in the CSD that possess all three OH 
and Narom and CN moieties (competing moieties are absent) resulted in only 3 entries, 
thereby precluding a meaningful statistical evaluation.218 Thus, the competition between I 
and II could only be assessed based upon experimental results. Herein, a series of co-
crystals that can help to evaluate the relative hierarchy of I and II is presented.   
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Figure 2.1. Histograms of contacts for supramolecular synthons: a) O–H···Narom in I; b) O–
H···N≡C in II; and c) O–H···O in III 
 
 
 
2.2.2.  Structural Features of Neutral and Ionic Hydroxyl···Aromatic Nitrogen Interaction  
Phenols and pyridines can form neutral co-crystals or organic salts.219 The neutral 
nature of heterosynthon I was confirmed by spectroscopy, proton location in the 
difference Fourier map, and structural parameters of ancillary groups, namely the C–N–C 
angle in the pyridine moieties and C–O bond lengths in the phenolic moieties.220,221 The 
C–N–C angle in pyridines is known to be sensitive to protonation and its cationic form 
exhibits higher values (ca. 121°) than that of the corresponding neutral molecules (ca. 
116°).222,223 The histograms representing carbon-oxygen bond lengths distribution in 
neutral and ionic phenolic moieties were generated using the CSD and are shown in 
Figure 2.2 (only good quality crystal structures: ordered, error free, nonpolymeric with 
  30
3D coordinates determined and R<5%, were chosen for the analysis). The CSD analysis 
of 2588 crystal structures that contain neutral phenolic moieties reveals that the average 
C–OH bond length is 1.36(2) Å. There are 260 crystal structures that contain 
deprotonated phenolic moieties. The calculated average for ionic C–O- bond length in 
such structures is 1.28(3) Å.224   
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Figure 2.2. Histograms representing the distribution of carbon-oxygen bond lengths in a) 
neutral phenolic moieties and b) deprotonated phenolic moieties 
 
 
2.2.3. Crystal Structure Descriptions  
 The crystal structure of 3-cyanophenol•4-phenylpyridine, 1, reveals discrete 1:1 
supramolecular adducts sustained by O–H···Narom supramolecular heterosynthon I, also 
coded as D graph-set.75 In addition to IR spectroscopic evidence, the neutral nature of I is 
supported by structural data: the C–O distance is 1.363(6) Å and the C–N–C angle within 
the pyridine ring is 115.6(2)°.  The O–H···Narom hydrogen bond distance (D: 2.708(3) Å) 
is within the expected range for hydroxyl···pyridine interactions (Table 2.1). In this 
structure the phenpy is twisted, with a torsion angle of 24.6° between the aromatic rings. 
The dihedral angle formed by the 3cyphe and phenpy rings is 79.7°. The glide related 
supramolecular adducts are stabilized via π- π stacking occurring between the adjacent 
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phenpy molecules with an interplanar separation of ca. 3.79 Å. Such organization of 
molecules results in a columnar arrangement of the supramolecular adducts along the c 
axis. The adjacent columns are related by translation along the b axis and are connected 
via weak C–H···N≡C interactions, which results in 2D molecular sheets (Figure 2.3).   
 
Figure 2.3. Crystal structure of 3-cyanophenol•4-phenylpyridine, 1 
 
The crystal structure of (3-cyanophenol)2•1,2-bis-(4-pyridyl)ethane, 2, reveals 
centrosymmetric 2:1 adducts sustained by two supramolecular heterosynthons I (D: 
2.691(2) Å). The C–O distance is 1.352(2) Å and the C–N–C angle within the pyridine 
ring is 116.6(2)°, indicating a neutral O–H···Narom hydrogen bond. The dihedral angle 
formed by 3cyphe and the bipyeta rings is 132.5°. The adjacent adducts interact via 
weak C–H···N≡C forces forming 1D zigzag chains. Translation related chains are 
connected via weak C–H···N≡C interaction along the b axis, thereby forming 2D 
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molecular sheets (Figure 2.4).  
 
Figure 2.4. Crystal structure of (3-cyanophenol)2•1,2-bis-(4-pyridyl)ethane, 2 
 
The asymmetric unit of (3-cyanophenol)2•trans-1,2-bis-(4-pyridyl)ethylene, 3, 
consists of two 3cyphe molecules and one bipyete molecule. The components form non-
centrosymmetric supramolecular adducts sustained by two supramolecular 
heterosynthons I (D1: 2.727(2) Å, D2: 2.730(2) Å). The C–O distances are 1.351(2) Å and 
1.357(2) Å and the C–N–C angles within the two bipyete rings are 116.2(2)° and 
116.1(2)°, respectively. The dihedral angles between the 3cyphe and the bipyete rings 
are 145.4° and 66.9°. The adjacent supramolecular adducts are stabilized by face-to-face 
stacking occurring between the aromatic moieties of 3cyphe and bipyete molecules. 
Such molecular assembly affords a columnar alignment of the adducts along the b axis. 
The molecular columns are further interconnected by weak C–H···N≡C interactions, 
thereby forming 2D sheets (Figure 2.5).   
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Figure 2.5. Crystal structure of (3-cyanophenol)2•t-1,2-bis-(4-pyridyl)ethylene, 3 
 
3-cyanophenol•trans-1,2-bis-(4-pyridyl)ethylene co-crystal 4 consists of 1:1 
discrete supramolecular adducts sustained by I (D: 2.663(3) Å). The C–O distance is 
1.361(3) Å and the C–N–C angle of the hydrogen bonded bipyete pyridyl ring is 
116.2(3)°. The dihedral angle between the 3cyphe and the bipyete ring is 98.8°. The 
inversion related dimers are stabilized by π-π stacking along b axis. The stacking occurs 
between parallel oriented bipyete molecules with the interplanar separation of ca. 3.44 Å. 
The presence of the weak C–H···N≡C interaction between the adjacent 3cyphe molecules 
leads to the formation of centrosymmetric pairs of the supramolecular adducts, which in 
turn directs  the molecular assembly into 2D layers (Figure 2.6). It should be noted that 
the alignment of the two bipyete in 4,  satisfies the topochemical principle for [2+2] 
photodimerization in the solid state, which states that the olefins should be parallel and 
separated by less than 4.2 Å.45 In this context, successful covalent synthesis of new cyclic 
molecules in high yields and in a solvent-free manner225 based upon bipyete and 
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resorcinol co-crystals has been recently demonstrated.89,226   
Furthermore, it should be pointed out that the 1:1 stoichiometry of the 
components in 4 is somewhat unexpected, considering that the ratio of hydrogen bond 
acceptor : donor (in this case Narom : OH) between the two components is 2:1. While the 
O–H moieties of 3cyphe are utilized in a strong O–H···Narom hydrogen bond, only one of 
the two Narom sites of bipyete acts as an O–H···Narom acceptor. The remaining Narom 
moiety participates in a weak C–H···Narom interaction227-230 with the neighboring 3cyphe 
molecules. In effect, the adjacent bipyete molecules are aligned on top of each other and 
stabilized via continuous π-π stacking.  
A literature search reveals that similar molecular arrangements are exhibited in 
several co-crystals of phenazines.231,232 For instance, the crystal structure of 
phenazine•hydroquinone, (CSD refcode FOQHEY),231 Figure 2.7, is reminiscent of the 
crystal structure of 4 with respect to the unexpected 2:1 stoichiometry of the components 
interacting via a similar set of intermolecular interactions. These observations suggest a 
significant contribution of C–H···Narom and aromatic stacking to the overall crystal 
packing of the presented co-crystals. In particular, the existence of non-bonded Narom is 
not uncommon, as revealed by the CSD survey. In the set of 135 crystal structures 
comprised only by OH and Narom moieties (Table 2.1) there are 19 entries (14%) that 
exhibit non-bonded weak C–H···Narom interactions, in addition to the primary 
supramolecular heterosynthon I. 
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Figure 2.6. Crystal structure of 3-cyanophenol•t-1,2-bis-(4-pyridyl)ethylene, 4 
 
 
Figure 2.7. Crystal structure of phenazine•hydroquinone, FOQHEY 
 
 
Similarly to 1, co-crystal of 4-cyanophenol•4-phenylpyridine, 5, is comprised of 
1:1 discrete supramolecular entities sustained via I (D: 2.695(4) Å). The C–O distance is 
1.345(3) Å and the C–N–C angle within the phenpy rings is 116.9(3)° and the dihedral 
angle between the 4cyphe and the phenpy rings is 108.8°. In this crystal structure the 
phenpy is twisted, and the torsion angle is 33.6°, which is similar to phenpy in 1 (24.6°). 
The glide related supramolecular adducts are stabilized via π- π stacking (ca. 3.74 Å) 
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occurring between the phenpy molecules along the b axis. The adjacent columns of the 
1:1 adducts are connected by centrosymmetric C–H···N≡C dimers thereby generating 2D 
sheets (Figure 2.8). 
 
Figure 2.8. Crystal structure of 4-cyanophenol•4-phenylpyridine, 5 
 
 
 
The crystal structure of (4-cyanophenol)2•4,4’-bipyridine, 6, reveals 2:1 
centrosymmetric supramolecular adduct sustained by I (D: 2.718(3) Å). The C–O 
distance is 1.346(3) Å and the C–N–C angle is 116.3(3)°. The dihedral angle between the 
4cyphe and the pyridine ring is 30.1°. The bipy molecules are flat and stack on top of 
each other along the a axis with an interplanar separation of ca. 3.59 Å. The packing of 
supramolecular adducts is further extended into 2D through centrosymmetric C–H···N≡C 
dimer formed between the neighboring 4cyphe molecules (Figure 2.9).  
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Figure 2.9. Crystal structure of (4-cyanophenol)2•4,4’-bipyridine, 6 
 
 
 
In the crystal structure of (4-cyanophenol)2•1,2-bis-(4-pyridyl)ethane, 7, the 2:1 
supramolecular aggregates are sustained by supramolecular heterosynthons I (D: 2.698(4) 
Å), Figure 2.10. The C–O distance is 1.359(4) Å and the C–N–C angle is 117.2(3)°. The 
dihedral angle between the 4cyphe and the bipyeta ring is ca. 66.8°. The adducts interact 
via C–H···O dimer along the c axis, thereby forming 1D chains. These chains are then 
interconnected via weak C–H···N≡C thus generating 2D molecular sheets.   
 
Figure 2.10. Crystal structures of (4-cyanophenol)2•1,2-bis-(4-pyridyl)ethane, 7 
 
The crystal structure of (4-cyanophenol)2•trans-1,2-bis-(4-pyridyl)ethylene, 8, 
is reminiscent of that in co-crystal 6. It is comprised by 2:1 centrosymmetric 
supramolecular adducts sustained by I (D: 2.714(4) Å vs. 2.718(3) Å in 6). The C–O 
distance is 1.349(3) Å and the C–N–C angle of the bipyete ring is 114.8(3)°. The 
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dihedral angle between the 4cyphe and the bipyete rings is 142.6° (vs. 30.1° in 6). The 
supramolecular adducts are stabilized by π- π interactions occurring between the bipyete 
molecules (ca. 3.66 Å) along b axis and they further extended into 2D through a 
centrosymmetric C–H···N≡C dimer formed between the neighboring 4cyphe molecules 
(Figure 2.11). Although the primary (stacked 2:1 adducts) and secondary (2D network 
resulting from the presence of the C–H···N≡C dimers) architectures of 6 and 8 are similar, 
the two crystal structures differ in the relative orientations of the 2:1 adducts down the a 
and b axes for 6 and 8 respectively. In 6, the 2:1 adducts are packed side by side, and 
generate planar layers, Figure 2.12a. In 8 the adjacent adducts, rather than adopting co-
planar orientation, are aligned at ca. 40° with respect to each other, Figure 2.12b.   
 
Figure 2.11. Crystal structure of (4-cyanophenol)2•t-1,2-bis-(4-pyridyl)ethylene, 8 
 
 
 
a) b) 
 
Figure 2.12. Representation of the relative orientation of the adjacent 2:1 adducts: a) down 
the a axis in 6, and b) down the b axis in 8  
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In the crystal structure of (3-cyanopyridine)2•4,4’-biphenol, 9, a 2:1 
centrosymmetric supramolecular aggregate exists that is sustained by two supramolecular 
heterosynthons I (D: 2.765(3) Å). The C–O distance is 1.381(3) Å and the C–N–C angle 
of the hydrogen bonded 3cypy ring is 117.79(2)° suggesting the neutral nature of the O–
H···Narom hydrogen bond. The dihedral angle between the flat bphe and the 3cypy rings is 
54.1°. The adducts assemble further through C–H···N≡C dimer into 2D molecular sheets 
(Figure 2.13).  
 
Figure 2.13. Crystal structure of (3-cyanopyridine)2•4,4’-biphenol, 9 
 
The components of (4-cyanopyridine)2•resorcinol co-crystal, 10, assemble to 
form 2:1 discrete adducts sustained by I (D1: 2.856(2) Å, D2: 2.763(2) Å).  The C–O 
distances in a res molecule are 1.361(2) Å and 1.360(2) Å and the C–N–C angles of the 
hydrogen bonded 4cypy rings are 117.1(1)° and 117.2(1)°, respectively. The dihedral 
angle between the res and the 4cypy rings are 68.6° and 75.1°. The hydroxyl moieties of 
res molecules adopt a convergent orientation and interact with two 4cypy molecules (ca. 
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3.88 Å) which are stacked in face-to-face manner. These discrete 2:1 entities are 
extended into 1D chain via weak C–H···O233,234 and C–H···N≡C forces along c axis. The 
translation related 1D chains are then packed side by side through weak C–H···N≡C 
interactions to form 2D layers (Figure 2.14).    
 
Figure 2.14. Crystal structure of (4-cyanopyridine)2•resorcinol, 10 
 
The asymmetric unit of (4-cyanopyridine)2•4,4’-biphenol, 11, consists of half a 
bphe molecule and one 4cypy molecule and the resulting 2:1 centrosymmetric 
supramolecular adducts are sustained by I (D: 2.733(4) Å; C–O distance: 1.353(3) Å; C–
N–C angle: 116.3(3)°). The bphe molecules are flat (similarly to bphe in 9) and the 
dihedral angle between the bphe and the 4cypy rings is 49.2°. The 2:1 adducts are 
connected through C–H···N≡C dimers forming 1D chains. The packing is further 
stabilized by C–H···O and C–H···N≡C interactions existing between chains which are 
aligned side by side along the b axis (Figure 2.15). Based upon further investigations 
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involving solid state co-crystallization, co-crystal 11 (thereafter form I, 11a ) was found 
to exhibit additional  polymorphic modification.235 The comparative structural analysis of 
both forms I and II will be discussed in more details in chapter 3.      
 
Figure 2.15. Crystal structure of (4-cyanopyridine)2•4,4’-biphenol, 11a 
 
Co-crystal of (4-cyanopyridine)3•phloroglucinol, 12, consists of discrete 3:1 
entities sustained by I (D1: 2.721(4) Å, D2: 2.784(3) Å, D3: 2.795(3) Å), Figure 2.16. The 
C–O distances are 1.353(3) Å, 1.359(3) Å, 1.367(3) Å, and the C–N–C angle of the 
hydrogen bonded 4cypy rings are 116.3(3)°, 116.8(3)°, and 116.3(3)°, respectively. The 
dihedral angles between the phlgl and the 4cypy rings are 94.9°, 98.4°, and 99.3°. 
Despite that phgl can adopt a 3-fold geometry,216 in this structure, the phlgl molecules 
exhibit convergent orientation. In effect, two of the three 4cypy molecules interact via 
face-to-face stacking (ca. 3.84 Å). Such aggregates self-assemble via C–H···N≡C dimers 
into centrosymmetric pairs of adducts. These pairs are further extended through a C–
H···N≡C interactions to form 1D tapes.  Such tapes are then packed side by side along the 
b axis forming 2D molecular layers.  
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The CSD analysis contain several co-crystals of phlgl with pyridines, of which 
one is particularly relevant from the crystal structure perspective, namely (4,4’-
bipyridine)3•(phloroglucinol)2 (CSD refcode: TEKKOY),236 Figure 2.17. Its crystal 
structures are also sustained by heterosynthon I, and the O–H···Narom hydrogen bond 
lengths are similar to those observed in 12 (D1: 2.71(1) Å, D2: 2.75(1) Å, D3: 2.794(9), 
D4: 2.71(1) Å, D5: 2.73(1) Å, D6: 2.76(1) Å). In the crystal structure of TEKKOJ, phlgl 
molecules also adopt convergent conformation. In effect, the adjacent bipy molecules 
stack in face-to-face manner (ca. 4.02 Å). Similar arrangement of molecules is observed 
in 12 (4cypy molecules indicated by the capped stick style). Such aggregates are then 
linked together by the remaining bipy molecule into 1D chains. The adjacent chains are 
related by 21 screw axis and stabilized via weak C–H···O interactions occurring between 
the phlgl molecules, thereby generating 2D molecular sheets.    
 
Figure 2.16. Crystal structure of (4-cyanopyridine)3•phloroglucinol, 12 
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Figure 2.17. Crystal structure of (4,4’-bipyridine)3•phloroglucinol, TEKKOJ 
 
 
While the presented co-crystal structures resulted from successful experiments, 
attempts that involved co-crystallization of 1-hexadecanol (hexdec) with 3-cyanopyridine 
(3cypy) and 4-cyanopyridine (4cypy) were ineffective. The unsuccessful attempts were 
also confirmed by grinding, solvent-drop grinding and melting precedures (more details 
in chapter 3). Since both (3cypy) and (4cypy) are capable of forming co-crystals with 
other molecules, e.g. res, bphe, phlgl, the lack of success with hexdec perhaps can be 
contributed to the molecular features of hexdec. The existence of long hydrophobic 
chains that are stabilized by a series of cooperative van der Waal forces237 can possibly 
inhibit the dissociation of hexdec structure and the formation of hydrogen bonded 
adducts with other molecules. An analysis of the CSD showed that of the 135 structures 
that are sustained by I (Table 2.1), none contain long chain aliphatic monoalcohols.  
In summary, the crystal structures of the 12 co-crystals demonstrate the 
recurrence of supramolecular heterosynthon I in the presence of the CN moiety in all 
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reported cases. Such a high reliability of I is further confirmed by the unsuccessful co-
crystallizations of 3hypy and 5hyquin with CN-containing compounds: cynaphth, o-
cyben, and p-cyben. These “negative” results can be rationalized by the existence of 
OH/Narom moieties in the molecular structures of 3hypy and 5hyquin. For instance, the 
crystal structure of 3hypy238 exhibits the O–H···Narom supramolecular heterosynthon 
(Figure 2.18), which, as shown by 1-12, can not be easily altered by the introduction of a 
CN moiety.  
 
Figure 2.18. Supramolecular hetrosynthon I present in the crystal structure of 3-
hydroxypyridine  
 
 
The hydrogen bond lengths of I in all co-crystals correspond to the expected 
values of a typical O–H···Narom interaction (Table 2.1) and the structural parameters (C–O 
lengths and C–N–C angles) of the ancillary groups suggest a neutral character of I. The 
supramolecular chemistry of I can also be predicted to a certain extent. Depending on the 
geometrical distribution and the ratio of the OH and Narom moieties, the formation of I 
leads to 1:1 or 1:2 discrete supramolecular entities, which due to the presence of CN 
moieties, can be further extended to 1D chains or 2D sheets sustained by weak C–
H···N≡C interactions.  
The existence of co-crystal 4 and the CSD statistical data that reveals the presence 
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of the C–H···Narom interaction in ca. 14% of the crystal structures sustained primarily by 
I, indicates the importance of these weak interactions in the molecular 
association.104,233,239-242 Although inherently soft, these interactions combined with other 
weak forces, e.g. π-π stacking, prove to be directional enough to lead to the formation of 
co-crystals that would otherwise be unexpected if only strong hydrogen bonds would be 
taken into consideration.243 Furthermore, this result suggests that, while it is possible to 
anticipate the existence of some primary interactions, due to the contribution of weaker 
forces, it is difficult to predict the ultimate crystal packing of a substance based upon the 
knowledge of molecular structure of the constituent(s). 
     Co-crystals 1-12 were examined in the context of their thermal stability. 
Recent reports of Aakeröy et al. and Nangia et al., related to systematic studies of co-
crystals that contain dicarboxylic acid as one of the components, suggest that their 
melting point alteration can be rationalized based upon the thermal properties of the acid 
component; i.e. the alternating trend exhibited in the aliphatic carboxylic acid series (in a 
homologous series, a carboxylic acid with odd number of carbon atoms has a relatively 
lower melting point than those with an even number of carbon atoms)244 is maintained in 
co-crystals.133,245 However, whether a co-crystal will melt at a temperature higher, lower, 
or in between the melting temperatures of the co-crystal constituents, could not be 
predicted. The analysis of the thermal behavior of co-crystals 1-12 (Table 2.3) shows no 
correlation with respect to the melting points of the corresponding co-crystal formers. 
Co-crystals 1 and 5 melt at temperatures lower than their constituents, while co-crystals 6 
and 7 melt at temperatures higher than their components. The remaining co-crystals 2, 3, 
  46
4, 8, 9, 10, and 12 melt at temperatures within the ranges indicated by the melting points 
of the respective co-crystal formers. Therefore, although the rationalization of the melting 
trends in a specific class of co-crystals can be possible,94,246 the anticipation of the 
melting point for a given co-crystal still remains elusive.91,98,247  
  
2.3. Conclusions 
In summary, the study presented herein involves a series of model co-crystals 
adds to the limited amount of the CSD information related to the frequency of occurrence 
of supramolecular heterosynthon I in the presence of the competing acceptor, CN moiety.  
That I occurs reliably in the presence of a CN moiety, suggests that O–H···Narom 
hydrogen bond is favored over the possible O–H···N≡C hydrogen bond II. Considering 
that I and II are favored over III, the relative ranking of these supramolecular synthons 
can be presented as: I>II>III. Therefore, I can be particularly suitable for crystal 
engineering of co-crystals comprised by the OH, Narom, and CN moieties. Furthermore, if 
the robustness of I remains intact in the presence of broader range of hydrogen bonding 
donors and acceptors, I could perhaps, be considered as a remarkably predictable 
interaction, which can be reliably utilized in co-crystallization of more complex 
compounds that possess multiple hydrogen bonding sites. This conclusion is particularly 
relevant to co-crystals of APIs, since they are relatively complex molecules that often 
contain either OH or Narom moieties, or can interact with OH- or Narom-containing co-
crystal formers. Modification of the physicochemical properties that is associated with 
the co-crystal formation may lead to interesting opportunities toward new formulations 
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for the improved performance of an API.  
   
2.4.  Experimental  
 
2.4.1. Syntheses 
All reagents were purchased from Aldrich and used without further purification. 
Single crystals of compounds 1-12 were obtained via slow evaporation of stoichiometric 
amounts of starting materials in appropriate solvents and were isolated from solution 
before complete evaporation of the solvents.  
Co-crystal 1: 3-Cyanophenol•4-phenylpyridine. To 3-cyanophenol (0.015 g, 0.13 
mmol) was added 4-phenylpyridine (0.020 g, 0.13 mmol) and 2 mL of 1:1 of acetone and 
ethyl acetate solvent mixture. Slow evaporation of the solution afforded colorless crystals 
of 1 (0.027 g, 0.10 mmol, 77%), mp = 54-57 °C after 3 days.   
Co-crystal 2: (3-Cyanophenol)2•1,2-bis(4-pyridyl)ethane. To 3-cyanophenol 
(0.026 g, 0.22 mmol) was added 1,2-bis-(4-pyridyl)ethane (0.020 g, 0.11 mmol) and the 
mixture was dissolved in 2 mL of acetone. After 3 days colorless crystals of 2 (0.035 g, 
0.083 mmol, 75%), mp = 106-108 °C, were observed.  
Co-crystal 3: (3-Cyanophenol)2•trans-1,2-bis(4-pyridyl)ethylene. Co-crystal 3 
was obtained using the reagents in 4:1 molar ratio. To 3-cyanophenol (0.052 g, 0.44 
mmol) was added trans-1,2-bis(4-pyridyl)ethylene (0.020 g, 0.11 mmol) and 2 mL of 1:1 
acetone and ethyl acetate mixture. After 2 days colorless crystals of 3 (0.031 g, 0.074 
mmol, 67%), mp = 112-114 °C, were obtained.  
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Co-crystal 4: 3-Cyanophenol•trans-1,2-bis(4-pyridyl)ethylene. Co-crystal 4 was 
obtained using the starting materials in 2:1 ratio. To 3-cyanophenol (0.026 g, 0.22 mmol) 
was added trans-1,2-bis(4-pyridyl)ethylene (0.020 g, 0.11 mmol) and the mixture was 
dissolved in 2 mL of ethyl acetate. Colorless crystals of 4 (0.026 g, 0.086 mmol, 79%), 
mp = 124-125 °C, appeared after 2 days. Co-crystal 4 can also be obtained by using the 
reagents in 1:1 molar ratio.  
Co-crystal 5: 4-Cyanophenol•4-phenylpyridine. To 4-cyanophenol (0.015 g, 0.13 
mmol) was added 4-phenylpyridine (0.020 g, 0.13 mmol). The mixture was dissolved in 
2 mL of chloroform and left to evaporate slowly at 4 °C. After 4 days colorless crystals 
of 5 (0.030 g, 0.11 mmol, 85%), mp = 65-66 °C, were observed.  
Co-crystal 6: (4-Cyanophenol)2•4,4’-bipyridine. To 4-cyanophenol (0.031 g, 
0.26mmol) was added 4,4’-bipyridine (0.020 g, 0.13 mmol). The solid mixture was 
dissolved in 2 mL of methanol and the solution was left undisturbed to evaporate under 
ambient conditions. After 12 days yellow needles of 6, (0.042 g, 0.097 mmol, 0.75%), mp 
= 143-146 °C, were formed.  
Co-crystal 7: (4-Cyanophenol)2•1,2-bis(4-pyridyl)ethane. To 4-cyanophenol 
(0.026 g, 0.22 mmol) was added 1,2-bis(4-pyridyl)ethane (0.020 g, 0.11 mmol) and the 
mixture was dissolved in 2 mL of methanol. After 8 days colorless crystals of 7 (0.031 g, 
0.073 mmol, 67%), mp = 138-139 °C, were obtained.  
Co-crystal 8: (4-Cyanophenol)2•trans-1,2-bis(4-pyridyl)ethylene. To 4-
cyanophenol (0.026 mg, 0.22 mmol) was added 1,2-bis(4-pyridyl)ethylene (0.020 mg, 
0.11 mmol). The solid mixture was dissolved in 2 mL of acetonitrile. After 2 days 
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colorless crystals of 8 , mp = 141-142 °C were observed.  
Co-crystal 9: (3-Cyanopyridine)2•4,4’-biphenol. To 3-cyanopyridine (0.040 g, 
0.38 mmol) was added 4,4’-biphenol (0.036 g, 0.19 mmol) and the mixture was dissolved 
in 2 mL of methanol. After 6 days colorless crystals of 9 (0.052 g, 0.13 mmol, 68%), mp 
= 250 °C (followed by decomposition), were observed. 
Co-crystal 10: (4-Cyanopyridine)2•resorcinol. To 4-cyanopyridine (0.040 g, 0.38 
mmol) was added resorcinol (0.021g, 0.19 mmol) and 2 mL of acetonitrile. The solution 
was left to evaporate at ambient temperature and after 8 days colorless crystals of 10 
(0.055 g, 0.16 mmol, 84%), mp = 93-94 °C, were formed.  
Co-crystal 11a: (4-Cyanopyridine)2•4,4’-biphenol. To 4-cyanopyridine (0.040 g, 
0.38 mmol) was added 4,4’-biphenol (0.036 g, 0.19 mmol). To the solid mixture was 
added 2 mL of methanol and the solution was left to evaporate at ambient conditions. 
After 4 days, yellow crystals of 11a (0.044 g, 0.13 mmol, 67%) were formed. Melting 
point of 11a was not determined due to its decomposition followed by melting of 4,4’-
biphenol (more details related to this co-crystal and its polymorphs are included in 
chapter 3).   
Co-crystal 12: (4-Cyanopyridine)3•phloroglucinol. To 4-cyanopyridine (0.041 g, 
0.39 mmol) was added phloroglucinol (0.016 g, 0.13 mmol) and the mixture was 
dissolved in 2 mL of acetone. After 3 days yellow needles of 13 (0.045 g, 0.10 mmol, 
77%), mp = 116-117 °C were observed.  
 
Additional data: 
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Solution co-crystallization attempts to obtain 3-cyanopyridine•1-hexadecanol and 
4-cyanopyridine•1-hexadecanol were unsuccessful; the IR spectroscopy and PXRD 
spectra of the solid obtained from solution evaporation of the corresponding components 
in equimolar ratio revealed a mixture of starting materials. 
  Solution co-crystallizations that involved stoichiometric amounts of the following 
pairs: 3-cyanopyridine and 1-naphthol, 3-cyanopyridine and resorcinol, 3-cyanopyridine 
and phloroglucinol, and 4-cyanopyridine and 1-naphthol, resulted in liquid products, 
unsuitable for solid state characterizations.  
Solution co-crystallization attempts to obtain: 3-hydroxypyridine•1-
cyanonaphthalene, (3-hydroxypyridine)2•1,3-dicyanobenzene, (3-hydroxypyridine)2•1,4-
dicyanobenzene, 5-hydroxyisoquinoline•1-cyanonaphthalene, (5-
hydroxyisoquinoline)2•1,3-dicyanobenzene, and (5-hydroxyisoquinoline)2•1,4-
dicyanobenzene resulted in mixtures of the starting materials. 
 
All co-crystals were analyzed by infrared spectroscopy using a Nicolet Avatar 
320 FTIR instrument. The purity of bulk samples was confirmed by X-ray powder 
diffraction. Co-crystals 1, 5, 6, 8, 9, and 11a were analyzed on a Rigaku Miniflex 
Diffractometer using Cu Kα (λ = 1.54056 Ǻ), 30 kV, 15 mA. The data was collected over 
an angular range of 3° to 40° 2θ in continuous scan mode using a step size of 0.02° 2θ 
and a scan speed of 2.0º/min. Compounds 2-4, 7, 10, and 12 were analyzed on Bruker 
AXS D8 discover X-ray diffractometer equipped with GADDSTM (General Area 
Diffraction Detection System), a Bruker AXS HI-STAR area detector at a distance of 
  51
15.05 cm as per system calibration, a copper source, automated x-y-z stage, and 0.5 mm 
collimator. Data were collected over 2.1-37.0 2θ range at a step size of 0.02 2θ. Melting 
points of compounds 1-10 and 12 were determined on a MEL-TEMP® apparatus, and the 
comparison of the melting points of 1-12 with the corresponding constituents is 
summarized in Table 2.2. 
 
 
Table 2.2. Comparison of the melting points of co-crystals 1-12 and the corresponding 
components 
 
Co-crystal Mp of co-crystal [°C] Mp of component 1 [°C] Mp of component 2 [°C] 
1 54 – 57 81 - 82 (3cyph) 68 - 71 (phenpy) 
2 106 – 108 81 - 82 (3cyph) 110 - 112 (bipyeta) 
3 112 – 114 81 - 82 (3cyph) 150 - 153 (bipyete) 
4 124 - 125 81 - 82 (3cyph) 150 - 153 (bipyete) 
5 65 - 66 110 - 113 (4cyph) 68 - 71 (phenpy) 
6 143 - 146 110 - 113 (4cyph) 110 - 114 (bipy) 
7 138 - 139 110 - 113 (4cyph) 110 - 112 (bipyeta) 
8 141 - 142 110 - 113 (4cyph) 150 - 153 (bipyete) 
9 250 (dec) 49 - 50 (3cypy) 283 (bphe) 
10 93 - 94 76 - 79 (4cypy) 109 - 111 (res) 
11 - 76 - 79 (4cypy) 283 (bphe) 
12 116 - 117 76 - 79 (4cypy) 216 (phlgl) 
 
2.4.2. Single Crystal X-ray Crystallography  
Co-crystals 1-12 were examined under a microscope and suitable single crystals 
were selected for X-ray diffraction. Data were collected on a Bruker–AXS SMART 
APEX CCD diffractometer with monochromatized Mo Kα radiation (λ = 0.71073 Å) 
connected to KRYO-FLEX low temperature device. Data for 2, 3, 6, 7, and 9, were 
collected at 100 K. Data for 1, 4, 5, 8, and 10-12 were collected at 298 K. Lattice 
parameters were determined from least square analysis, and reflection data were 
  52
integrated using the program SAINT. Lorentz and polarization corrections were applied 
for diffracted reflections. In addition, the data of all compounds, except one (12) was 
corrected for absorption using SADABS.248 Structures were solved by direct methods and 
refined by full matrix least squares based on F2 using SHELXTL.249 All non-hydrogen 
atoms were refined with anisotropic displacement parameters. All H-atoms bonded to 
carbon atoms, were placed geometrically and refined with an isotropic displacement 
parameter fixed at 1.2 times Uq of the atoms to which they were attached. The O bonded 
protons were located from Fourier difference map and refined isotropically based upon 
the corresponding O atom (U(H)=1.2Uq(O)). Crystallographic data for 1-12 are presented 
in Table 2.3 and selected hydrogen bond distances are listed in Table 2.4. 
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Table 2.3. Crystallographic data and structure refinement parameters for co-crystals 1-12 
 
 1 2 3 4 5 6 7 8 9 
Chemical 
formula 
C7H5NO 
•C11H9N 
(C7H5NO)2
•C12H12N2
(C7H5NO)2
•C12H10N2
C7H5NO 
•C12H10N2
C7H5NO 
•C11H9N 
(C7H5NO)2
•C10H8N2 
(C7H5NO)2
•C12H12N2
(C7H5NO)2
•C12H10N2
(C6H4N2)2 
•C12H10O2
Formula .wt. 274.31 422.48 420.46 301.34 274.31 394.42 422.48 420.46 394.42 
Crystal system Monoclinic Monoclinic Monoclinic Monoclinic Monoclinic Triclinic Monoclinic Monoclinic Monoclinic
Space group P21/c P21/c P21/n C2/c C2/c P 1  P21/c P21/c P21/c 
a (Å) 9.90(1) 13.223(3) 16.542(2) 18.715(8) 26.22(1) 3.848(2) 11.195(3) 14.660(3) 20.866(6) 
b (Å) 21.65(3) 6.197(1) 7.506(1) 7.228(3) 7.481(5) 8.755(4) 7.335(2) 4.110(1) 7.437(2) 
c (Å) 7.590(9) 14.630(3) 18.709(2) 23.208(9) 19.41(1) 14.364(6) 13.530(4) 18.290(4) 6.766(2) 
α (°) 90 90 90 90 90 96.647(7) 90 90 90 
β (°) 112.14(2) 113.661(3) 106.763(2) 90.48(1) 128.31(1) 94.498(8) 99.456(7) 90.74(3) 98.142(5) 
γ (°) 90 90 90 90 90 95.474(7) 90 90 90 
Volume (Å3) 1508(3) 1098.1(4) 2224.2(4) 3139(2) 2987(3) 476.6(4) 1095.9(6) 1101.9(4) 1039.4(5) 
Dcalc ( g cm-3) 1.208 1.278 1.256 1.275 1.220 1.374 1.280 1.267 1.260 
Z 4 2 4 8 8 1 2 2 2 
θ range 1.88-24.99 1.68-26.73 1.95-25.00 1.75-24.99 1.98-25.00 1.43-26.37 1.84-25.00 2.61-23.35 0.99-26.73
Nref./Npara. 2607/191 2314/145 3798/290 2748/208 2585/190 1888/136 1818/145 1565/145 2181/136 
T (K) 298 100 298 100 298 100 100 298 100 
R1 0.0558 0.0597 0.0504 0.0688 0.0630 0.0659 0.0672 0.0502 0.0685 
wR2 0.1461 0.1550 0.1501 0.1492 0.1759 0.1926 0.1752 0.1307 0.1747 
GOF 0.924 1.103 1.069 1.002 0.805 1.042 1.044 0.814 1.082 
Abs coef. 0.076 0.083 0.082 0.081 0.077 0.090 0.083 0.083 0.083 
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Table 2.3. Crystallographic data and structure refinement parameters for co-crystals 1-12 
(continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10 11a 12 
Chemical 
formula 
(C6H4N2)2 
•C6H6O2 
(C6H4N2)2 
•C12H10O2
(C6H4N2)3 
•C6H6O3 
Formula .wt. 318.33 394.42 438.44 
Crystal system Triclinic Monoclinic Triclinic 
Space group P 1  C2/c P 1  
a (Å) 9.171(4) 39.87(2) 7.889(3) 
b (Å) 9.941(5) 7.586(5) 8.156(3) 
c (Å) 10.265(5) 6.915(2) 19.673(7)
α (°) 95.674(8) 90 83.866(7)
β (°) 94.987(8) 91.97(2) 85.627(6)
γ (°) 114.784(8) 90 63.512(5)
Volume (Å3) 836(7) 2090(2) 1125.9(6)
Dcalc ( g cm-3) 1.263 1.253 1.293 
Z 2 4 2 
θ range 2.01-24.99 1.02-25.09 1.04-25.00
Nref./Npara. 2875/217 1830/136 3915/298
T (K) 298 298 298 
R1 0.0506 0.0682 0.0586 
wR2 0.1397 0.2121 0.1676 
GOF 1.058 0.875 0.938 
Abs coef. 0.086 0.082 0.089 
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Table 2.4. Geometrical parameters of supramolecular heterosynthon I present in co-crystals 
1-12 
 
 Hydrogen bond d (Å) D (Å) θ (°) 
1 O–H···Narom 1.63 2.708(3) 168.9 
2 O–H···Narom 1.77 2.691(2) 176.3 
O–H···Narom 1.69 2.727(2) 173.3 3 
O–H···Narom 1.75 2.729(2) 173.6 
4 O–H···Narom 1.64 2.663(3) 165.6 
5 O–H···Narom 1.60 2.695(4) 175.7 
6 O–H···Narom 1.84 2.718(3) 175.4 
7 O–H···Narom 1.80 2.698(4) 175.5 
8 O–H···Narom 1.74 2.714(4) 159.5 
9 O–H···Narom 1.77 2.765(3) 166.3 
O–H···Narom 1.96 2.856(2) 169.9 10 
O–H···Narom 1.86 2.763(2) 175.0 
11a O–H···Narom 1.80 2.733(4) 174.1 
O–H···Narom 1.84 2.784(3) 161.6 
O–H···Narom 1.77 2.721(4) 167.7 12 
O–H···Narom 1.77 2.795(3) 176.0 
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Chapter 3 ─ Methods of Preparation of Co-crystals and Polymorphism in Co-
crystals 
 
3.1. Focus 
As demonstrated in chapter 2, the single crystal analysis of model co-crystals 
revealed the existence of the O–H···Narom supramolecular heterosynthon (I) in all 
described structures. The reliability of supramolecular synthons can be related to their 
recurrence in co-crystals prepared via different methods and under variable conditions. 
Considering the recent reports related to the successful utilization of mechanochemical 
approach toward co-crystallization,141,151 model co-crystals 1-12 have been investigated 
in the context of their reproducibility via dry grinding and solvent-drop grinding. 
Grinding co-crystallization procedures involve grinding stoichiometric amounts of two 
(or more) co-crystal formers using mortal and pestle or in a mechanical grinder.143 
Solvent-drop grinding relies on the addition of a small amount of solvent to the grinding 
procedure.151 In addition, growth of co-crystals from melt was utilized and was based 
upon melting stoichiometric amounts of co-crystal formers to a temperature slightly 
higher than the melting point of the higher melting co-crystal former and allowing the 
melted mixture to cool down to room temperature.    
Due to the increasing awareness of polymorphism in organic compounds and its 
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important implications in terms of both fundamental and commercial interest, it was 
appropriate to address the existence of this phenomenon in the set of model co-crystals 
presented herein, with special emphasis on the origin of polymorphism. Solvent-drop 
grinding method has been utilized herein, due to its efficiency in the polymorphism 
screen and control, as reported in recent literature.186,188,208   
 
3.2.  Results and Discussion 
 
3.2.1.  Methods of Preparations of Co-crystals   
The reproducibility of co-crystals obtained from solvent evaporation approach 
was evaluated via co-crystallization methods that involved dry grinding, solvent-drop 
grinding, and growth from melt. To search for other possible polymorphs of co-crystals 
1-12, solvent-drop grinding involving seven solvents of different polarities: cyclohexane, 
toluene, chloroform, ethyl acetate, methanol, dimethyl sulfoxide (DMSO), and water 
were utilized. It was observed that whereas 4-minute grinding with solvent-drop was 
efficient enough to obtain pure co-crystals, the dry grinding approach has not always led 
to complete conversions. To achieve complete co-crystallizations, the time of dry 
grinding needed to be extended to 20 minutes.   
As confirmed by PXRD and FTIR analysis, co-crystals 1, 2, 5, 6, 7, 9, 10, and 12 
were reproduced using the above procedures and no additional forms were observed. 
However, the mechanical co-crystallization was found to have additional effects on the 
remaining co-crystals 3, 4, 8, and 11.  
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Co-crystallization of 3-cyanophenol and trans-1,2-bis(4-pyridyl)ethylene. 3cyphe 
and bipyete can form co-crystals with 2:1 stoichiometry (3) and with 1:1 stoichiometry 
(4). It was observed that dry grinding or melting the components in 2:1 ratio result in 
mixtures of 3 and 4, whereas solvent-drop grinding with all the applied solvents affords 
pure 3. When the two components are combined in 1:1 ratio, the dry grinding and 
melting, also afford mixtures of 3 and 4. The solvent-drop grinding with cyclohexane, 
toluene, chloroform, ethyl acetate, methanol, and water solvents afforded mixtures of 3 
and 4, however, DMSO-drop grinding revealed the formation of pure 4.  
Co-crystallization of 4-cyanophenol and trans-1,2-bis(4-pyridyl)ethylene. The 
PXRD patterns obtained based upon melting, dry grinding, solvent-drop grinding 
(cyclohexane, toluene, chloroform, ethyl acetate, methanol, and water) of 4cyphe and 
bipyete in 2:1 ratio revealed additional peaks and shifts as compared to the PXRD pattern 
of 8. Of the seven solvents only DMSO-drop grinding resulted in a product of which the 
PXRD pattern matched the pattern of 8. Interestingly, when the components in 1:1 ratio 
were subjected to melting, grinding and solvent-drop grinding, similar peaks and shifts 
were observed. Search for additional forms of this co-crystal based upon a series of 
solution crystallizations of the components in various ratios (1:1, 2:1, and 4:1), followed 
by single crystal X-ray analysis, revealed the existence of a 1:1 co-crystal of 4cyphe and 
bipyete, which exhibit two concomitant polymorphic modifications, form I (13a) and 
from II (13b). Detailed discussion and structural comparison of 13a and 13b will be 
presented in section 3.2.2. 
Co-crystallization of 4-cyanopyridine and 4,4’-biphenol. Dry grinding and 
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solvent-drop grinding of 4cypy and bphe in 2:1 ratio revealed consistent, however 
drastically different PXRD patterns, as compared to the XPD pattern of 11a (the crystal 
structure of 11a was introduced in chapter 2). In search for the unknown forms, a series 
of solution crystallization experiments, followed by single crystal X-ray analysis, 
revealed the existence of an additional polymorph form II, 11b. The two polymorphs 
appeared concomitantly when a mixture of MeOH and EtOAc in 1:1 ratio was used.  It 
was established that form II was exclusively afforded from the solvent-drop grinding 
experiments involving cyclohexane, toluene, chloroform, ethyl acetate, methanol, and 
water, whereas the utilization of DMSO lead to the formation of a reported DMSO 
solvate of bphe (CSD refcode ECELON01, see appendix 24).250 Detailed discussion and 
structural comparison of 11a and 11b will be presented in section 3.2.3. 
The attempts to obtain 3-hydroxypyridine•1-cyanonaphthalene, (3-
hydroxypyridine)2•1,3-dicyanobenzene, (3-hydroxypyridine)2•1,4-dicyanobenzene, 5-
hydroxyisoquinoline•1-cyanonaphthalene, (5-hydroxyisoquinoline)2•1,3-
dicyanobenzene, and (5-hydroxyisoquinoline)2•1,4-dicyanobenzene via 
mechanochemical and melting co-crystallizations resulted in mixtures of the 
corresponding starting materials, which confirmed, mentioned in chapter 2, unsuccessful 
solution co-crystallizations of the listed pairs of co-crystal formers. These results were 
expected based upon the observation that CN-contaning compounds would not interact 
with the OH/Narom-contaning compounds. 
A series of co-crystallization experiments that involved stoichiometric amounts of 
the following pairs: 3-cyanopyridine and 1-naphthol, 3-cyanopyridine and resorcinol, 3-
  60
cyanopyridine and phloroglucinol, and 4-cyanopyridine and 1-naphthol, resulted in liquid 
products. Additional co-crystallization experiments carried out at -4 °C also resulted in 
liquid products. An illustration of the solid-to-liquid conversion when 3-cyanopyridine 
and 1-napthol are combined is presented in Figure 3.1. Based upon the high reliability of 
heterosynthon I (chapter 2) and the fact that co-crystals 9-12 (comprised of 3cypy, 4cypy 
and phenols) exist, it could be speculated that the listed co-crystal formers reacted, and 
that the melting points of the co-crystalline products are much lower than room 
temperature. However, to prove or disprove this hypothesis additional experimentations 
are needed. 
 
  
Figure 3.1. Solid-to-liquid conversion occurring in a mixture of 3-cyanopyridine and 1-
napthol 
 
3.2.2. Polymorphism in 4-cyanophenol•trans-1,2-bis-(4-pyridyl)ethylene co-crystal 
4-cyanophenol•t-1,2-bis-(4-pyridyl)ethylene co-crystal, 13, exhibits two 
concomitant polymorphs: monoclinic form I (13a) and triclinic form II (13b). The 
asymmetric unit of 13a consists of two 4cyphe molecules and two bipyete molecules. 
Interestingly, the assembly of the two components results in two distinct supramolecular 
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entities (Figure 3.2). The first entity is a non-centrosymmetric 2:1 adduct sustained by I 
(D1: 2.721(3) Å, D2: 2.669(4) Å; C–O distances: 1.336(3) Å, 1.355(4) Å; C–N–C angles: 
116.6(3)° and 116.1(3)° ) with the dihedral angle between the 4cyphe and the bipyete 
rings being ca. 76.9° and 79.4°. The second entity is a non-hydrogen bonded bipyete 
residing in between the 2:1 adducts. The free and hydrogen bonded bipyete molecules 
alternate through π-π stacking along the b axis. The stacking involves face-to-face 
aromatic interactions of relatively short interplanar distance of ca. 3.61 Å, which can 
make the unsaturated moieties of bipyete suitable for [2+2] photodimerization in the 
solid state. The crystal packing is further extended into 2D planar sheets in result of the 
formation of C–H···N≡C dimer between the stacked columns.  
 
Figure 3.2. Crystal structure of 4-cyanophenol•t-1,2-bis(4-pyridyl)bipyethylene form I, 13a 
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Figure 3.3. Crystal structure of 4-cyanophenol•t-1,2-bis(4-pyridyl)bipyethylene form II, 13b 
 
The asymmetric unit of 13b also consists of two 4cyphe molecules and two 
bipyete molecules. However, unlike in 13a, the components form two 
crystallographically independent 1:1 supramolecular adducts sustained by I (D1: 2.689(4) 
Å, D2: 2.717(4) Å; C–O distances: 1.327(5) Å, 1.347(4) Å; C–N–C angles: 117.2(3)°, 
116.6(4)°). The dihedral angles between the 4cyphe and the bipyete rings in the 
respective adducts are ca. 74.5° and 79.7°. The 1:1 adducts stack on top of each other in 
face-to-face fashion along the a axis, and the distance between the adjacent bipyete 
molecules is ca. 3.48 Å. Such columns of the stacked adducts expand into 2D planar 
sheets through centrosymmetric C–H···N≡C dimer formed between adjacent 4cyphe 
molecules (Figure 3.3).  The similarity of crystal packings of 13a and 13b is manifested 
on the calculated powder diffraction patterns (Figure 3.4.). The major peaks of the two 
forms overlap, while the difference between the patterns lay in the small intensity peaks 
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at ca. 16°-17° 2θ and ca. 26° 2θ .   
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Figure 3.4. X-ray powder diffraction patterns of 4-cyanophenol•t-1,2-bis(4-
pyridyl)bipyethylene polymorphs: bulk sample (green) and simulated patterns of form I 
(black) and form II (red) 
 
 
3.2.3. Polymorphism in (4-cyanopyridine)2•4,4’-biphenol co-crystal 
An examination by IR spectroscopy, powder X-ray diffraction and single crystal 
X-ray diffraction of the irregular hexagons and parallelepiped plates (Figure 3.5) obtained 
from solution crystallization confirmed the presence of two concomitant polymorphs of 
(4cypy)2•bphe, form I (11a) and form II (11b), respectively (numbering is based on order 
of discovery).  
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a) b) 
 
Figure 3.5. Concomitant polymorphs of (4-cyanopyridine)2•4,4’-biphenol co-crystal: a) 
form I – irregular hexagons, b) form II – parallelepiped plates 
 
 
The single crystal X-ray structures of form I and form II confirm the expected 2:1 
stoichiometry and reveal the presence of supramolecular heterosynthon I between the 
4cypy and bphe molecules. However, the crystal packing patterns of the two forms are 
distinct due to conformational differences in the bphe molecules (Figures 3.6 and 3.7). 
Form I crystallizes in C2/c and the asymmetric unit consists of half a bphe molecule 
(residing on crystallographic inversion center) and one 4cypy molecule. The bphe 
molecules are flat (torsion angle between two phenol rings is 180.0°), sustain 
centrosymmetric (4cypy)2•bphe supramolecular adducts (Figure 3.6a). The dihedral 
angle between 4cypy and bphe molecules (planes of the aromatic rings represented by 
atoms C11–N11–C15 and C2–C1–C6) is 128.5°. The O–H···Narom hydrogen bond distance 
(D: 2.733(4) Å) is within the expected range for alcohol-aromatic nitrogen interactions 
(Table 2.1). The crystal structure of 11a was already described in chapter 2 (co-crystal 
11a). 
Form II (11b) crystallizes in P21/n. The asymmetric unit consists of four bphe 
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molecules and two bphe molecules, which differ in their torsion angles: ca. 145.7(3)° 
(torsion represented by C3–C4–C7–C12) in bphe’, and ca. 160.2(3)° (torsion represented 
by C23–C24–C27–C32) in bphe’’, Figure 3.5b. The dihedral angles between the planes 
of the aromatic rings of 4cypy and bphe’ are 153.1° (planes represented by C61–N61–
C65 and C9–C10–C11) and 112.0° (planes represented by C41–N41–C45 and C2–C1–
C6). The dihedral angles between the planes of the aromatic rings of 4cypy and bphe’’ 
are 141.1° (planes represented by C51–N51–C55 and C22–C21–C26) and 104.1° (planes 
represented by C71–N71–C75 and C29–C30–C31). This range of dihedral angles in the 
(4cypy)2•bphe adducts in form II (Figure 3.6b) is unsurprising given that supramolecular 
heterosynthon I is a one-point recognition interaction with rotational freedom. The O–
H···Narom hydrogen bond distances within the supramolecular adducts are 2.693(3) Å and 
2.789(4) Å in (4cypy)2•bphe’, and 2.838(3) Å and 2.766(3) Å in (4cypy)2•bphe’’.  
 
 
(a) 
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(b) 
 
Figure 3.6. ORTEP plot of supramolecular adducts in (4-cyanopyridine)2•4,4’-biphenol 
drawn at 50% probability level for non-hydrogen atoms: (a) form I, (b) form II. Note that 
bphe molecules are flat in form I, whereas twisted in form II 
 
 
 
The crystal structure of 11b is shown in Figure 3.7. The adjacent 2:1 adducts are 
connected via non-centrosymmetric C–H···N≡C dimers forming 1D chains. The chains 
are packed side by side along the a axis, thereby generating a 2D network.  
   
Figure 3.7. Crystal packing in (4-cyanopyridine)2•4,4’-biphenol form II, 11b 
 
(4cypy)2•bphe’ 
 
 
(4cypy)2•bphe” 
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The CSD contains only 22 structures involving bphe.251 The number of 
crystallographically independent bphe molecules in these structures is 33. Figure 3.8 
reveals that one molecule is flat (torsion angle is 0°), 16 molecules are slightly twisted (0-
5°), and torsion angles of the remaining 16 molecules are spread over a wide range (5-
70°). Furthermore, 3 of the 22 structures exhibit conformational isomorphism252 and one 
compound exhibits conformational polymorphism.253 To our knowledge, (4cypy)2•bphe 
form II is the first bphe-containing compound that exhibits both phenomena.  
A similar analysis involving biphenyl derivatives and their complexes reveals 623 
structures with 1,026 crystallographically independent molecules. The histogram of 
torsion angles (Figure 3.9a) shows a maximum corresponding to a 1-5° torsion angle 
range (189 molecules), however there is a second maximum occurring within the torsion 
angle range of 25-45° (651 molecules). These statistics are in agreement with previous 
reports and suggest that such molecules are especially influential upon crystal packing 
effects because of a small rotational barrier around the central C–C bond.254,255 The 
torsion angles encountered in bphe (form I), bphe’ and bphe” (form II), ca. 0.0°, 34.3° 
and 19.8°, respectively, are consistent with the statistical data. Interestingly, 92 of the 623 
structures were found to exhibit conformational isomorphism. Furthermore, 19 of the 623 
exhibit conformational polymorphism, of which 11 also exhibit conformational 
isomorphism. This subset of 92 structures was analyzed to determine the torsion angle 
differences between conformers that co-exist in the same crystal structure. To simplify 
the analysis, only structures that contain two conformational isomorphs were taken into 
consideration. This resulted in a subset of 67 entries. In 57 of these structures the torsion 
  68
angle differences are rather subtle (ca. 1-10°), whereas the remaining 10 pairs of 
conformational isomorphs exhibit higher torsion angle deviations (10-40°), Figure 3.9b. 
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Figure 3.8. Histogram representing the torsion angle distribution in 22 crystal structures of 
4,4’-biphenols   
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Figure 3.9. a) Distribution of torsion angles in the 623 crystal structures that contain 
biphenyl moieties; b) Distribution of torsion angle deviations within pairs of conformers 
present in 67 crystal structures 
 
    
The calculated density of form I is slightly lower than the calculated density of 
form II (1.253 Mg/m3 vs. 1.266 Mg/m3). The melting points of both co-crystal forms was 
not recorded because (4cypy)2•bphe decomposes upon heating. The DSC thermograms 
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(see appendix 11) of the two polymorphs show two endothermic peaks; one 
corresponding to the co-crystal decomposition (ca. 94.3°C in form I and ca. 96.1°C in 
form II) and another corresponding to melting of bphe (ca. 284.1°C), respectively.   
Polymorphic transformations between the two forms of (4cypy)2•bphe were also 
investigated, as illustrated in Figure 3.10. When form I is dry or solvent-drop ground with 
methanol, acetone, or ethyl acetate, conversion to form II is observed. Conversely, slow 
evaporation of methanol, ethyl acetate, or acetone solutions of form II yield form I. 
Slurry experiments involving 1:1 mixtures of form I and form II in methanol, ethyl 
acetate or acetone afford form II. Experimental and simulated PXRD patterns of both 
polymorphs are presented in Figure 3.11.  
 
(4-Cyanopyridine)2
+ 
4,4'-Biphenol
MeOH : EtOAc (1:1) Co-crystal
Form I + Form II
Form I
MeOH, 
EtOAc, or 
Acetone
Grinding or solvent drop grinding
Form II
Grinding or solvent drop grinding
MeOH, EtOAc, or Acetone 
Slurry in
MeOH, 
EtOAc, or
Acetone
 
 
Figure 3.10. Polymorphic conversions between form I and form II of the (4-
cyanopyridine)2•4,4’-biphenol co-crystal 
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Figure 3.11. PXRD patterns of  (4-cyanopyridine)2•4,4’-biphenol co-crystals: (a) simulated 
form I and (b) experimental form I obtained via slow evaporation from acetone; (c) 
simulated form II and (d) experimental form II obtained via acetone-drop grinding 
 
 
In summary, the combination of various methods of co-crystallization, namely 
grinding, solvent-drop grinding, growth from melt, and solution co-crystallization, have 
led to new discoveries. The first finding is related to the existence of a dimorphic co-
crystal of 4cyphe•bipyete (13a and 13b), which was observed in result of grinding, 
solvent-drop grinding and melting co-crystallization methods. The two forms of 
4cyphe•bipyete exhibit 1:1 stoichiometry and they occur concomitantly. The formation 
of this co-crystal is somewhat surprising from the perspective that a co-crystal of 4cyphe 
and bipyete with the expected 2:1 stoichiometry exists (8). Interestingly, 2:1 and 1:1 
stoichiometries, although polymorphic forms were not detected, also exist in the co-
crystals of 3cyphe and bipyete (3 and 4). Similar molecular arrangement of bipyethe in 
co-crystals 4, 13a, and 13b, may suggest that the crystal packings are strongly stabilized 
by aromatic stacking and C–H···Narom interactions, in addition to the primary 
supramolecular heterosynthon I.  
The second finding is related to the existence of an additional polymorph of 
10 15 20 25 30 35 40 4510 15 20 25 30 35 40 45
a)
b)
c)
d)
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(4cypy)2•bphe, form II, which was discovered based on grinding and solvent-drop 
grinding co-crystallizations. Form II of (4cypy)2•bphe (11a) exhibits concomitant and 
conformational polymorphism and conformational isomorphism. To our knowledge, 
concomitant or conformational polymorphism, or both phenomena, have been observed 
in several co-crystals,186,256,257 whereas all three phenomena have only been reported for 
the triphenylsilanol•4,4’-dipyridyl co-crystal.256  
It is interesting to note that the supramolecular heterosynthon, I, which sustains 
both (4cypy)2•bphe and 4cyphe•bipyete co-crystals remains unchanged in their 
polymorphic modifications. The origin of polymorphism in 11a and 11b can be related to 
the conformational flexibility of the bphe molecules, while polymorphism in 13a and 
13b results from the variations in the crystal packing. A detailed structural analysis of the 
11 polymorphic co-crystals reported in the CSD reveals, that within the set of 
polymorphs of a given co-crystal, supramolecular heterosynthons also persit.182,183,185 For 
instance, the crystal structures of two quinhydrone polymorphs, form α and form β, 
Figure 3.12, are sustained by alternating p-benzoquinone and hydroquinone molecules 
that interact via O–H···O hydrogen bonds. Such a molecular arrangement leads to the 
generation of infinite linear chains.116,258  The two crystal packings differ in the relative 
orientation of these chains. In form α (Figure 3.12a) the chains are oriented nearly 
orthogonally with respect to each other, whereas in form β, (Figure 3.12b) the chains are 
packed side by side. Although concomitant polymorphism was not reported, a review of 
the relevant literature, revealed that both forms of quinhydrone can be crystallized from 
acetone.  
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a)                                                                      b) 
Figure 3.12. Crystal structures of the polymorphic forms of quinhydrone: a) form α and b) 
form β 
 
The persistency of supramolecular heterosynthons is also seen in the dimorphic 
co-crystal of caffeine•glutaric acid.186 In form I and form II of this co-crystal the 
components interact via carboxylic acid···imidazole supramolecular heterosynthon, 
Figure 3.13. The difference between the two polymorphs is related to rather subtle 
conformational variations of the methylene groups of glutaric acid (conformational 
polymorphism).179 Form I and form II occur concomitantly when the co-crystallization is 
carried out in chloroform. Interestingly, the polymorphic outcome of co-crystallization 
can be controlled by applying solvent-drop grinding methodology. Form I could be 
obtained when non-polar solvents (e.g. hexane) were added to the grinding procedure, 
whereas form II could be obtained upon the addition of polar solvents (e.g. acetonitrile).  
Further structural analysis of the 9 remaining co-crystals shows that the 
supramolecular heterosynthons also persist within a given set of polymorphs. This 
indicates that the differences in crystal packings that result from the engagement of 
molecules in different hydrogen bonding modes, observed in single-component 
compounds, do not occur in co-crystals.  
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a)                                                                      b) 
Figure 3.13. Crystal structures of the polymorphic forms of caffeine•glutaric acid co-
crystal: a) form I and b) form II 
 
 
The existence of concomitant polymorphism in co-crystals 11 and 13 implies that 
the free energy difference between the crystalline forms is small.56,181 Despite the fact 
that the phenomenon of concomitancy of polymorphs has been long known,259 there has 
been little information related to the frequency of its occurrence in organic compounds.260 
This perhaps can be explained by the general difficulty to quantitatively assess 
polymorphism. An overview of the literature related to the 11 existing polymorphic co-
crystals revealed that in four cases, concomitant polymorphism was apparent.261 By 
including (4cypy)2•bphe and 4cyphe•bipyete to the total number of structurally 
characterized polymorphic co-crystals, it becomes clear that in nearly 50% of cases 
concomitancy is present. This is a relatively high frequency of occurrence, which perhaps 
could be higher considering that not all polymorphs may have been reported or 
discovered yet. With the emergence of X-ray diffraction and the development of more 
sophisticated methods of analysis, as well as the increasing awareness of the 
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phenomenon, more discoveries of concomitant polymorphism could perhaps be expected. 
 
 
3.3.      Conclusions  
The presented series of co-crystallization experiments have demonstrated that the 
utilization of grinding, solvent-drop grinding and melting techniques in the co-
crystallization procedures offers a viable means for supramolecular synthesis. Such 
synthetic approaches can be advantageous from the perspective of green chemistry 
principles. Additionally, the solvent-drop grinding approach showed to be useful in 
addressing the issue of stoichiometry and polymorph control in co-crystals. Although the 
role of a solvent in the nucleation process is still not entirely understood, the results 
obtained based upon solvent-drop grinding suggest that it is generally possible to find 
experimental conditions, under which a specific co-crystal form exists.187 
In the total number of co-crystals, (13 presented herein and 1487 archived the 
CSD), 23 have been found to exhibit polymorphic behavior (2 presented herein and 21 
archived in the CSD).185 Thus, the percentage occurrence of polymorphic co-crystals is 
1.5%, as compared to the 1.7% of occurrence of polymorphic single component 
compounds (Table 1.2).183 It can be therefore concluded that the extent of polymorphism 
in both classes of compounds is comparable. It should be noted, however, that the 
information related to polymorphism in co-crystals is limited (23 polymorphic co-crystals 
vs. 1600 polymorphic single component compounds) and that further investigations 
conducted on a broader range of co-crystals would enhance the significance of the 
presented results. Furthermore, drawing a meaningful conclusion from such studies is 
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complicated by the fact that the absence of a polymorphic behavior in a given co-crystal 
at given experimental conditions does not mean that polymorphism can not be observed 
at other conditions. From this perspective, assessing the frequency of concomitant 
polymorphism is also complicated, although based on the available data (albeit limited) it 
could be determined that at least ca. 50% of known co-crystal polymorphs can exist 
concomitantly. This result may be relevant from a commercial perspective, as 
concomitant crystallizations need to be avoided because they can lead to materials that do 
not meet prescribed norms.181 In this context, utilization of high-throughput screening 
within a wider range of experimental conditions (e.g. range of solvent systems, 
temperature variations) offers a suitable means in the identification of polymorphs.     
If the persistency of supramolecular heterosynthons within a set of polymorphs 
holds true over a broader range of co-crystals it may become of importance in the context 
of polymorphism control. In particular, the variety of factors that influence polymorphic 
behaviors of organic compounds (supramolecular synthon, conformational, and crystal 
packing variations) could be reduced by eliminating the possibility for molecular self-
assembly through different supramolecular synthons. Advancements in the context of 
understanding and controlling polymorphism is of high relevance from the perspective of 
crystal engineering, where the control over the design and preparation of desired crystal 
structures is fundamental. Polymorphism is also of utmost importance in the context of 
preparation of solid forms of APIs and the opportunity to reduce its extent co-crystal 
formulations would represent a particularly attractive approach.        
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3.4.  Experimental  
 
3.4.1.  Syntheses 
Co-crystallization via grinding: Stoichiometric amounts of the starting materials 
were ground with a mortar and pestle for ca. 20 minutes.  
Co-crystallization via solvent-drop grinding: Stoichiometric amounts of the 
starting materials were ground with a mortar and pestle for ca. 4 minutes with the 
addition of seven solvents (10 μL per 50 mg of co-crystal):  cyclohexane, toluene, 
chloroform, ethyl acetate, methanol, DMSO, and water.  
Co-crystallization via melting: Stoichiometric amounts of the starting materials 
were heated until melt and the mixture was left to crystallize at ambient conditions. Co-
crystals 11 and 12 could not be obtained by this procedure due to decomposition of 4,4’-
biphenol and sublimation of phloroglucinol upon heating. 
Co-crystallization via solution evaporation.  
Co-crystal 11a and 11b: (4-cyanopyridine)2•4,4’-biphenol, form I and form II. 
A solution of 4-cyanopyridine (0.040 g, 0.38 mmol) and 4,4’-biphenol (0.036 g, 0.19 
mmol) in 2 mL of 1:1 methanol and ethyl acetate was allowed to evaporate slowly at 
ambient conditions. Yellow crystals of two distinct morphologies, irregular hexagonal 
plates and parallelepiped plates (total: 0.056 g, 0.14 mmol, 74%), appeared within four 
days.  
Co-crystal 13a and 13b: 4-cyanophenol•trans-1,2-bis(4-pyridyl)ethylene, form I 
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and form II.  To 4-cyanophenol (0.026 g, 0.22 mmol) was added trans-1,2-bis(4-
pyridyl)ethylene (0.040 g, 0.22 mmol) and the mixture was dissolved in 2 mL of 
methanol. After 14 days colorless crystalline product (total: 0.029 g, 0.096 mmol, 88%), 
mp = 153-156 °C was observed. Single crystal X-ray diffraction analysis performed on 
several selected crystals revealed the presence of two concomitant polymorphs.  
 
3.4.2. Single Crystal X-ray Crystallography  
Suitable crystals of the polymorphs studied herein were examined under a 
microscope and suitable single crystals were selected for X-ray analysis. Data were 
collected on a Bruker–AXS SMART APEX CCD diffractometer with monochromatized 
Mo Kα radiation (λ = 0.71073 Å). Data were collected at 298 K. Lattice parameters were 
determined from least square analysis, and reflection data were integrated using the 
program SAINT. Lorentz and polarization corrections were applied for diffracted 
reflections. In addition, the data was corrected for absorption using SADABS.248 
Structures were solved by direct methods and refined by full matrix least squares based 
on F2 using SHELXTL.249 All non-hydrogen atoms were refined with anisotropic 
displacement parameters. All H-atoms bonded to carbon atoms were placed 
geometrically and refined with an isotropic displacement parameter fixed at 1.2 times Uq 
of C atoms. OH protons were located from Fourier difference map inspection and refined 
isotropically with thermal parameters based upon the corresponding O atom 
(U(H)=1.2Uq(O)). Crystallographic data for 11b, 13a and 13b are presented in Table 3.1 
and selected hydrogen bond distances are listed in Table 3.2. Crystallographic data and 
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selected hydrogen bond distances of 11a were included in the experimental section of 
chapter 2). 
 
Table 3.1. Crystallographic data and structure refinement parameters for co-crystals 11b, 
13a, and 13b 
 
 11b 13a 13b 
Chemical 
formula 
(C6H4N2)2 
•C12H10O2
C7H5NO 
•C12H10N2
C7H5NO 
•C12H10N2
Formula .wt. 394.42 301.34 301.34 
Crystal system Monoclinic Monoclinic Triclinic 
Space group P21/n Cc P 1  
a (Å) 12.787(2) 18.719(8) 7.616(2) 
b (Å) 7.2838(9) 7.602(3) 10.003(3) 
c (Å) 44.445(6) 22.09(1) 22.497(6) 
α(°) 90 90 87.342(5) 
β(°) 90.895 90.762(9) 81.024(6) 
γ (°) 90 90 69.737(6) 
Volume (Å3) 4139.1(9) 3144(2) 1588.1(8) 
Dcalc ( g cm-3) 1.266 1.273 1.260 
Z 8 8 4 
θ range 0.92-25.00 2.18-27.00 0.92-22.50
Nref./Npara. 7284/541 5352/417 4046/415 
T (K) 298 298 298 
R1 0.0510 0.0505 0.0502 
wR2 0.1654 0.1390 0.1291 
GOF 0.812 1.058 0.791 
Abs coef. 0.083 0.081 0.080 
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Table 3.2. Geometrical parameters of supramolecular heterosynthon I present in co-crystals 
11b, 13a, and 13b 
 
 Hydrogen bond d (Å) D (Å) θ (°) 
O–H···Narom 1.72 2.838(3) 173.7 
O–H···Narom 1.69 2.766(3) 164.2 
O–H···Narom 1.56 2.693(3) 163.2 
11b 
O–H···Narom 1.79 2.789(4) 172.3 
O–H···Narom 1.73 2.721(3) 160.9 13a 
O–H···Narom 1.72 2.669(4) 161.3 
O–H···Narom 1.52 2.689(4) 164.9 13b 
O–H···Narom 1.52 2.717(4) 172.0 
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Chapter 4 ─ Robustness of Supramolecular Heterosynthons: 2-Aminopyridinium 
Carboxylate 
 
4.1. Focus  
 In the previous sections, it was illustrated that the understanding of the interplay 
of intermolecular interactions in the solid state can be facilitated by studies of model co-
crystals comprised of components preselected for their chemical and geometrical 
attributes. Thus far the presented investigations have been related to 1-point recognition 
supramolecular synthons,262 such us hydroxyl···pyridine, hydroxyl···cyano, and 
hydroxyl···hydroxyl.  
It is generally accepted that the probability of formation of a supramolecular motif 
increases proportionally to the number of involved hydrogen bonds.39 In this context, 
carboxylic acids and 2-aminopyrdines represent a suitable pair of moieties that engage in 
a 2-point recognition supramolecular synthon262 with high probability of formation, as 
determined by the pioneering work of Allen et al. based upon extensive CSD studies.65   
Carboxylic acids play a significant role in crystal engineering because they are 
self-complementary and they can form supramolecular heterosythons with a wide range 
of other functional groups.80,85,86,91-95,137 In fact, a CSD search reveals that there are over 
7,500 crystal structures of carboxylic acids. However, only ca. 25% of total structures 
exhibit homosynthon IV (Figure 4.1), whereas the remaining 75% of compounds exhibit 
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a variety of supramolecular heterosynthons.  2-aminopyridines and their derivatives such 
as 2-aminopyrimidines and melamines, which are often encountered in biological 
systems, are likewise capable of forming either supramolecular homosynthon V (Figure 
4.1)263 or supramolecular heterosynthons.264,265 
 
                             IV                                                          V 
Figure 4.1. Examples of supramolecular homosynthons: a carboxylic acid homosynthon IV  
and a 2-aminopyridine homosynthon V  
 
 
In this section, the presented research is focused on the ability of 2-
aminopyridines and carboxylic acids to form a reliable supramolecular heterosynthon, 
with an ultimate view to employing this supramolecular heterosynthon in a rational 
design of new multiple-component compounds that also contain structurally more 
complex APIs. 
 
4.2.  Results and Discussion   
2-aminopyridine and 2-amino-5-methylpyridine were used in this study. They 
were reacted with a series of mono- and di- carboxylic acids (Scheme 4.1) to form the 
following compounds: 2-aminopyridinium 4-aminobenzoate, 14; 2-aminopyridinium 
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isophthalate, 15; bis(2-aminopyridinium) terephthalate, 16; 2-amino-5-methylpyridinium 
benzoate, 17; bis(2-amino-5-methylpyridinium) 5-tertbutylisophthalate, 18; bis(2-amino-
5-methylpyridinium) terephthalate, 19; bis(2-amino-5-methylpyridinium) 2,6-
napthalenedicarboxylate, 20; 2-amino-5-methylpyridinium adipate adipic acid, 21; and 2-
amino-5-methylpyridinium 2,5-thiophenedicarboxylate 2,5-thiophenedicarboxylic acid, 
22. 
N NH2 N NH2
CH3
COOH
COOH
NH2
COOH
COOH
COOH
HOOC
S COOHHOOC
COOH
COOH
COOH
COOHt-Bu
COOH
HOOC
2-aminopyridine 2-amino-5-methylpyridine
benzoic acid                    4-aminobenzoic acid                         terephthalic acid                   2,6-naphthalenedicarboxylic acid  
  2,5-thiophenedicarboxylic acid            isophthalic acid                         5-t-butylisopthalic acid                              adipic acid  
Scheme 4.1. Molecular structures of components present in complexes 14-22 
 
4.2.1. CSD Analysis  
There are several possible two-point recognition supramolecular synthons that can 
be formed between 2-aminopyridines and carboxylic acids: supramolecular homosynthon 
IV; a 2-aminopyridine supramolecular homosynthon V; a 2-aminopyridine-carboxylic 
acid supramolecular heterosynthon VI; the ionic form of VI, i.e. supramolecular 
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heterosynthon VII (Scheme 4.2). As will become clear, both statistical and experimental 
data indicate that the supramolecular heterosynthons VI or VII are favored over the 
related supramolecular homosynthons IV and V.  
 
N
N H
H
N
N H
H
H O
O
R
O
O
R
H
VI                                                  VII  
Scheme 4.2. Supramolecular heterosynthons that can be formed between carboxylic acids and 2-
aminopyridines: 2-aminopyridine-carboxylic acid supramolecular heterosynthon VI and 2-
aminopyridinium-carboxylate supramolecular heterosynthon VII 
 
A CSD study of compounds that contain at least one 2-aminopyridine and one 
carboxylic acid moiety was conducted in order to determine the occurrence of 2-point 
molecular recognition supramolecular heterosynthon, also coded as R24(8) graph-set.66,75   
It should be noted that ambiguity can arise with regards to the position of carboxylic acid 
proton in such complexes. However, the character of the interaction does not influence 
whether or not a supramolecular heterosynthon occurs. The proton position was therefore 
omitted from the search parameters, and the resulting data covers both neutral and 
charge-assisted hydrogen bonds. The percentage occurrence and hydrogen bond distances 
of supramolecular synthons IV-VII are presented in Table 4.1. 
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Table 4.1. Percentage occurrence, distance ranges, and average distance for supramolecular 
synthons IV-VII 
 
 Number of entries Distance range [Å] Mean  (σ ) [Å] 
Both groups 123 - - 
Synthon IV 0 O···O          2.50-3.00 - 
Synthon V 40 (33%) N···N          2.90-3.25 3.03(6) 
N(py)···O    2.50-2.85 2.66(6) 
Synthon VI or VII 95 (77%) 
N(am)···O   2.70-3.10 2.87(8) 
 
 
The CSD contains 123 crystal structures with both 2-aminopyridine and 
carboxylic acid groups.266 In order to determine appropriate ranges for defining contact 
limits, distance distribution plots were generated. Based on visual inspection of the 
resulting histograms, the lower and higher cut offs for hydrogen bonds were determined. 
The histograms (Figure 4.2) reveal that VI or VII exhibit ranges of 2.50 - 2.85 Å 
(average 2.66(6) Å) for N(py)···O and 2.70 - 3.10 Å (average of 2.87(8) Å) for N(am)···O, 
respectively. Based upon these limits, IV is not found in any of the 123 compounds, 
while 40/123 structures (33%) exhibit the 2-aminopyridine supramolecular homosynthon 
V. 95/123 structures (77%) exhibit supramolecular heterosynthons VI or VII. It should 
be noted that 12 structures that exhibit VI or VII, also contain V due to the presence of 
multiple 2-aminopyridine moieties. In the remaining 27/123 structures that do not exhibit 
VI or VII, the carboxylic acid functionality forms hydrogen bonds with other competitive 
proton donors or acceptors such as amines, amides, imidazoles, water molecules and 
chloride ions. The same search was performed in the absence of other strong donors 
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and/or acceptors that can compete with either aminopyridine or carboxylic acid moieties, 
e.g. alcohols, 1° and 2° amides, 1° and 2° sulfonamides, imidazoles, carbonyls, nitriles, 
nitro-compounds, phosphine oxides, chloride ions, bromide ions and water molecules. 
The number of structures containing both 2-aminopyridine and carboxylic acid moieties 
is thereby reduced from 123 to 34. In this subset, the percentage occurrence of VI or VII 
increased to 97% (33/34), although 7/33 compounds also contained the 2-aminopyridine 
supramolecular homosynthon V. These statistics suggest that supramolecular 
heterosynthons VI or VII are robust even in the presence of competing hydrogen bonding 
moieties. This observation is tested based upon study of the new compounds presented 
herein. 
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Figure 4.2. Histograms of contacts for crystal structures containing both 2-aminopyridine 
and carboxylic acid moieties: a) N(py)···O contacts in supramolecular heterosynthon VI or 
VII, b) N(am)···O contacts in supramolecular heterosynthon VI or VII, c) N(am)···N(py) 
contacts in supramolecular homosynthon V 
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4.2.2.  Structural Features of Neutral and Ionic 2-Aminopyridine···Carboxylic Acid 
Interaction 
The ionic nature of the supramolecular heterosynthon present in compounds 14-
22 was confirmed by spectroscopy, proton location, and structural parameters of ancillary 
groups. It is well known that the geometrical features of neutral carboxylic group are 
different from those of a carboxylate anion.267 The scatter plot for C–O vs. C=O bond 
distances in carboxylic acids and carboxylate anions is presented in Figure 4.3 (only good 
quality neutral carboxylic acid structures containing ordered, error free and non-
polymeric organic compounds with 3D coordinates determined and R < 5% were chosen 
for the analysis). 1827 carboxylic acid crystal structures reveal that C–O distances 
average is 1.31(2) Å, whereas C=O distances average is 1.21(2) Å. On the other hand, the 
scatter plot of the 1696 compounds containing at least one carboxylate moiety indicates 
that the C–O distances average is 1.25(2) Å.  
a)
1.1
1.15
1.2
1.25
1.3
1.35
1.4
1.45
1.1 1.15 1.2 1.25 1.3 1.35 1.4 1.45
C=O distance [Å]
C
-O
 d
is
ta
nc
e 
[Å
]
 
 
b)
1.1
1.15
1.2
1.25
1.3
1.35
1.4
1.45
1.1 1.15 1.2 1.25 1.3 1.35 1.4 1.45
C-O distance [Å]
C
-O
 d
is
ta
nc
e 
[Å
]
 
Figure 4.3. Scatter plot of carbon-oxygen bond lengths in: a) neutral carboxylic acids, b) 
carboxylate anions 
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The C–N–C angle in pyridines is known to be sensitive to protonation,222,223,268,269 
and the cationic form exhibits higher values than that of the corresponding neutral 
molecules. A graphical representation of the C–N–C angle distribution in both protonated 
and unprotonated 2-aminopyridines is presented in Figure 4.4. Histograms were 
generated from good quality crystal structures (only ordered, error free and non-
polymeric organic compounds with 3D coordinates determined and R < 5%). In order to 
distinguish protonated 2-aminopyridines from neutral 2-aminopyridines specific 
restrictions were applied during the CSD searches.  For neutral 2-aminopyridines, the 
aromatic nitrogen was defined to be uncharged and the number of bonded atoms was set 
to 2. In the case of protonated 2-aminopyridines, hydrogen atoms were placed on the 
aromatic nitrogen, the charge was set to +1 and the coordination number was set to 3. 
The average C–N–C angle encountered in 213 neutral 2-aminopyridines is 116(2)°. In 
comparison, the set of 127 cationic 2-aminopyridines exhibits a higher C–N–C angle with 
an average value of 121(2)°. 
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Figure 4.4. Histograms that present distribution of the C–N–C angle in a) neutral 2-
aminopyridines, and b) protonated 2-aminopyridines 
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4.2.3. Crystal Structure Descriptions 
The crystal structure of 2-aminopyridinium 4-aminobenzoate, 14 reveals the 
expected 1:1 cation:anion supramolecular complex, sustained by supramolecular 
heterosynthon VII (Figure 4.5). The hydrogen atom of the primary amine moiety 
involved in the formation of the R22(8) supramolecular heterosynthon is assigned as syn- 
oriented, and the exterior hydrogen atom as anti- oriented. This terminology is used 
herein. 
In addition to IR spectroscopic evidence, the presence of heterosynthon VII is 
supported by structural data: the C–O bond distances of the carboxylate group are 
1.273(2) Å and 1.256(2) Å; the C–N–C angle within the 2-aminopyridinium cation is 
122.3°. The hydrogen bond distances of supramolecular heterosynthon VII, 2.611(2) Å 
and 2.814(2) Å for N+(py)···O- and N(am)···O-, respectively, are within the excepted ranges. 
The carboxylate group of the 4-aminobenzoate is oriented at 19.2° with respect to the 
benzene ring plane and the dihedral angle between the 2-aminopyridinium cation and the 
carboxylate group is 15.1°. However, the 1:1 supramolecular adduct is almost planar 
(6.8°). The anti- oriented N–H of the amine of the 2-aminopyridinium cation is involved 
in an additional N(am)···O- hydrogen bond with an oxygen atom of the adjacent 
carboxylate (D: 2.800(2) Å), thereby generating a 1D chain of supramolecular 
heterosynthons along the c axis (Figure 4.6).  
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Figure 4.5.  Supramolecular interactions in 2-aminopyridinium 4-aminobenzoate, 14  
 
 
 
 
Figure 4.6. Crystal structure of  2-aminopyridinium 4-aminobenzoate,14. 1D hydrogen 
bonded chains are interconnected via a benzoate amine N–H···O- interactions to form 2D 
corrugated supramolecular sheet 
 
 
 
Within the chain of supramolecular heterosynthons the supramolecular adducts align in a 
zigzag fashion. The angle between core planes parallel to the interactions OA···NA–CA–
NA···OA in heterosynthon VIIA and OB···NB–CB–NB···OB in adjacent heterosynthon VIIB 
is 101.6° (Figure 4.7). This pattern has been called the “shallow glide motif”,270 and is 
also observed in crystal packing of primary amides.83,271 The aminopyridinium-
carboxylate heterosynthons VII are related by a glide plane and are also inclined with 
 Anti                   
                   
               Syn 
1D hydrogen  
bonded chain of 
supramolecular 
heterosynthons
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respect to each other. A similar networking pattern occurs in several of the compounds 
reported herein. 
 
 
Figure 4.7.  The angle between core planes parallel to the interactions OA···NA–CA–NA···OA 
and OB···NB–CB–NB···OB  
 
It is interesting to note that supramolecular heterosynthon VII occurs even in the 
presence of a functional group with hydrogen bonding capability, a primary amine. The –
NH2 of the 4-aminobenzoate anion acts as a hydrogen bond donor to one of the lone pairs 
of the carboxylate from an adjacent chain (N···O-: 3.087(2) Å), thereby connecting the 
chains in the direction of the a axis. The overall crystal packing of 14 can therefore be 
described as a corrugated 2D network resulting from interconnected 1D hydrogen-bonded 
chains of supramolecular heterosynthons (Figure 4.6). 
Isophthalic acid possesses two carboxylic groups that are amenable to the 
formation of VI or VII, but a 1:1 complex is formed in 2-aminopyridinium isophthalate, 
15, since the acid molecule only undergoes single deprotonation. The carboxylate and 
aminopyridinium moieties form the expected R22(8) supramolecular heterosynthon VII. 
                                       O1     Heterosynthon VIIA 
 
                N1 
 
                C1                      O1 
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    N2 
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The C–O bond distances in the carboxylate moiety are 1.266(1) Å and 1.262(1) Å and the 
C–N–C angle of the 2-aminopyridinium is 122.5°. The C–O bond lengths in the acid 
moiety are 1.210(1) Å and 1.330(2) Å. The hydrogen bond distances of supramolecular 
heterosynthon VII are 2.703(1) Å and 2.836 (1) Å for N+(py)···O- and N(am)···O-, 
respectively. The anti- oriented N–H of the amine group interacts with another 
carboxylate (N···O-: 2.942(1) Å), thereby bridging the adjacent supramolecular 
heterosynthons. The carboxylic acid group is involved in a charge-assisted O-H···O- 
(O···O-: 2.623(2) Å) interaction with a neighboring carboxylate group (Figure 4.8).  
 
 
Figure 4.8. Hydrogen bonding interactions in 2-aminopyridinium isophthalate, 15 
 
 
The components of 15 form almost planar (dihedral angle is 5.8°) adducts and the angle 
between core planes parallel to the interactions OA···NA–CA–NA···OA in heterosynthon 
VIIA and OB···NB–CB–NB···OB in heterosynthon VIIB is 69.6°. The existence of both 
carboxylic and carboxylate groups in 15 was confirmed by IR spectroscopy which 
revealed absorption bands at 1556 cm-1 and 1378 cm-1 (corresponding to carboxylate 
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ions) and  1682 cm-1 and 1261 cm-1 (corresponding to C=O and C–O stretches, 
respectively).  
Compound 16, bis(2-aminopyridinium terephthalate), is sustained by three-
component aggregates consisting of two aminopyridinium cations and one terephthalate 
anion (Figure 4.9). 
 
 
 
Figure 4.9. Supramolecular interactions in bis(2-aminopyridinium) terephthalate, 16  
 
 
(b) 
 
Figure 4.10. Crystal structure of bis(2-aminopyridinium) terephthalate, 16 
 
The hydrogen bonds within supramolecular heterosynthon VII are 2.624(2) Å and 
2.797(2) Å for N+(py)···O- and N(am)···O-, respectively. The C–O bond distances in the 
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carboxylate group (1.271(2) Å and 1.244(2) Å) and C–N–C angle in the 2-
aminopyridinium (122.8°) support the proposed ionic character of 16. The anti- oriented 
N–H of the amine group hydrogen bonds to the carboxylate of an adjacent 
supramolecular adduct (D: 2.809(2) Å) and the dihedral angle between core planes of 
neighbouring heterosynthons is 97.9°. A chain of supramolecular heterosynthons is 
thereby formed and it is connected to another chain through the terephthalate anion. The 
overall hydrogen-bonding pattern in 16 can therefore be described as a corrugated 2D 
network consisting of interconnected trimeric supramolecular adducts aligning nearly 
perpendicularly with respect to each other (Figure 4.10).  
2-amino-5-methylpyridinium benzoate, 17,  consists of 1:1 supramolecular 
adducts sustained by supramolecular heterosynthon VII (Figure 4.11). Protonation occurs 
on the aromatic nitrogen of 2-amino5-methylpyridine as evidenced by the C–N–C angle 
of 122.8° and C–O distances of 1.271(2) Å and 1.242(2) Å. Both benzoate and 2-amino-
5-methylpyridinium ions are flat (the maximum deviations from the plane are 0.95° and 
0.71° for benzoate and aminopyridinium, respectively) but their planes are twisted at 
9.9°. Supramolecular heterosynthons VII are connected in one direction as the result of 
an additional hydrogen bond involving the anti-oriented N–H of the amine (D: 2.846(2) 
Å). The dihedral angle between the planes parallel to the interactions, OA···NA–CA–
NA···OA in heterosynthon VIIA and OB···NB–CB–NB···OB in adjacent heterosynthon VIIB, 
is 102.5°.  
  94
 
 
Figure 4.11. Supramolecular adducts in 2-amino-5-methylpyridinium benzoate, 17, are 
sustained via charge-assisted heterosynthons VII that form 1D chains 
 
 
 
 
Figure 4.12. Crystal structure of 2-amino-5-methylpyridinium benzoate, 17, viewed along 
the c axis (down the intercalating 1D chains which are colored green, red, blue and gray)  
 
Several 2-aminopyridinium monocarboxylate supramolecular compounds have 
been already reported in the literature, e.g. 2-aminopyridinium benzoate272 and 2-
aminopyridinium salicylate,273 2-aminopyridinium butynoate.274 Their crystal structures 
are also sustained by 1D H-bonded chains. The N+(py)···O- and N(am)···O- hydrogen bonds 
in 17 and the three related compounds are similar: 2.688 Å and 2.801 Å in 17;  2.699 Å 
and 2.868 Å in 2-aminopyridinium benzoate; 2.699 Å and 2.845 Å in 2-aminopyridinium 
salicylate; 2.670 Å and  2.889 Å in 2-aminopyridinium butynoate. These four compounds 
exhibit similar crystal packing in which the 1D chains intercalate with each other along 
the b axis (Figure 4.12). One dimensional chains of supramolecular heterosynthons also 
occur in 2-aminopyridinium-sulfonates.275 Similarly, the aminopyridinium-sulfonate 
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supramolecular heterosynthon exhibits charge-assisted character with proton transfer 
occurring to the aromatic nitrogen of the 2-aminopyridine moiety.   
In bis(2-amino-5-methylpyridinium) 5-tertbutylisophthalate, 18, 2-amino-5-
methylpyridinium ions interact with both carboxylate groups of the 5-t-butylisophtalate 
anions via supramolecular heterosynthon VII. The 2:1 adducts extend along the c axis via 
two centrosymmetric hydrogen bonds formed between the anti- oriented N–H moiety of 
the amine groups and adjacent carboxylates (D: 2.914(2) Å), Figure 4.13. The inversion 
center between two adjacent heterosynthons leads to the formation of a four component 
supramolecular unit consisting of three cyclic supramolecular heterosynthons (graph-set 
notation: R22(8), R24(8), R22(8)). This type of motif has also been observed in related 
aminopyrimidinium-carboxylate salts276,277 and several carboxylic acid-amide co-
crystals.86,87 
The C–O bond distances are 1.258(2) Å, 1.261(2) Å and 1.261(2) Å, 1.262(2) Å 
within the carboxylate groups and the C–N–C angles in the 2-aminopyridinium cations 
are 122.7° and 122.5°. The carboxylate groups are twisted from the plane of the aromatic 
moiety at 20.0° and 6.2°, respectively. The intermolecular hydrogen bonds of the 
heterosynthons VII are within anticipated ranges: 2.623(2) Å, and 2.619(2) Å, for 
N(py)···O- , and 2.788(2) Å and for 2.799(2) Å for N(am)···O-.  
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Figure 4.13. Hydrogen bonding in bis(2-amino-5-methylpyridinium) 5-
tertbutylisophthalate, 18 
 
 
The crystal structure of bis(2-amino-5-methylpyridinium) terephthalate, 19 
compares closely to that of 16. 2-amino-5-methylpyridinium cations interact with both 
carboxylate moieties via charge-assisted supramolecular heterosynthons VII, thereby 
affording 2:1 supramolecular adducts. The adducts are further interconnected into a chain 
of supramolecular heterosynthons via N(am)···O- hydrogen bonds formed between the anti- 
oriented N–H of amine groups and adjacent carboxylates (Figure 4.14).  
The C–O bond lengths are 1.242(4) Å and 1.272(4) Å and the C–N–C angle in the 
2-amino-5-methylpyridinium residue is 123.3°. The torsion angle of the carboxylate 
group with respect to the aromatic moiety of terephthalate anion is 18.6° (vs. 17.4° in 16) 
and the angle between core planes parallel to the supramolecular heterosynthons, 
OA···NA–CA–NA···OA in VIIA and OB···NB–CB–NB···OB in adjacent supramolecular 
heterosynthon VIIB is 100.8° (vs. 97.9° in 16). The hydrogen bond distances in 
supramolecular heterosynthon VII are 2.679(4) Å and 2.812(4) Å for N+(py)···O- and 
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N(am)···O, respectively. The anti- oriented N–H of the amine group hydrogen bonds with 
the carboxylate of the adjacent heterosynthon (D: 2.800(2) Å). All three H-bond distances 
are within excepted ranges and they correspond closely to the distances exhibited by 16. 
 
 
 
Figure 4.14. Crystal structure of bis(2-amino-5- methylpyridinium) terephthalate, 19. 1D 
hydrogen bonded chains are cross-linked via N–H···O- interaction to form 2D sheets 
 
Therefore, compounds 16 and 19 are related in terms of their composition, hydrogen 
bond motifs and packing modes. The difference in the molecular structure of the 
components in 16 and 19 (a methyl substituent in the aminopyridinium residue) is not big 
enough to disrupt the 2D corrugated packing mode. Indeed, 16 and 19 are isostructural, 
crystallizing in space group P21/n with similar unit cell dimensions: a=5.1991(8) Å, 
b=14.606(2) Å, c=11.190(2) Å, β=95.094(3)° and a=5.627(2) Å, b=14.480(6) Å, 
c=11.351(4) Å β=99.622(7)° for 16 and 19, respectively, and a unit cell similarity index 
(∏)278 of 0.013.   
Bis(2-amino-5-methylpyridinium) 2,6-napthalenedicarboxylate, 20 consists of 
three-component adducts sustained by supramolecular heterosynthon VII. The C–O bond 
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distances are 1.241(3) Å and 1.277(3) Å and C–N–C angle is 122.5°. The carboxylate 
functionalities are twisted at 36.7° with respect to the aromatic core of the anion and the 
angle between planes parallel to the interactions OA···NA–CA–NA···OA in A and OB···NB–
CB–NB···OB in adjacent supramolecular heterosynthon B is 60.9°. The hydrogen bonds 
within VII are 2.631(3) Å and 2.897(3) Å for N+(py)···O- and N(am)···O- respectively. The 
anti- oriented N–H of the amine group hydrogen bonds with the carboxylate of the 
adjacent supramolecular heterosynthon (D: 2.837(3) Å). The crystal packing of 20 is 
remarkably similar to 16 and 19 (Figure 4.15). 
 
 
 
Figure 4.15. Crystal packing of bis(2-amino-5-methylpyridinium) 2,6-
napthalenedicarboxylate, 20. 1D hydrogen bonded chains are cross-linked via N–H···O- 
hydrogen bonds to form 2D sheets 
 
 
 
 
The asymmetric unit of bis(2-amino-5-methylpyridinium) adipate adipic acid,  21, 
consists of one 2-amino-5-methylpyridinium cation, half an adipate anion and half a free 
adipic acid. The crystal structure reveals formation of supramolecular heterosynthon VII 
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between the 2-aminopyridinium cation and both sides of the adipate anion. The ions 
further self-assemble via centrosymmetric hydrogen bonds between the anti- oriented N–
H’s of the amine groups and adjacent carboxylates (D: 2815(2) Å), Figure 4.16. The four-
component core is extended into two dimensions via charge-assisted O-H···O- hydrogen 
bonds between neutral adipic acid molecules and adjacent carboxylate anions (O···O-: 
2.557(1) Å). The hydrogen bonds of VII are 2.719(2) Å and 2.816(2) Å for N+(py)···O- and 
N(am)···O- respectively. The four-component supramolecular adducts are nearly flat, with 
the maximum deviation from planarity being 3.8°. The crystal packing of 21 can be 
described as 2D infinite sheets parallel to the plane with an inter-planar distance of ca. 
3.3 Å. The presence of both COOH and COO- groups is supported by structural data and 
IR spectroscopy. The C–O bond distances in the carboxylate groups are 1.243(2) Å and 
1.280(2) Å whereas those in the acid are 1.316(2) Å and 1.217(2) Å. The C–N–C angle in 
the aminopyridinium residue is 122.9(1)°. IR spectroscopy reveals a strong band at 1681 
cm-1 and moderate band at 1265 cm-1 corresponding to C=O and C–O stretches, 
respectively. The bands assigned to COO- stretches are observed near 1550 cm-1 and 1395 
cm-1.  
The CSD contains several compounds that exhibit a 2-aminopyridinium cation, 
dicarboxylate anions, and dicarboxylic acids. One of these compounds, 2-
aminopyridinium adipate adipic acid dihydrate,279 exhibits similar crystal packing to that 
of 21 (Figure 4.17).  
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Figure 4.16. Crystal structures of a) 2-amino-5-methylpyridinium adipate adipic acid, 21  
  
(b) 
Figure 4.17. Crystal structure of 2-aminopyridinium adipate adipic acid dihydrate. Herein, 
the voids between adipic acid molecules are occupied by water molecules  
 
In the dihydrate, water molecules occupy the voids between two adjacent adipic 
acids. The acid molecules can therefore form bridges between adjacent four-component 
cores. Unexpectedly, the presence of methyl group in 21 does not lead to changes in 
crystal packing.  The similarity in packing between the dihydrate and 21 might result 
from the fact that the methyl groups of 2-amino-5-methylpyridine occupy the space of the 
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two water molecules. Both compounds crystallize in P-1 and their unit cell dimensions 
are: a=5.070(7) Å, b=7.208(1) Å, c=18.388(3) Å, α=88.468(2)°, β= 85.015(2)°, γ= 
72.373(2)° for 21 and a=5.019(7) Å, b=7.369(1) Å, c=18.025(3) Å, α=86.481(2)°, β= 
88.999 (2)°, γ= 72.231(2)° for the dihydrate. The isostructurality descriptor, ∏, is 0.078. 
The structures of 2-aminopyridinium succinate succinic acid (2:1:1)280 and 2-
aminopyridinium fumarate fumaric acid281 exhibit different supramolecular networks 
since the components are non-planar.  
The asymmetric unit of bis(2-amino-5-picolinium) 2,5-thiophenedicarboxylate 
2,5-thiophenedicarboxylic acid, 22, consists of one 2-amino-5-methylpyridinium cation, 
half a 2,5-thiophenedicarboxylate anion and half a 2,5-thiophenedicarboxylic acid. 
Although the acid molecule possesses two functional groups capable of two-point 
recognition supramolecular heterosynthon VII is absent (Figure 4.18). Instead, the 
carboxylate group is involved in three 1-point supramolecular heterosynthons: one with 
the protonated nitrogen atom of 2-amino-5-methylpyridinium (D: 2.686(2) Å), a second 
with the adjacent carboxylic acid molecule (D: 2.545(1) Å), and a third with the anti- 
oriented N–H of the amine moiety of another 2-amino-5-methylpyridinium residue (D: 
2.806(2) Å). The C–O bond distances are 1.251(2) Å, 1.267(2) Å and 1.219(2) Å, 
1.318(2) Å for the carboxylate and carboxylic acid moiety, respectively. The C–N–C 
angle of the aminopyridinium is 123.3(2)°. The IR spectrum supports the existence of 
both ionic and neutral functional groups in 9 as it exhibits absorption bands at 1673 cm-1 
and 1237 cm-1 for C=O and C–O, respectively and a COO- asymmetric stretch is present 
at 1627 cm-1. Compound 9 is the only example presented herein that does not exhibit 
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supramolecular heterosynthon VII.   
   
(a) (b) 
 
Figure 4.18. Crystal structure of bis(2-amino-5-picolinium) 2,5-thiophenedicarboxylate 2,5-
thiophenedicarboxylic acid, 22: a) the supramolecular adduct reveals that the expected 
supramolecular heterosynthon VII is absent; b) a view of the chain that is generated by 
three 1-point supramolecular heterosynthons. The interacting components are not 
represented stoichiometrically for clarity  
 
  
In summary, the CSD survey and model compound studies reported herein 
indicate that supramolecular heterosynthons VI and/or VII will occur reliably when 2-
aminopyridine and carboxylic acid moieties are present in the same compound. The CSD 
analysis suggests 77% probability of the supramolecular heterosynthon, which means that 
from an empirical perspective it is strongly favored over the related carboxylic acid, IV, 
or 2-aminopyridine V, supramolecular homosynthons. In the absence of other competing 
functionalities the probability of the occurrence of VI or VII is ca. 97%. The statistical 
reliability of these supramolecular heterosynthons was confirmed by compounds 14-22 in 
which 8/9 were found to exhibit supramolecular heterosynthon VII. The supramolecular 
chemistry of supramolecular heterosynthon VII is also predictable to a certain extent. It is 
see Figure 12 b 
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capable of further self-assembly into chains and sheets and it is noteworthy that very 
similar crystal packing was observed in several compounds despite the presence of 
methyl groups. That supramolecular heterosynthon VI was not observed in 14-22 does 
not mean it is not relevant. Indeed, several co-crystal structures have been reported that 
are based upon 2-aminopyrimidine.127,264 Whether or not a salt or co-crystal forms seems 
to be related to the ancillary groups that are bonded to the 2-aminopyridine moiety. For 
example, all 2-aminopyridines that interact with carboxylic acids appear to be in the form 
of salts whereas 2-aminopyrimidines form either neutral or ionic supramolecular 
heterosynthons and melamines tend to exist as monoprotonated salts. Taking into 
consideration the strength of the three bases (2-aminopyrimidine < melamine < 2-
aminopyridine), one can speculate that the pKa value of the 2-aminopyridine moiety 
influences whether a supramolecular heterosynthon is neutral or ionic. Prediction of what 
will happen for a given carboxylic acid is further complicated by factors such as the pKa 
value of the acid, the nature of substituents and the fact that pKa values are determined in 
solution. 
 
4.3.      Conclusions  
   In conclusion, the charge assisted 2-aminopyridinium-carboxylate or neutral 2-
aminopyridine-carboxylic acid supramolecular heterosynthons occur in 77% of the 
compounds in which these two functional groups are present. This is a high level of 
probability when one considers that such well-known 2-point supramolecular synthons as 
carboxylic acid dimers only occur in ca. 25% of the compounds in which carboxylic 
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acids are present because of competing supramolecular heterosynthons.   This level of 
predictability makes the 2-aminopyridine-carboxylic acid supramolecular synthon 
particularly suitable for crystal engineering of networks, salts and/or co-crystals. The 
modification of the physicochemical properties that occurs with salt or co-crystal 
formation is relevant to the pharmaceutical industry, where formulation of API’s for 
optimal solubility, bioavailability or stability of drugs are of great importance.  
 
4.4. Experimental 
 
4.4.1.  Syntheses 
All reagents used to synthesize 14-22 were purchased from Aldrich. Compounds 
14-22 were prepared by dissolving stoichiometric amounts of starting materials in an 
appropriate solvent. Crystals suitable for single crystal X-ray diffractometry were 
obtained by slow evaporation of the solvent under ambient conditions.  
Compound 14: 2-aminopyridinium 4-aminobenzoate. A solution of 2-
aminopyridine (0.010 g, 0.11 mmol) and 4-aminobenzoic acid (0.015 g, 0.11 mmol) in 2 
mL of ethanol was allowed to evaporate slowly at room temperature. Colorless crystals of 
14 (0.025 g, 0.065 mmol, 59%), mp=152-153 °C, were obtained after 7 days. 
Compound 15: 2-aminopyridinium isophthalate.  The crystallization of 2-
aminopyridine (0.029 g, 0.31 mmol) with isophthalic acid (0.051 g, 0.31 mmol) in 2 mL 
of ethanol afforded colorless crystals of 15 (0.042 g, 0.16 mmol, 52%), mp=198-201 °C, 
within 7 days. 
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Compound 16: bis(2-aminopyridinium) terephthalate. A solution of 2-
aminopyridine (0.060 g, 0.64 mmol) and terephthalic acid (0.053 g, 0.32 mmol) in 2 mL 
of methanol evaporated slowly at room temperature. Colorless crystals of 16 (0.056 g, 
0.16 mmol, 50%), mp=294 °C dec., suitable for X-ray crystallography appeared within 6 
days. 
Compound 17: 2-amino-5-methylpyridinium benzoate. A solution of 2-amino-5-
methylpyridine (0.019 g, 0.18 mmol) and benzoic acid (0.22 g, 0.18 mmol) in 2 mL of 
ethanol was left undisturbed to evaporate slowly under ambient conditions. Colorless 
crystals of 17 (0.033 g, 0.014 mmol, 77%), mp=140-141 °C, were obtained within 7 days. 
Compound 18: bis(2-amino-5-methylpyridinium) 5-tertbutylisophthalate. 
Colorless crystals of 18, mp=174-175 °C, were obtained from the reaction of 2-amino-5-
methylpyridine (0.020 g, 0.18 mmol) with 5-tertbutylisophthalic acid (0.021 g, 0.090 
mmol) in 2 mL of ethanol. The solution was left to evaporate slowly at room temperature 
and yielded 0.025 g (0.057 mmol, 63%) of the product within 8 days. 
Compound 19: bis(2-amino-5-methylpyridinium) terephthalate. Compound 19 
was formed via reaction of 2-amino-5-methylpyridine (0.030 g, 0.28 mmol) with 
terephthalic acid (0.023 g, 0.14 mmol) in 2 mL of methanol. Colorless crystals (0.038 g, 
0.099 mmol, 72%), mp=250 °C dec., appeared within 6 days. 
Compound 20: bis(2-amino-5-methylpyridinium) 2,6-napthalenedicarboxylate. 
A solution of 2-amino-5-methylpyridine (0.030 g, 0.28 mmol) and 2,6-
napthalenedicarboxylic acid (0.030 g, 0.14 mmol) in 2 mL of dimethyl formamide, was 
left undisturbed to evaporate slowly at ambient conditions. Colorless crystals of 20 (0.036 
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g, 0.083 mmol, 60%), mp=390 °C dec.,  were obtained within 9 days.  
Compound 21: bis(2-amino-5-methylpyridinium) adipate adipic acid. 2-amino-
5-methylpyridine (0.030 g, 0.28 mmol) and adipic acid (0.041 g, 0.28 mmol) dissolved in 
2 mL of ethanol afforded colorless crystals of 21 (0.036 g, 0. 14 mmol, 50%), mp=151-
152 °C,  within 7 days.  
Compound 22: bis(2-amino-5-methylpyridinium) 2,5-thiophenedicarboxylate 
2,5-thiophenedicarboxylic acid.  Compound 22 was obtained via reaction of 2-amino-5-
methylpyridine (0.030 g, 0.28 mmol) and 2,5-thiophenedicarboxylic acid (0.048 g, 0.28 
mmol) in 2 mL of ethanol. Colorless crystals (0.062 g, 0.22 mmol, 80%), mp=221-222 
°C, appeared within 7 days.   
 
All compounds were analyzed by infrared spectroscopy using a Nicolet Avatar 
320 FTIR instrument. The purity of bulk samples was confirmed by X-ray powder 
diffraction analysis conducted on a Rigaku Miniflex Diffractometer using Cu Kα (λ= 
1.540562 Å), 30 kV, 15 mA. The data were collected over an angular range of 3° to 40° 
2θ in continuous scan mode using a step size of 0.02° 2θ and a scan speed of 2.0º/min.  
The syntheses of compounds 14-22 were also accomplished via solvent-drop 
grinding using the same solvents as those in the solution crystallizations. Stoichiometric 
amounts of starting materials were processed for 4 minutes in a ball mill. The IR and 
XPD spectra of the products obtained from solvent-drop grindings, matched those of the 
products obtained from slow evaporation. 
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4.4.2.  Single Crystal X-ray Crystallography 
Compounds 14-22 were examined under a microscope and suitable single crystals 
were selected for X-ray analysis. Data were collected on a Bruker–AXS SMART APEX 
CCD diffractometer with monochromatized Mo Kα radiation (λ = 0.71073 Å) connected 
to KRYO-FLEX low temperature device. Data for 14-22 were collected at 100 K. Lattice 
parameters were determined from least square analysis, and reflection data were 
integrated using the program SAINT. Lorentz and polarization corrections were applied 
for diffracted reflections. In addition, the data was corrected for absorption using 
SADABS.248 Structures were solved by direct methods and refined by full matrix least 
squares based on F2 using SHELXTL.249 All non-hydrogen atoms were refined with 
anisotropic displacement parameters. All H-atoms bonded to carbon atoms, except 
methyl groups, were placed geometrically and refined with an isotropic displacement 
parameter fixed at 1.2 times Uq of the atoms to which they were attached. N or O bonded 
protons, as well as H-atoms of methyl groups, were located from Fourier difference map 
and refined isotropically based upon the corresponding N, O or C atom (U(H)=1.2Uq(N, 
O)). Crystallographic data for 14-22 are presented in Table 4.2, whereas selected 
hydrogen bond distances are listed in Table 4.3. 
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Table 4.2. Crystallographic data and structure refinement parameters for compounds 14-22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14 15 16 17 18 19 20 21 22 
Chemical 
formula 
C5H7N2  
•C7H6NO2 
C5H7N2  
•C8H5N2O4
(C5H7N2)2 
•C8H4O4 
C6H9N2  
•C7H5O2 
(C6H9N2)2  
•C12H12O4 
(C6H9N2)2  
•C8H4O4 
(C6H9N2)2  
•C12H6O2 
(C6H9N2)2  
•C6H8O4 
•C6H10O4 
(C6H9N2)2  
•C6H4O4S 
•C6H2O4S 
Formula .wt. 231.25 260.25 354.36 230.26 438.52 382.42 432.47 508.57 560.59 
Crystal system orthorhombic monoclinic monoclinic monoclinic triclinic monoclinic monoclinic triclinic orthorhombic
space group Pca21 P21/c P21/n P21/c P-1 P21/n P21/n P-1 Pnma 
a (Å) 18.932(2) 12.562(1) 5.1991(8) 9.678(3) 8.5420(1) 5.627(2) 5.834(2) 5.0700(7) 14.735(1) 
b (Å) 5.6894(7) 8.0768(9) 14.606(2) 10.838(4) 11.050(2) 14.480(6) 16.260(7) 7.2081(10) 18.752(1) 
c (Å) 10.415(1) 12.236(1) 11.190(2) 11.836(4) 13.096(2) 11.351(4) 10.985(4) 18.388(3) 9.0740(6) 
α (°) 90 90 90 90 101.086(2) 90 90 88.468(2) 90 
β(°) 90 109.831(2) 95.094(3) 111.210(6) 103.007(2) 99.622(7) 92.141(7) 85.015(2) 90 
γ(°) 90 90 90 90 98.983(2) 90 90 72.373(2) 90 
volume (Å3) 1121.8(2) 1167.8(2) 846.4(2) 1157.3(7) 1155.9(3) 911.9(6) 1041.3(7) 638.0(2) 2507.3(3) 
Dcalc ( g cm-3) 1.369 1.48 1.39 1.322 1.26 1.393 1.379 1.324 1.485 
Z 4 4 2 4 2 2 2 1 4 
θ range 2.15-24.95 1.72-25.01 2.30-27.08 2.26-25.15 1.64-25.37 2.30-25.11 2.24-24.70 1.11-26.39 2.17-27.07 
Nref./Npara. 1954/155 2056/172 1855/118 2067/154 4593/289 1615/127 1771/145 2532/163 2846/175 
T (K) 100 100 100 100 100 100 100 100 100 
R1 0.0284 0.0331 0.0434 0.0553 0.0582 0.0743 0.0536 0.0433 0.0339 
wR2 0.0721 0.0959 0.1091 0.1625 0.1681 0.1826 0.1424 0.1324 0.0907 
GOF 1.087 0.966 1.029 1.058 1.056 1.103 1.047 1.121 1.064 
abs coef. 0.096 0.112 0.101 0.091 0.087 0.099 0.096 0.100 0.270 
  109
Table 4.3. Geometrical parameters of selected intermolecular interactions present in 
compounds 14-22 
 
 Interactiona d(Å) D (Å) θ (deg) 
N+–H(py)···O- 1.74 2.611(2) 171.7 
N–Hs···O- 1.99 2.814(2) 175.2 
N–Ha···O- 2.01 2.800 (2) 162.7 
  14 
N–H···O- 2.30 3.087(2) 162.2 
O–H···O- 1.76 2.623(1) 173.4 
N+–H(py)···O- 1.84 2.703(1) 166.0 
N–Hs···O- 1.98 2.836 (1) 169.6 
15 
N–Ha···O- 2.10 2.942(1) 167.0 
N+–H(py)···O- 1.75 2.624(2) 172.3 
N–Hs···O- 1.85 2.797(2) 178.8 16 
N–Ha···O- 1.92 2.809(2) 179.3 
N+–H(py)···O- 1.81 2.688(2) 172.4 
N–Hs···O- 1.87 2.801(2) 168.2 17 
N–Ha···O- 1.92 2.846(2) 165.4 
N+–H(py)···O- 1.77 2.623(2) 161.9 
N–Hs···O- 1.95 2.788(2) 177.2 
N–Ha···O- 2.20 2.914(2) 144.1 
N–Hs···O- 1.74 2.619(2) 172.2 
N–Ha···O- 1.91 2.799(2) 176.6 
18 
N–Ha···O- 2.18 2.940(2) 146.5 
N+–H(py)···O- 1.80 2.679(4) 174.5 
N–Hs···O- 1.92 2.812(4) 172.7 19 
N–Ha···O- 1.86 2.800(4) 168.3 
N+–H(py)···O- 1.75 2.631(3) 175.2 
N–Hs···O- 2.02 2.897(3) 170.0 20 
N–Ha···O- 1.95 2.837(3) 170.6 
O–H···O- 1.68 2.557(1) 173.9 
N+–H(py)···O- 1.84 2.719(2) 176.3 
N–Hs···O- 1.96 2.816(2) 178.9 
21 
N–Ha···O- 2.07 2.815(2) 145.0 
O–H···O- 1.67 2.545(1) 172.1 
N+–H(py)···O- 1.84 2.686(2) 159.4 22 
N–Ha···O- 1.93 2.806(2) 174.0 
 
a The syn- and anti- N–H groups of the 2-aminopyridiniums are referred with subscript 
‘s’ and ‘a’, respectively.  
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Chapter 5 ─ Crystal Engineering of Pharmaceuticals  
 
5.1.  Focus  
Thus far it has been demonstrated that the hydroxyl···aromatic nitrogen (I) and 2-
aminopyridinium-carboxylate (VII) supramolecular heterosynthons are reliable 
interactions and that they persist regardless of the method of preparation of the model co-
crystals and salts.  However, it should be noted that the model compounds have been 
prepared using relatively simple and rigid molecules. The conclusions drawn from the 
presented studies would gain more significance if the acquired observations held true 
over more complex multiple-component systems. In this respect, the chemical nature of 
drug molecules related to their biological activity is determined by their multiple 
hydrogen bonding sites, which also makes them suitable for crystal engineering studies.  
 The research presented in this section is a strategic extension of the model 
compound studies and will demonstrate how the supramolecular heterosynthons I and 
VII can be exploited via crystal engineering of two drug molecules, bicalutamide and 
indomethacin, both of which contain multiple hydrogen bonding sites. Furthermore, the 
viability of solid-state co-crystallization and susceptibility toward polymorphism or 
solvate formation of the obtained API co-crystals will be addressed.  
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5.2. Results and Discussion  
 
5.2.1.  CSD Analysis and Literature Overview 
The examination of the 1487 co-crystals archived in the CSD, has revealed that 
only ca. 5% of the whole dataset contain API molecules, and these include: barbital (32  
entries),282 sulfonamide drugs (14),283 phenathiazines (8),284 carbamazapine (5),285 
theophyllines (5),286 caffeine (6),287 flurbiprofen (2),288 ibuprofen (1),289 itraconazole 
(1),290 diphenylhydantoin (1),291 and trimethoprim (1).292 Whereas some of the examples 
tend to be the result of serendipity, perhaps the first crystal engineered API co-crystals 
appeared from the extensive research of Whitesides et al. concerning  supramolecular 
assemblies sustained by 3-point recognition hydrogen bonds262 formed in co-crystals of 
melamine derivatives and barbital, a central nervous system depressant, Figure 5.1.125,293-
296 Although the studies were not originally oriented toward pharmaceutical applications, 
the resulting series of co-crystals delineated the enormous potential represented by the 
APIs with respect to diversity of the co-crystal compositions and the inherent 
modification of their physicochemical properties.  
 
Figure 5.1. Co-crystal of barbital and N,N’-bis(4-bromophenyl)melamine, JICTUK10, 
sustained by 3-point recognition supramolecular heterosynthon 
  112
 
 Due to the growing interest in the subject, several examples of designed binary 
co-crystals of APIs have appeared in the recent literature.61,80,86,87,132,154,195,204,208 Crystal 
engineering approach to APIs based upon rational utilization of reliable supramolecular 
heterosynthons have been exemplified by a series of co-crystals that involve 
carbamazepine, CBZ, an anti-epileptic drug.61,86,87 The primary amide supramolecular 
homosynthon present in pure CBZ crystal structures,297-300 Figure 5.2, is replaced by 
carboxylic acid···amide heterosynthon, through an introduction of a carboxylic acid 
component. As an example, CBZ•aspirin co-crystal is presented in Figure 5.3a. The 
successful strategic approach founded on utlilization of the same supramolecular 
heterosynthon has been employed in co-crystallization of several carboxylic acids with 
another amide-containing drug, piracetam, a nervous system stimulant176,177,301 The 
crystal structure of piracetam•gentisic acid,208 sustained by carboxylic acid···amide 
heterosynthon is shown in Figure 5.3b.     
                   
 
Figure 5.2. Amide supramolecular homosynthon present the crystal structure of pure CBZ  
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a)                                                                 b) 
 
Figure 5.3. Carboxylic acid···amide supramolecular heterosynthon present in co-crystals of 
a) CBZ•aspirin and b) piracetam•gentisic acid    
 
Further examples concerning crystal engineering of APIs based upon utilization 
of reliable intermolecular interactions include co-crystals sustained by carboxylic 
acid···aromatic nitrogen supramolecular heterosynthon, as exemplified by co-crystals of 
itraconazole,132 ibuprofen and flurbiprofen,80 and caffeine.154 Crystal structures of 
ibuprofen•4,4’-bipyridine is presented in Figure 5.4.  
         
 
   Figure 5.4. Carboxylic acid···pyridine supramolecular heterosynthon present in 
(ibuprofen)2•4,4’-bipyridine co-crystal   
 
Rational design of API co-crystals has been also based upon the utilization of 
charge-assisted O–H···Cl- and N–H···Cl- hydrogen bonds,137,302,303 as demonstrated 
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recently by Childs et al.204 The study involved successful co-crystallizations of an anti-
depressant, fluoxetine hydrochloride (Prozac) with several pharmaceutically acceptable 
carboxylic acids, of which one, Prozac•succinic acid co-crystal, is presented in Figure 
5.5. An important trait resulting from this study is that depending on the aqueous 
solubility of the utilized co-crystal former, it is possible to fine-tune the dissolution rate 
the API. In addition, it was observed that the solubility of the Prozac•succinic acid co-
crystal is doubled as compared to the fluoxetine hydrochloride salt.    
 
Figure 5.5. Charge-assisted supramolecular heterosynthons are present in Prozac•succinic 
acid co-crystal 
 
 
 
It should be noted, that due to the lack of a generally accepted definition of a co-
crystal, there may be ambiguity concerning whether or not a compound is a co-crystal, a 
salt or a solvate. The distinction between a co-crystal and a salt can be especially 
problematic if X-ray crystallography is the only method of characterization and the 
difference between the two extremes is ca. 1Å in a hydrogen atom position. For instance, 
3-[2-(N’,N’-dimethylhydrazino)-4-thiazolylmethylthio]-N2-
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sulfamoylpropionamidine•maleic acid (CSD refcode JATMEW), was reported as a 
neutral complex.304 However, the structural parameters (C−O bond lengths and C−N−C 
bond angles) suggest the formation of a maleate anion and a propionamidinium cation, 
therefore denoting a salt, Figure 5.6a. When searching for co-crystals, the physical state 
of the components must also be taken into consideration. For instance, a molecular 
complex of mebendazole and propionic acid (SAGQEW),305 shown in Figure 5.6b should 
be classified as a solvate rather than a co-crystal, as the propionic acid exists as a liquid 
under ambient conditions (mp −21°C).  
          
a)                                                                     b) 
Figure 5.6. (a) JATMEW, 3-[2-(N’,N’-dimethylhydrazino)-4-thiazolylmethylthio]-N2-
sulfamoylpropionamidine maleic acid. Structural parameters suggest formation of a salt, 
(b) SAGQEW – a propionic acid solvate of mebendazole 
 
Additionally, the CSD mining for co-crystals may be complicated by the database 
errors; the CSD searches retrieve ionic compounds despite limiting the searches to neutral 
compounds. For example, salts EBIBEW, PIKLEA, QAWNAD, VAPBAP, VENLUV, 
etc. are all retrieved as neutral compounds.306-310 These findings suggest that the 
identification of co-crystals archived in the CSD should be supported by inspection of the 
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structural parameters of co-crystal components, and/or revision of the corresponding 
publications.    
In summary, design strategies that target reliable supramolecular heterosynthons 
(determined by preceding CSD searches or model compound studies), which can be 
formed between an API and a co-crystal former, represents an attractive approach to 
discovering new crystalline forms of APIs. Considering the profound implications of 
developing new forms of APIs in the context of both intellectual property and 
physicochemical properties, it is somewhat surprising that a rational design and 
generation of API co-crystals has only been endeavored in recent years.49 The 
applicability of a crystal engineering approach toward generating new forms of APIs has 
been demonstrated by the diverse set of the reported API co-crystals, although some of 
them are sustained by co-crystal formers that are not pharmaceutically acceptable. 
However, the limited number of examples indicates the need for further exploration in 
order to achieve a better understanding of the intermolecular forces that influence the 
formation of API co-crystals, as well as the factors that determine their physicochemical 
properties.  
 
5.2.2.  Bicalutamide 
Bicalutamide (propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[4-
fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-(±)), is a non-steroidal antiandrogen used in 
the treatment of prostate cancer.311 From a supramolecular perspective, bicalutamide is a 
relatively complex molecule due to the conformational flexibility and the presence of 
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multiple hydrogen bonding moieties: hydroxyl (O–H), 2° amine (N–H), carbonyl (C=O), 
cyano (C≡N), and sulfonyl (O=S=O), Scheme 5.1. The anticipation of the supramolecular 
chemistry of this API is therefore complicated by both conformational variations and the 
possibility of existance of various hydrogen bonded synthons. Indeed, the multiple-
complementary nature of bicalutamide is manifested by the existence of two polymorphic 
modifications, Figure 5.7.312,313 Form I of bicalutamide is sustained by O–H···O (D: 
3.145(3) Å) hydrogen bonds occurring between the hydroxyl and carbonyl moieties. 
Bicalutamide form II exhibits two primary supramolecular heterosynthons. The first 
heterosynthon, O–H···N≡C (D: 2.905(3) Å), occurs between the hydroxyl and cyano 
moiety and the second heterosynthon, N–H···O (D: 3.104(2) Å), exists between the N–H 
of the 2° amide and the sulfonyl moieties.      
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Scheme 5.1. Molecular structure of bicalutamide 
 
 
To date, no examples of bicalutamide co-crystals, solvates, or hydrates have been 
deposited in the CSD. Therefore, bicalutamide represents a suitable candidate for a 
crystal engineering case study that addresses its feasibility toward rational design of co-
crystals, considering the presence of multiple hydrogen bonding functionalities in its 
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molecular structure. 
 
a)  
 
b) 
 
Figure 5.7. Representation of the crystal packing of bicalutamide in a) form I and b) form II 
 
 
The first step of the crystal engineering experiment was based upon careful 
examination of molecular structure of bicalutamide to identify the hydrogen bonding sites 
capable of forming reliable supramolecular synthons. The next step, however, which 
involves a CSD analysis of the existing structures that are chemically related to the 
targeted compound to find how they engage in molecular association, was not successful. 
There are no compounds in the database that exhibit exactly the same set of hydrogen 
bond donors and acceptors  as the set present in bicalutamide (O–H, N–H, C≡N, C=O, 
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and O=S=O). With this viewpoint it become apparent that the design strategy needed to 
rely upon a simplified approach, in which one or two moieties would be targeted at a time 
for their interactions with other functional groups. The formation of supramolecular 
heterosynthons was considered to occur with co-crystal formers that possess moieties 
different than those already present in bicalutamide. With the perspective of the model 
co-crystal studies presented in chapter 2, that delineated the remarkably high reliability of 
hydroxyl···aromatic nitrogen (O–H···Narom) supramolecular heterosynthon I in the 
presence of cyano moiety, and considering that these two moieties (OH and CN) are 
present in bicalutamide, the OH moiety was selected as the primary target for 
heterosynthon formation with Narom-based co-crystal formers. Taking into account the 
complexity of the API, the initial selection of co-crystal formers was aimed toward 
simple Narom-containing heterocycles. Two co-crystal formers were chosen: 4,4’-
bipyridyl (bipy) and trans-1,2-bis(4-pyridyl)ethylene (bipyete), and although these 
molecules are not pharmaceutically acceptable, they represent good model candidates 
from the viewpoint of a crystal engineering strategy.      
From the co-crystallization experiments, two co-crystals were obtained: 
bicalutamide•4,4’bipyridyl (23) and bicalutamide•trans-1,2-bis(4-pyridyl)ethylene (24). 
In addition, it was observed that co-crystal 24 tends to be solvated in the presence of 
acetone. The crystal structure of (bicalutamide)2•trans-1,2-bis(4-
pyridyl)ethane•(acetone)2 (25) is also presented. 
Crystal structure of bicalutamide•bipy, 23, reveals discrete 2:2 centrosymmetric 
supramolecular adducts sustained by the targeted heterosynthon I (O–H···Narom) and a N–
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H···Narom heterosynthon, Figure 5.8. The hydrogen bond distance of O–H···Narom is 
2.759(5) Å, which corresponds to the average length of I, observed in the model co-
crystals (chapter 2) and other compounds reported in the CSD (Table 2.1). The distance 
of the second hydrogen bond, N–H···Narom, is 3.499(7) Å, which is relatively long, as 
compared to a typical N–H···Narom interaction.314 The contacts distribution for the N–
H···Narom heterosynthon retrieved from the CSD, (Figure 5.9) reveals that the N–H···Narom 
interaction occurs in the range of 2.75 - 3.30 Å (average of 3.0(1) Å). 
 
Figure 5.8. 2:2 supramolecular adducts formed between bicalutamide and 4,4’bipyridyl in 
23 
 
 
 
In this structure the bipy molecule is twisted at 26.14°. Although the bipy 
molecule in co-crystal 6 is flat, the torsion angle observed in 23 corresponds closely to 
the twist angles of the phenpy molecules in co-crystals 1 and 5 (24.6° and 30.1° 
respectively). The supramolecular adducts are stabilized by continuous aromatic stacking 
occurring between the adjacent bipy molecules, along the a axis. The stacked adducts are 
further connected via weak C–H···N≡C interactions and form 2D sheets Figure 5.10. 
Similar crystal packing, characterized by the columnar arrangement of the 
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supramolecular adducts, was also observed in co-crystals 1, 4, 5, 6 and 8.   
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Figure 5.9. Histogram representing the N–H···Narom contact distribution in the crystal 
structures containing both N–H and Narom moieties 
 
Co-crystal 23 can also be prepared by solvent-drop grinding. The screen for 
polymorphs of 23 based upon solvent-drop grinding with cyclohexane, toluene, 
chloroform, ethyl acetate, methanol, DMSO, and water has not revealed additional forms.     
 
Figure 5.10. Crystal  structure of bicalutamide•4,4’bipyridyl, 23 
 
 
Crystal structure of bicalutamide•bipyete, 24, is reminiscent to that of 23. The 
bicalutamide and bipyete interact via heterosynthon I (D: 2.811(3) Å). The adjacent 
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aggregates are related by a center of inversion and engage in formation of 2:2 
supramolecular adducts via N–H···Narom (D: 3.119(3) Å) interaction, and are additionally 
stabilized by π-π stacking occurring between the bipyete molecules (ca. 3.76 Å), Figure 
5.11. Such supramolecular dimers are further translated along the a axis forming 1D 
columns of continuously π-π stacked 2:2 adducts. The columns are related by translation 
and interconnected by weak C–H···N≡C interaction, thereby generating 2D layers, Figure 
5.12. Similar crystal packing was observed in model co-crystals 6 and 8.  
 
Figure 5.11. 2:2 supramolecular adducts formed between bicalutamide and t-1,2-bis(4-
pyridyl)ethylene in 24 
 
 
 
Co-crystal 24 can also be prepared by solvent-drop grinding. The screen for 
polymorphs of 24 based upon solvent-drop grinding with: cyclohexane, toluene, 
chloroform, ethyl acetate, methanol, DMSO, and water has not revealed any additional 
polymorphs. However, it was observed that when co-crystallization of bicalutamide and 
bipyete is carried out in acetone, a solvate of the co-crystal (25) results. As revealed by 
XPD and FTIR analysis, 25 can be reproducibly obtained from acetone-drop grinding. 
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Figure 5.12. Crystal structure of  bicalutamide•t-1,2-bis(4-pyridyl)ethylene, 24 
 
 
The crystal structure of 25 reveals that the crystallization of bicalutamide and 
bipyete from acetone (acet) affords new composition of the co-crystal, 
(bicalutamide)2•bipyete•(acet)2, and the components assemble into five-member 
supramolecular aggregates. Two bicalutamide molecules interact with one bipyete 
molecule via the heterosynthon I (D: 2.739(6) Å) and with two acet molecules via a N–
H···O(acet) heterosynthon (D: 3.235(7) Å), Figure 5.13. In this structure, one bipyete 
molecule is replaced by two acet molecules. In effect, the continuous π-π stacking 
observed in 24 is disrupted by the insertion of the acet molecules in between the 2:1 
adducts formed by bicalutamide and bipyete molecules, Figure 5.14.  
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Figure 5.13. 5-member supramolecular aggregate formed between bicalutamide, t-1,2-bis(4-
pyridyl)ethylene and acetone in 25 
 
 
Figure 5.14. Crystal structure of (bicalutamide)2• t-1,2-bis(4-pyridyl)ethylene•(acetone)2, 25 
 
 
The melting points of 23-25 (Table 5.1.) are in between the melting points of the 
corresponding constituents. Interestingly, the melting points of 24 and 25 are very close 
(161-163 °C vs. 163-164 °C) despite the difference in the compositions. The solvent loss 
in 25 is observed at 98 °C (crystals become opaque and the phase change is confirmed by 
DSC) and the remaining co-crystal exhibits 2:1 stoichiometry of bicalutamide and 
bipyete, which differ from the 1:1 stoichiometry of bicalutamide and bipyete in 24. No 
correlation was observed when the melting points of 23-25 were compared to the melting 
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points of the related model co-crystals. The melting points distribution in co-crystals 1-13 
and 23-25 highlight the difficulty in correlating the effect of the composition and 
structural variations with the resulting change of thermal behavior. 
 
Table 5.1. Comparison of the melting points of co-crystals 23-25  and the corresponding 
components 
 
Compound Mp of co-crystal [°C] 
Mp of Bicalutamide 
 [°C] 
Mp of component 2 
[°C] 
23 157-159 191-192 110 - 114 (bipy) 
24 161-163 191-192 150 - 153 (bipyete) 
25 164-165  191-192 150 - 153 (bipyete) - 94 (acet) 
 
 
5.2.3.  Indomethacin 
Indomethacin (1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid) is 
known for its analgesic and anti-inflammatory activity. It possesses three functional 
groups that are capable of forming hydrogen bonds: carboxylic acid (COOH), methoxy 
(C–O–CH3), and carbonyl (C=O), Scheme 5.2. Indomethacin exists in three polymorphic 
modifications: a monoclinic and two triclinic.315-317 The triclinic structures are sustained 
by supramolecular homosynthon VII whereas the monoclinic form, exhibits a carbonyl-
carboxylic acid supramolecular heterosynthon, in addition to VII, Figure 5.15.  
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Scheme 5.2. Molecular structure of indomethacin 
   
a)                                                                           b) 
Figure 5.15. Representation of the crystal packing of bicalutamide in a) two triclinic forms 
and b) monoclinic form 
 
In addition to the three polymorphs, only two solvates of indomethacin have been 
so far structurally characterized.318,319 The crystal structures of the reported methanol 
(CSD refcode: BANMUZ) and tert-butanol (CSD refcode: BANMOT) solvates are 
sustained by a cyclic hydrogen bonding motif formed due to an insertion of two hydroxyl 
moieties of the alcohol molecule in between the carboxylic acid dimer, Figure 5.16. Up to 
date, no co-crystals or salts of indomethacin have been deposited in the CSD.   
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Figure 5.16. Methanol solvate of indomethacin, BANMUZ. Similar hydrogen bonding motif 
exists in tert-butanol solvate of indomethacin, BANMOT 
 
Indomethacin was chosen for this study because it represents a suitable candidate 
for the extension of the model compound series (chapter 4) toward crystal engineering of 
APIs based upon supramolecular heterosynthons I and VII. Indomethacin possesses 
several hydrogen bonding sites, of which one is carboxylic acid, the target moiety. 
Considering the high probability of formation of heterosynthon VII, demonstrated based 
upon simple model molecules, it is anticipated that the COOH moiety of indomethacin 
will also be utilized in the 2-point recognition supramolecular heterosynthon with 2-
aminopyridines. 2-amino-5-methylpyridine was selected as a simple counterpart for co-
crystallization with the relatively complex indomethacin. Although not pharmaceutically 
acceptable, 2-amino-5-methylpyridine is a good candidate from the perspective of its 
chemical and geometrical features that match with the features of the COOH functional 
group, as proved in the preceding studies involving model compounds (chapter 4).   
Crystallization of indomethacin with 2-amino-5-methylpyridine afforded 
compound 26, which is sustained by supramolecular heterosynthon VII (Figure 5.17). 
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The crystal structure of compound 26 exhibits the expected 1:1 stoichiometry. The 
hydrogen bond distances in the charge-assisted supramolecular heterosynthon VII are 
within expected ranges: 2.728(4) Å and 2.790(5) Å for N+(py)···O- and and N(am)···O-, 
respectively. The C–O bond lengths are 1.228(5) Å, 1.258(5) Å and the C–N–C angle in 
the 2-aminopyridinium cation is 123.1°. The angle between core planes parallel to the 
interactions OA···NA–CA–NA···OA in synthon VIIA and OB···NB–CB–NB···OB in synthon 
VIIB is 92.4° (Figure 4.7). The anti- oriented N–H of the amine moiety forms H-bond 
with carboxylate (D: 2.843(4) Å) of the neighboring anion thereby bridging adjacent 
supramolecular heterosynthons. Similar hydrogen bonding motif has also been seen in 
compounds 14, 16, 17, 19, and 20.  
The reproducibility of 26 was confirmed by solvent-drop grinding involving 
seven solvents: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and 
water no additional forms. The susceptibility of 26 toward solvent-drop grinding suggests 
that solid-state methods can be efficiently utilized in screening for crystalline salts of 
APIs.152      
 
Figure 5.17. Supramolecular heterosynthon VII exhibited in 2-aminopyridinium 
indomethacin, 26  
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In summary, the application of heterosynthon VII has been demonstrated in a 
successful crystal engineering experiment of indomethacin, a carboxylic acid API, with 
2-amino-5-methylpyridine salt former. Conversily, VII can be targeted in crystal 
engineering of 2-aminopyridine-containing APIs and carboxylic acid co-crystal formers. 
For instance, trimethoprim, an antibacterial agent, forms organic salts with a range of 
carboxylic acids: formic acid,320 acetic acid,321 trifluoroacetic acid,322 malonic acid,323 
glutaric acid,277 benzoic acid,324 3-chlorobenzoic acid,325 2-nitrobenzoic acid,326 
terephthalic acid,327 through the 2-point recognition interaction VII, Figure 5.18.     
 
Figure 5.18. Crystal structure of trimethoprim benzoate is sustained by the 2-
aminopyridine-carboxylate suparmolecular heterosynthon VII 
 
 
5.3. Conclusions  
 In summary, the use of two robust supramolecular heterosynthons I and 
VII has been demonstrated in crystal engineering of two APIs: bicalutamide and 
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indomethacin. From a supramolecular perspective, the molecular structures of both drugs 
are relatively complex due to their multiple hydrogen bonding sites. The successful co-
crystallization of bicalutamide with pyridines confirms the robustness of I not only in the 
presence of the C≡N moiety, but also suggests that I can persist in the presence of other 
hydrogen bonding groups: carbonyl (C=O), 2° amine (N–H), and sulfonyl (O=S=O).  
Similarly, the application of heterosynthon VII toward modification of crystal structure 
of indomethacin also proved that VII is a reliable interaction even in the presence of 
carbonyl (C=O) and ether (C–O–C) moieties. The reliability of I and VII was also 
determined based upon reproducibility of 23, 24, and 26 in solvent-drop grinding 
experiments. In addition, that polymorphism was not observed in 23, 24, and 26 can be 
an important observation considering that both bicalutamide and indomethacin are 
polymorphic in their pure states. It should be noted that in several cases, API co-crystals 
comprised by polymorphic components have not yet exhibited polymorphism,208,211 
which may have an important implications from the viewpoint of polymorphism control. 
With the perspective of the necessity of better understanding and control of 
crystalline forms of APIs, pharmaceutical co-crystals appear to represent a significant 
class of compounds. It is important to note that the crystal engineering approach leaves 
the molecular structure of an API intact, while diverse range of new compositions with 
modified physicochemical properties is readily accessible. Furthermore, they may offer 
more opportunities than, for example, salts, which are formed only when the API 
possesses moieties that are sufficiently basic/acidic for protonation/deprotonation.In co-
crystallization, molecules possessing wider range of hydrogen bonding moieties can be 
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targeted. In particular, utilization of GRAS (generally regarded as safe)328 compounds, 
food additives or even sub-therapeutics, such us aspirin or acetaminophen, as the co-
crystal formers is feasible.   
Nevertheless, there still remains a need for further exploration of API co-crystals 
in order to address some fundamental issues. For instance, while the role of API salt 
forms in the optimization of API properties, e.g. solubility, has been established,191,193,194 
the role of API co-crystals in this context has been addressed only in a few cases.132,204,211 
Another question could be related to whether API co-crystals are more or less prone to 
polymorphism as compared to the pure API. It is not a trivial task to assess the frequency 
of occurrence of polymorphism in either of the mentioned categories as the absence of 
polymorphism is not synonymous with its non-existence. However, if one considers that 
co-crystallization is based upon satisfying the molecular recognition sites of a targeted 
API by matching it with a complementary co-crystal former, it is possible to anticipate a 
decreased tendency of the co-crystal to exhibit polymorphism as compared to the pure 
components. The fact that polymorphism seen in the 11 reported co-crystals has not been 
related to hydrogen bonding variations, could support these arguments, however more 
research needs to be conducted in this context.       
In conclusion, it is appropriate to highlight that despite many questions and 
challenges, API co-crystals represent valuable category of compounds. They offer many 
opportunities in the context of their viability to rational design and large diversity of 
composition and physicochemical properties, which can be utilized in new API 
formulations.     
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5.4. Experimental  
Bicalutamide was used as received from Transform Pharmaceuticals Inc., MA. 
Indomethacin was used as received from the Department of Pharmaceutical Sciences, 
College of Pharmacy, University of Michigan. 
 
5.4.1.  Syntheses 
Co-crystal 23: bicalutamide•4,4’bipyridyl. To bicalutamide (0.050 g, 0.115 
mmol) was added 4,4’-bipyridine (0.018 g, 0.115 mmol). To the solid mixture was added 
acetone (1 mL) and the solution was left to evaporate at ambient temperature. After 3 
days colorless plates of 23 were formed, mp=157-159 °C.  
Co-crystal 24: bicalutamide•t-1,2-bis(4-pyridyl)ethylene. To bicalutamide (0.100 
g, 0.23 mmol) was added t-1,2-bis(4-pyridyl)ethene (0.021 g, 0.115 mmol). To the solid 
mixture was added DMSO (0.5 mL) and the solution was left to evaporate at ambient 
temperature. After 3 days colorless plates of 24 were formed, mp=161-163 °C.  
Co-crystal solvate 25: (bicalutamide)2•trans-1,2-bis(4-
pyridyl)ethane•(acetone)2. To bicalutamide (0.100 g, 0.23 mmol) was added t-1,2-bis(4-
pyridyl)ethene (0.021 g, 0.115 mmol) in 2:1 molar ratio. To the solid mixture was added 
1mL hexane / acetone (1:1) and the solution was left to evaporate at ambient temperature. 
After 3 days colorless plates of 25 were formed, mp=163-164 °C (at 98 °C the crystal 
became opaque).  
Compound 26: 2-amino-5-methylpyridinium indomethacin. A solution of 2-
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amino-5-methylpyridine (0.010 g, 0.093 mmol) and indomethacin (0.033 g, 0.093 mmol) 
in 2 mL of ethanol was left undisturbed to evaporate slowly at room temperature. Yellow 
crystals of 26, mp=146-148 °C, appeared after 7 days. 
Co-crystallization via solvent-drop grinding: Stoichiometric amounts of the 
starting materials were ground with a mortar and pestle for ca. 4 minutes with the 
addition of seven solvents (10 μL per 50 mg of product):  cyclohexane, toluene, 
chloroform, ethyl acetate, methanol, DMSO, and water. In case of 25, acetone was also 
used. 
 
5.4.2. Single Crystal X-ray Crystallography 
Compounds 23-26 were examined under a microscope and suitable single crystals 
were selected for X-ray analysis. Data were collected on a Bruker–AXS SMART APEX 
CCD diffractometer with monochromatized Mo Kα radiation (λ = 0.71073 Å) connected 
to KRYO-FLEX low temperature device. Data for 23-25 were collected at 298 K, 
whereas data for 26 were collected at 100 K. Lattice parameters were determined from 
least square analysis, and reflection data were integrated using the program SAINT. 
Lorentz and polarization corrections were applied for diffracted reflections. In addition, 
the data was corrected for absorption using SADABS.248 Structures were solved by direct 
methods and refined by full matrix least squares based on F2 using SHELXTL.249 All 
non-hydrogen atoms were refined with anisotropic displacement parameters. All H-atoms 
bonded to carbon atoms, except methyl groups, were placed geometrically and refined 
with an isotropic displacement parameter fixed at 1.2 times Uq of the atoms to which they 
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were attached. N or O bonded protons, as well as H-atoms of methyl groups, were located 
from Fourier difference map and refined isotropically based upon the corresponding N, O 
or C atom (U(H)=1.2Uq(N, O)). Crystallographic data for 23-25 are presented in Table 
5.2, whereas selected hydrogen bond distances are listed in Table 5.3. 
 
Table 5.2. Crystallographic data and structure refinement parameters for compounds 23-26 
 
 23 24 25 26 
Chemical 
formula 
C18H14F4N2O4S
•C10H8N2 
C18H14F4N2O4S
• C12H10N2 
C18H14F4N2O4S
• C12H10N2 
•C3H6O 
C6H9N2 
•C19H15NO2Cl 
Formula wt. 1173.11 612.59 1159.12 465.92 
Crystal system triclinic triclinic triclinic orthorhombic 
space group P-1 P-1 P-1 Pca21 
a (Å) 8.298(2) 8.274(3) 11.214(2) 12.564(2) 
b (Å) 11.434(3) 10.172(3) 11.724(2) 11.338(1) 
c (Å) 15.299(4) 18.601(7) 12.198(3) 30.501(4) 
α(°) 74.506(4) 87.521(7) 73.721(4) 90 
β(°) 75.852(5) 78.256(6) 83.866(4) 90 
γ(°) 79.963(4) 71.067(7) 66.461(4) 90 
volume (Å3) 1347.0(6) 1449.4(9) 1411.4(5) 4344.7(1) 
Dcalc ( g cm-3) 1.446 1.404 1.364 1.425 
Z 1 2 1 8 
θ range 1.41-25.00 1.12-26.73 1.74 to 25.00 1.34-28.29 
Nref./Npara. 4680/ 370 5985/ 388 4786 / 363 10289/595 
T (K) 298 298 298 100 
R1 0.0724 0.0554 0.1004 0.0718 
wR2 0.2208 0.1498 0.3434 0.1837 
GOF 0.786 1.028 1.011 1.038 
abs coef. 0.190 0.180 0.182 0.215 
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Table 5.3. Geometrical parameters of supramolecular heterosynthons present in 
compounds 23-26 
 
 Interactiona d(Å) D (Å) θ (deg) 
O–H···Narom 1.68 2.759(5) 163.1 23 
N–H···Narom 2.55 3.499(7) 157.4 
O–H···Narom 1.93 2.811(3) 157.5 24 
N–H···Narom 2.25 3.119(3) 157.7 
O–H···Narom 1.81 2.739(6) 154.1 25 
N–H···Oacet 2.33 3.235(7) 147.9 
N+–H(py)···O- 1.87 2.728(4) 163.3 
N–Hs···O- 1.82 2.790(5) 165.1 26 
N–Ha···O- 1.76 2.843(4) 169.3 
  136
 
 
Chapter 6 ─ Summary and Future Directions  
 
6.1.  Summary  
The goal of the presented work is to illustrate the application of crystal 
engineering principles toward a generation of multiple-component organic crystalline 
materials with pre-determined composition and intermolecular interactions in a rational 
and controllable manner. Specifically, the systematic studies involving preparation and 
structural analysis of hydrogen bonded multi-component compounds have afforded a 
basis for a better understanding and control of the supramolecular synthons in the solid 
state. In particular, the knowledge acquired from the investigation of organic co-crystals 
and salts sustained by simple components has led to the delineation of the reliability of 
two supramolecular synthons, namely hydroxyl···aromatic nitrogen (I) and 2-
aminopyridine···carboxylate (VII) heterosynthons. The determination of the reliable 
reccurence of I and VII subsequently lead to a development of strategies for the design of 
multiple-component compounds that involve more complex molecules possessing 
multiple functional groups, such as APIs.  The exploitation of these strategies toward 
drug molecules that possess several hydrogen bonding sites has proved to be successful 
in the case of bicalutamide and indomethacin. Both bicalutamide and indomethacin 
formed co-crystals and a salt, respectively, with pre-determined composition and 
predictable intermolecular interactions. The presented results can be particularly 
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attractive, from the viewpoint that the traditional API forms, such as polymorphs and 
solvates/hydrates tend to appear serendipitously, rather than based upon a rationally 
designed experiment.        
In addition, it has been illustrated that organic co-crystals and salts exhibit high 
susceptibility toward solid-state preparation methods, such us growth form melt, dry 
grinding, and solvent-drop grinding. In particular, the later has been confirmed to 
constitute a reliable technique for a reproducible formation of multiple-component 
compounds. It has been determined that the utilization of an appropriate solvent can 
direct co-crystallization toward specific co-crystal stoichiometries. In particular, DMSO-
drop grinding of 3-cyanophenol and trans-1,2-bis(4-pyridyl)ethylene in 1:1 ratio affords 
complete conversion of the starting materials into a 3-cyanophenol•trans-1,2-bis(4-
pyridyl)ethylene co-crystal, which otherwise occurs concomitantly with the (3-
cyanophenol)2•trans-1,2-bis(4-pyridyl)ethylene co-crystal when other solvents are used 
in the grinding or solution evaporation methods. In addition, the mechanochemical 
approach to supramolecular synthesis is inherently relevant in the generation of a bulk 
material according to green chemistry practices: directly from starting materials and 
based upon clean and high yielding procedures.       
 The investigations in the context of polymorphism provided new insights 
concerning the origin of this phenomenon in co-crystals. Specifically, the structural 
analysis of the two dimorphic co-crystals, (4-cyanopyridine)2•4,4’-biphenol and 4-
cyanophenol•t-1,2-bis(4-pyridyl)ethylene, revealed the existence of identical hydrogen 
bonded heterosynthons in both forms of the corresponding co-crystals. These results 
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support the observations formulated based upon the analysis of the existing polymorphic 
co-crystals: polymorphism in co-crystals is related to conformational and crystal packing 
variations rather than supramolecular synthons. Although these conclusions are made 
from the study of a limited number of examples, a generality of this observation over a 
broader set of co-crystals may have important implications in the context of controlling 
polymorphism. Furthermore, the use of solvent-drop grinding to obtain specific 
polymorphs of co-crystals has been successful, as illustrated based on (4-
cyanopyridine)2•4,4’-biphenol co-crystal.    
In summary, the presented research has contributed to the overall progress of the 
field of crystal engineering, whose ultimate goal is the understanding of intermolecular 
interactions and the ability to rationally design new crystalline solids for useful 
applications. Specifically, it has been demonstrated that crystal engineering of 
pharmaceuticals is possible with an appropriate understanding of their supramolecular 
chemistry and the interplay of a supramolecular synthons that can potentially exist when 
other components are introduced. Considering the dependability of physichochemical 
properties of APIs on the molecular arrangement in their crystals, the advantage of crystal 
engineered APIs is inherently related to the control of their physicochemical 
performance: solubility, bioavailability, stability, etc. While the role of salt forms of APIs 
can be considered as established, the role of co-crystal forms of APIs still remains to be 
explored and there are many questions and challenges that will need to be addressed. 
These challenges can be linked to scale up processes, evaluating properties of the bulk 
co-crystalline material, utilization of automatized methodologies, such as high-
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throughput co-crystallization, issues related to regulatory procedures, etc. Nevertheless, 
the need for further exploration of APIs remains clear because the value and 
opportunities of a successful development of co-crystallization strategies of APIs is 
significant in the context of both drug development and intellectual property.      
 
6.2.  Future Directions  
In conclusion, several directions for future research in the field of crystal 
engineering of can be highlighted.   
- Considering the viability of multi-component compounds, co-crystals or organic 
salts, toward the investigation of robustness and hierarchies of various supramolecular 
synthons, the potential of further studies that focus on an even broader range of hydrogen 
bonding moieties has become apparent. In particular, a systematic investigation of the 
competition of various hydrogen bonds in the presence of three, four, or even more 
functional groups should be addressed. 
- In the context of API co-crystals, the studies should be expanded to utilization of 
pharmaceutically acceptable co-crystal formers and further evaluation of their 
physicochemical performance, i.e. solubility, bioavailability, stability, toxicology, etc. In 
addition, the experimental protocols related to API co-crystallization on a large scale and 
determination of bulk properties may be important.   
- Since the existence of polymorphism in API co-crystals has attracted attention, 
exhaustive screen involving an HT approach could provide more insight toward better 
understanding the phenomenon and evaluating its frequency.  Specifically, addressing 
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whether or not co-crystals of APIs are more or less prone to polymorphism may lead to 
important scientific and intellectual property implications. Additionally, the observation 
related to the persistence of supramolecular synthons within a set of polymorphs perhaps 
requires further investigation.     
- Considering the multi-disciplinary character of crystal engineering, it would be 
interesting to utilize other classes of co-crystal formers, for instance, molecules that 
mimic biologically active compounds. When coupled with APIs, such biomolecular co-
crystals could be of use to study drug-DNA or drug-enzyme interactions in the solid state. 
The stability of co-crystals in aqueous environment could be evaluated based upon slurry 
experiments. 
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Appendix 1. Experimental data for compound 1 
DSC termogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(red) and calculated from the single crystal structure (black).  
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Appendix 2. Experimental data for compound 2 
DSC termogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(red) and calculated from the single crystal structure (black).  
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Appendix 3. Experimental data for compound 3 
DSC termogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(red) and calculated from the single crystal structure (black) 
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Appendix 4. Experimental data for compound 4 
DSC termogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(red) and calculated from the single crystal structure (black).   
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Appendix 5. Experimental data for compound 5 
DSC termogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(red) and calculated from the single crystal structure (black). 
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Appendix 6. Experimental data for compound 6 
DSC termogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(red) and calculated from the single crystal structure (black). 
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Appendix 7. Experimental data for compound 7 
DSC termogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(red) and calculated from the single crystal structure (black).  
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Appendix 8. Experimental data for compound 8 
DSC termogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(red) and calculated from the single crystal structure (black).  
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Appendix 9. Experimental data for compound 9 
DSC termogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(red) and calculated from the single crystal structure (black).  
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Appendix 10. Experimental data for compound 10 
DSC termogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(red) and calculated from the single crystal structure (black).  
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Appendix 11. Experimental data for compounds 11a and 11b 
DSC termograms, FT-IR spectra of Form I and Form II.  
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Appendix 12. Experimental data for compound 12 
DSC termogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(red) and calculated from the single crystal structure (black).  
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Appendix 13. Experimental data for compound 13a and 13b 
DSC termogram, FT-IR spectra Form I (blue) and Form II (red).  
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Appendix 14. Polymorphism screen data for compound 1  
FT-IR spectra and X-ray powder diffraction patterns of powders obtained based upon 
solvent-drop grinding with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, 
DMSO, and water.   
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Appendix 15. Polymorphism screen data for compound 2 
FT-IR spectra and X-ray powder diffraction patterns of powders obtained based upon 
solvent-drop grinding with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, 
DMSO, and water.   
 
 
0 5 10 15 20 25 30 35 40 45
0
50
100
150
200
250
Water
DMSO
Methanol
Ethyl acetate
Chloroform
Toluene
Cyclohexane
2θ  
  175
Appendix 16. Polymorphism screen data for compound 3  
FT-IR spectra and X-ray powder diffraction patterns of powders obtained based upon 
solvent-drop grinding with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, 
DMSO, and water. 
0 5 10 15 20 25 30 35 40 45
0
50
100
150
200
250
300
350
Water
DMSO
Methanol
Ethyl acetate
Chloroform
Toluene
Cyclohexane 
2θ  
  176
Appendix 17. Polymorphism screen data for compound 4  
FT-IR spectra and X-ray powder diffraction patterns of powders obtained based upon 
solvent-drop grinding with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, 
DMSO, and water. 
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Appendix 18. Polymorphism screen data for compound 5 
FT-IR spectra and X-ray powder diffraction patterns of powders obtained based upon 
solvent-drop grinding with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, 
DMSO, and water. 
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Appendix 19. Polymorphism screen data for compound 6 
FT-IR spectra and X-ray powder diffraction patterns of powders obtained based upon 
solvent-drop grinding with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, 
DMSO, and water. 
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Appendix 20. Polymorphism screen data for compound 7 
FT-IR spectra and X-ray powder diffraction patterns of powders obtained based upon 
solvent-drop grinding with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, 
DMSO, and water. 
0 5 10 15 20 25 30 35 40 45
0
50
100
150
200
Cyclohexane
Toluene
Chloroform
Ethyl acetate
Methanol
DMSO
Water
2θ  
  180
Appendix 21. Polymorphism screen data for compound 8 
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and water. 
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Appendix 22. Polymorphism screen data for compound 9 
FT-IR spectra and X-ray powder diffraction patterns of powders obtained based upon 
solvent-drop grinding with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, 
DMSO, and water. 
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Appendix 23. Polymorphism screen data for compound 10 
FT-IR spectra and X-ray powder diffraction patterns of powders obtained based upon 
solvent-drop grinding with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, 
DMSO, and water.  
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Appendix 24. Polymorphism screen data for compound 11a and 11b  
FT-IR spectra and X-ray powder diffraction patterns of powders obtained based upon 
solvent-drop grinding with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, 
DMSO, and water. 
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Appendix 24. Polymorphism screen data for compound 11a and 11b (continued)  
 
Comparison of experimental (pink) and calculated X-ray powder diffraction patterns of 
4,4’-biphenol DMSO solvate, ECELON01 (black). 
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Appendix 25. Polymorphism screen data for compound 12 
FT-IR spectra and X-ray powder diffraction patterns of powders obtained based upon 
solvent-drop grinding with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, 
DMSO, and water. 
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Appendix 26. Polymorphism screen data for compound 13a and 13b 
X-ray powder diffraction patterns of powders obtained based upon solvent-drop grinding 
with: cyclohexane, toluene, chloroform, ethyl acetate, methanol, DMSO, and water. 
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Appendix 27. Experimental data for compound 14 
FT-IR spectrum and X-ray powder diffraction patterns of bulk sample (red) and 
.calculated from the single crystal structure (black). 
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Appendix 28. Experimental data for compound 15 
FT-IR spectrum and X-ray powder diffraction patterns of bulk sample (red) and 
calculated from the single crystal structure (black). 
 
 
 
 
68
8.
00
73
0.
65
77
3.
19
93
4.
70
98
3.
35
10
76
.1
9
11
51
.9
1
12
57
.6
9
13
80
.4
1
14
30
.0
8
14
84
.5
1
16
06
.3
1
16
38
.5
0
16
68
.3
3
17
08
.2
2
 74
 76
 78
 80
 82
 84
 86
 88
 90
 92
 94
 96
 98
%
T
ra
ns
m
itt
an
ce
 1000   2000   3000   4000  
Wavenumbers (cm-1)  
 
0 5 10 15 20 25 30 35 40 45
0
200
400
600
800
1000
1200
1400
1600
1800
2θ
 
 
 
  
 
189
Appendix 29. Experimental data for compound 16 
FT-IR spectrum and X-ray powder diffraction patterns of bulk sample (red) and 
calculated from the single crystal structure (black). 
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Appendix 30. Experimental data for compound 17 
FT-IR spectrum and X-ray powder diffraction patterns of bulk sample (red) and 
calculated from the single crystal structure (black). 
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Appendix 31. Experimental data for compound 18 
FT-IR spectrum and X-ray powder diffraction patterns of bulk sample (red) and 
calculated from the single crystal structure (black). 
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Appendix 32. Experimental data for compound 19 
FT-IR spectrum and X-ray powder diffraction patterns of bulk sample (red) and 
calculated from the single crystal structure (black). 
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Appendix 33. Experimental data for compound 20 
FT-IR spectrum and X-ray powder diffraction patterns of bulk sample (red) and 
calculated from the single crystal structure (black). 
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Appendix 34. Experimental data for compound 21 
FT-IR spectrum and X-ray powder diffraction patterns of bulk sample (red) and 
calculated from the single crystal structure (black). 
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Appendix 35. Experimental data for compound 22 
FT-IR spectrum and X-ray powder diffraction patterns of bulk sample (red) and 
calculated from the single crystal structure (black). 
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Appendix 36. Experimental data for compound 23 
X-ray powder diffraction patterns of bulk sample (black) and calculated from the single 
crystal structure (red) of compound 14 
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Appendix 37. Experimental data for compound 24 
X-ray powder diffraction patterns of bulk sample (red) and calculated from the single 
crystal structure (black). 
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Appendix 38. Experimental data for compound 25 
X-ray powder diffraction patterns of bulk sample (red) and calculated from the single 
crystal structure (black). 
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Appendix 39. Experimental data for compound 26 
FT-IR spectrum and X-ray powder diffraction patterns of bulk sample (red) and 
calculated from the single crystal structure (black). 
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